Enzymes, cells and methods for making sesquiterpene oils

Abstract

The present disclosure in various aspects provides host cells and methods for making sesquiterpene components of cypriol oil or oud oil. In some embodiments, the host cells express one or more terpene synthase (TPS) enzymes. In some embodiments, the invention provides host cells producing oxidized sesquiterpene components of cypriol oil or oud oil. In these embodiments, the host cells further expresses one or more cytochrome P450 (CYP) enzymes.

Description

[0001]Attorney Docket No.: MAN-042PC / 107590-5041 ENZYMES, CELLS AND METHODS FOR MAKING SESQUITERPENE OILS PRIORITY This Application claims the benefit of, and priority to, US Application No. 63 / 571,147, filed March 28, 2024, which is hereby incorporated by reference in its entirety. SEQUENCE LISTING The instant application contains a sequence listing, which has been submitted in XML format via Patent Center. The contents of the XML file, named “MAN- 042PC_107590-5042_Sequence_Listing,” which was created on March 26, 2025, and is 234,205 bytes in size, are incorporated herein by reference in their entirety. BACKGROUND Various plants produce a variety of essential oils, which contain the essence of the plant’s fragrance. Essential oils are commonly used in perfumery and medicinal applications, such as aromatherapy, a form of alternative medicine. For example, cypriol oil is an essential oil Cyperus scariosus, a perennial herbaceous plant from Australia and New Guinea. It is used as a medicine, e.g., for treating digestive problems insufficient periods, mucus and scabies (a disease caused by mites) as well as in luxurious perfumes. Similarly, oud oil, also known as agarwood oil, is secreted in a resin produced by Aquilaria trees to combat the infection by Phialophora parasitica mold. The oud oil is used in religious practices in different religions, in traditional medicine to treat various illnesses and in luxurious perfumes. Both cypriol oil and oud oil are extracted from natural sources. Both cypriol oil and oud oil comprise of multiple sesquiterpenoid compounds, and a combination of which appear to provide the aroma of cypriol oil and oud oil. Chemical synthesis of cypriol oil and oud oil is challenging because constituents must be separately synthesized and combined. Therefore, sustainable and scalable processes for synthesizing cypriol oil and oud oil sesquilactones are needed. BRIEF DESCRIPTION OF THE DRAWINGS FIG.1 (top and right) illustrates a biosynthetic scheme for production of cypriol oil sesquiterpenes from glucose in E. coli. Biochemical intermediates / products are shown in a DB1 / 156198702.2 Attorney Docket No.: MAN-042PC / 107590-5041 boldface font and biosynthetic pathways / individual enzymes are indicated in an underlined font. FIG.1 (bottom left) shows the GC-MS chromatograms are labeled with numbers 1-4. 1, total ion chromatogram of cypriol oil; 2, a representative fragment ions of sesquiterpenes (a product of a terpene synthase (TPS)); 3, a representative fragment ions of sesquiterpenoids with one oxidation (produced by the action of TPS and one monooxygenase); and 4, a representative fragment ions of sesquiterpenoids with two oxidations (produced by the action of TPS and two oxidative enzymes). Peaks corresponding to a representative unoxidized sesquiterpene compound, cyprene, and a representative oxidized sesquiterpene compound, α-cyperone, are shown in the total ion chromatogram. FIG. 2A and FIG. 2B demonstrate the production of unoxidized cypriol oil sesquiterpene compounds by an engineered microbial strain. FIG.2A shows a comparison of a total ion current (TIC) chromatogram of cypriol oil, an extracted-ion chromatogram (EIC) cypriol oil and TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing Cyperus rotundus CroTPS2 (TPS2, SEQ ID NO: 2) enzyme. An internal standard is shown in the gray box. FIG.2B shows mass spectrometry data for the compounds identified in FIG.2A at various retention time. Some were identified as α-copaene, elemene, cyprene, caryophyllene, humulene, and rotundene. FIG. 3A to FIG. 3C demonstrate the production of β-selinene and α-selinene constituents of cypriol oil by an engineered microbial strain. FIG.3A shows a comparison of a total ion current (TIC) chromatogram of cypriol oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing one of Cyperus rotundus CroTPS1 (TPS1, SEQ ID NO: 1), Zingiber zerumbet ZSS2 (TPS36, SEQ ID NO: 36), Zea mays ZmTPS21 (TPS41, SEQ ID NO: 41) and Leucophylum frutescens LfTPS12a (TPS43, SEQ ID NO: 43) enzymes. FIG.3B shows a mass spectrometry-based identification of β-selinene to be the compound marked by the number 10 in FIG.3A. FIG. 3C shows a mass spectrometry-based identification of α-selinene to be the compound marked by the number 11 in FIG.3A. The compound marked by the number 4 and 6 in FIG. 3A were caryophyllene and humulene, respectively (See FIG.2B). FIG. 4A and FIG. 4B illustrate the production of oxidized sesquiterpenoids found in cypriol oil by an engineered microbial strain. FIG.4A shows a comparison of a total ion DB1 / 156198702.2 2 Attorney Docket No.: MAN-042PC / 107590-5041 current (TIC) chromatogram of cypriol oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing TPS2 (SEQ ID NO: 2) enzyme, and without a cytochrome P450 enzyme (CYP), or expressing one of Cyperus rotundus CroCYP1 (CYP15, SEQ ID NO: 59), Cyperus rotundus CroCYP14 (CYP28, SEQ ID NO: 72), and Aquilaria sinensis WT-AsCYP21 (CYP49, SEQ ID NO: 93) enzymes. FIG. 4B shows a mass spectrometry profile of compound in the peak 12. FIG. 5A and FIG. 5B illustrate a biosynthetic scheme for production of oud oil sesquiterpenes. FIG. 5A shows the GC-MS analysis of three different oud oil samples to identify major compounds common / unique between them. FIG.5B (top and right) shows a biosynthetic scheme for production of oud oil sesquiterpenes from glucose in E. coli. Biochemical intermediates / products are shown in a boldface font and biosynthetic pathways / individual enzymes are indicated in an underlined font. FIG. 5B (bottom left) shows the GC-MS chromatograms are labeled with numbers 1-4.1, total ion chromatogram of oud oil; 2, a representative fragment ions of sesquiterpenes (a product of a terpene synthase (TPS)); 3, a representative fragment ions of sesquiterpenoids with one oxidation (produced by the action of TPS and one monooxygenase); and 4, a representative fragment ions of sesquiterpenoids with two oxidations (produced by the action of TPS and two oxidative enzymes). Peaks corresponding to a representative compounds agarofuran, dihydroagarofuran, γ-eudesmol, and agarospirol are shown in the total ion chromatogram. FIG.6A to FIG.6D demonstrate the production of unoxidized oud oil sesquiterpene compounds by an engineered microbial strains and engineered enzymes. FIG.6A shows a comparison of a total ion current (TIC) chromatogram of oud oil, an extracted-ion chromatogram (EIC) oud oil and TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing the Aquilaria sinensis AsTPS10 (TPS21, SEQ ID NO: 21) enzyme. FIG. 6B shows mass spectrometry data for the compounds identified in FIG.6A at various retention time. Some were identified as dihydroagarofuran, elemol, γ-eudesmol, and agarospirol. FIG. 6C shows a comparison of a total ion current (TIC) chromatogram of whole cell extracts of E. coli strains that are capable of producing farnesyl diphosphate and expressing Aquilaria sinensis AsTPS10 (TPS21, SEQ ID NO: 21) enzyme or one of its engineered variants TPS45 (SEQ ID NO: 145), TPS46 (SEQ ID NO: DB1 / 156198702.2 3 Attorney Docket No.: MAN-042PC / 107590-5041 146) and TPS47 (SEQ ID NO: 147). Peaks represent the compounds identified in FIG.6B. FIG.6D shows a sequence alignment of TPS21, TPS45 , TPS46, and TPS47. FIG. 7A to FIG. 7B demonstrate the improved production of γ-eudesmol by an engineered microbial strain. FIG. 7A shows a comparison of a total ion current (TIC) chromatogram of oud oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing one of the TPS21 (SEQ ID NO: 21), Zeamays ZmEDS (TPS35, SEQ ID NO: 35), Zingiber zerumbet ZSS2 (TPS36, SEQ ID NO: 36), and Salvia miltorrhiza SmSTPS1 (TPS42, SEQ ID NO: 42) enzymes. FIG.7B shows a mass spectrometry-based identification of γ-eudesmol. FIG. 8A to FIG. 8C demonstrate the production of α-guaiene and α-bulnesene constituents of oud oil by an engineered microbial strain. FIG.8A shows a comparison of a total ion current (TIC) chromatogram of oud oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing one of the Aquilaria sinensis AsTPS1 (TPS5, SEQ ID NO: 5) and Aquilaria malaccensis AmTPS1 (TPS6, SEQ ID NO: 6) enzymes. FIG.8B shows a mass spectrometry-based identification of α-guaiene to be the compound marked by the number 10 in FIG.8A. FIG.8C shows a mass spectrometry-based identification of α-bulnesene to be the compound marked by the number 11 in FIG.8A. FIG. 9A to FIG. 9D demonstrate the production of agarofuran by an engineered microbial strain. FIG.9A shows a comparison of a total ion current (TIC) chromatogram of oud oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing the TPS21 (SEQ ID NO: 21) enzyme, and without a cytochrome P450 enzyme (CYP), or expressing one of Aquilaria sinensis AsCYP18 (CYP89, SEQ ID NO: 133) and Aquilaria sinensis AsCYP20 (CYP91, SEQ ID NO: 135). FIG.9B shows a mass spectrometry-based identification of agarofuran to be the compound marked by the number 12 in FIG.9A. FIG.9C and FIG.9D show two other hydroxylated products to be the compound marked by the numbers 13 and 14, respectively, in FIG.9A. FIG.10A and FIG. 10B demonstrate the semi-synthetic production of agarofuran. FIG. 10A shows a schematic representation of a proposed path of in vitro conversion of compound 14 (See FIG.9A and FIG.9D) to agarofuran. FIG.9B shows a comparison of a DB1 / 156198702.2 4 Attorney Docket No.: MAN-042PC / 107590-5041 total ion current (TIC) chromatogram of purified compound 14 with the reaction products of reactions with ethyl acetate alone for 2.5 hours, 40 mM para-toluene sulfonic acid in ethyl acetate for 2.5 hours, and 40 mM para-toluene sulfonic acid in ethyl acetate for 22 hours. DETAILED DESCRIPTION Cypriol oil, which is an essential oil extracted from Cyperus scariosus plant, comprises a mixture of sesquiterpenes, including α-copaene, elemene, cyprene, caryophyllene, humulene, rotundene, β-selinene and α-selinene. See FIG.1. Similarly, Oud oil, which is an essential oil extracted from a resin secreted by Aquilaria trees infected with Phialophora parasitica mold, comprises a mixture of sesquiterpenes, including agarofuran, dihydroagarofuran, γ-eudesmol, agarospirol, α-guaiene and α-bulnesene. See FIG.5B. The unique blend of sesquiterpenes and sesquiterpenoids present in these essential oils confer unique aromas on these essential oils. The present disclosure in various aspects provides host cells and methods for making sesquiterpene components of cypriol oil or oud oil. For example, in various aspects, the invention provides host cells producing unoxidized sesquiterpene components of cypriol oil or oud oil. In some embodiments, the host cells express one or more terpene synthase (TPS) enzymes. In some embodiments, the invention provides host cells producing oxidized sesquiterpene components of cypriol oil or oud oil. In these embodiments, the host cells further expresses one or more cytochrome P450 (CYP) enzymes. In some aspects, the present disclosure provides host cells and methods for producing one or more sesquiterpene components of cypriol oil. In some embodiments, the method comprises providing a host cell producing farnesyl diphosphate, and expressing a heterologous cypriol oil sesquiterpene biosynthesis pathway, the heterologous biosynthesis pathway comprising one or more terpene synthase (TPS) enzymes. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence having at least 70% sequence identity (or at least 80%, at least 85%, at least 90%, at least 95%, or at least 97% sequence identity) to an amino acid sequence selected from SEQ ID NOs: 1-44, 167, 168, and 169. In some embodiments, the heterologous biosynthesis pathway synthesizes unoxidized components of cypriol oil (e.g., α-copaene, elemene, cyprene, caryophyllene, DB1 / 156198702.2 5 Attorney Docket No.: MAN-042PC / 107590-5041 humulene, rotundene, β-selinene and α-selinene). In some embodiments, the heterologous biosynthesis pathway synthesizes at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight or more unoxidized components of cypriol oil. The one or more TPS enzymes comprises a TPS enzyme having an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the TPS enzyme comprises the amino acid sequence of SEQ ID NO: 2, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. In some embodiments, the heterologous biosynthesis pathway produces β-selinene and / or α-selinene. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme having an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 36, 41 and 43. In some embodiments, the TPS enzyme comprises an amino acid sequence selected from SEQ ID NOs: 36, 41 and 43, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. In some embodiments, the heterologous biosynthesis pathway synthesizes oxidized components of cypriol oil (e.g., α-cyperone). In these embodiments, the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes. In some embodiments, the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes comprising an amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 45-163. In some embodiments, the one or more CYP enzymes comprises a CYP enzyme having an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 59, 72, and 93. In some embodiments, the CYP enzyme comprises an amino acid sequence selected from SEQ ID NOs: 59, 72, and 93, DB1 / 156198702.2 6 Attorney Docket No.: MAN-042PC / 107590-5041 optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. In some aspects, the present disclosure provides host cells and methods for producing one or more sesquiterpene components of oud oil. In some embodiments, the method comprises providing a host cell producing farnesyl diphosphate, and expressing a heterologous oud oil sesquiterpene biosynthesis pathway, the heterologous biosynthesis pathway comprising one or more terpene synthase (TPS) enzymes. In some embodiments, the one or more TPS enzyme comprises a TPS enzyme comprising an amino acid sequence having at least 70% sequence identity (or at least 80%, at least 85%, at least 90%, at least 95%, or at least 97% sequence identity) to an amino acid sequence selected from SEQ ID NOs: 1-44, 167, 168, and 169. In some embodiments, the heterologous biosynthesis pathway synthesizes unoxidized components of oud oil (e.g., α- dihydroagarofuran, elemol, γ-eudesmol, agarospirol, α-guaiene and α-bulnesene). In some embodiments, the heterologous biosynthesis pathway synthesizes at least one, or at least two, or at least three, or at least four, or at least five, or at least six or more unoxidized components of oud oil. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NOs: 21, 35, 36, 42, 167, 168, and 169. In some embodiments, the TPS comprises the amino acid sequence selected from SEQ ID NOs: 21, 35, 36, 42, 167, 168, and 169, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO: 21. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme having a mutation of one or more amino acid residues with respect to SEQ ID NO: 21 DB1 / 156198702.2 7 Attorney Docket No.: MAN-042PC / 107590-5041 selected from N14, I21, K35, S67, N79, R83, F100, S112, D126, I135, L152, Y168, V173, S180, K204, L213, N215, V241, T261, I268, G269, C275, G279, F292, K327, G365, T369, F385, R391, N394, I409, D412, S427, L428, T434, A438, T471, E489, Q492 and C510. In some embodiments, N14 is substituted with a charged amino acid selected from Asp, Glu, Arg, Lys, and His. In some embodiments, I21 is substituted with an amino acid selected from Val, Leu, Ala, and Gly. In some embodiments, K35 is substituted with a negatively charged amino acid selected from Glu and Asp. In some embodiments, S67 is substituted with a non- polar amino acid selected from Leu, Ile, Ala, and Val. In some embodiments, N79 is substituted with a charged amino acid selected from Glu, Asp, Arg, Lys, and His. In some embodiments, R83 is substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val. In some embodiments, F100 is substituted with an amino acid selected from Gly, Ala, Ile, Leu, and Val. In some embodiments, S112 is substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val. In some embodiments, D126 is substituted with Glu. In some embodiments, I135 is substituted with an amino acid selected from Ser, Thr, Tyr, and Cys. In some embodiments, L152 is substituted with an amino acid selected from Val, Ile, Ala and Gly. In some embodiments, Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp. In some embodiments, V173 is substituted with an amino acid selected from with Ala and Gly. In some embodiments, S180 is substituted with a non-polar amino acid selected from Pro, Ala, Gly and Val. In some embodiments, K204 is substituted with an amino acid selected from Arg and His. In some embodiments, L213 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln. In some embodiments, N215 is substituted with an amino acid selected from Thr, Ser, and Gln. In some embodiments, V241 is substituted an amino acid selected from with Ala and Gly. In some embodiments, T261 is substituted with an amino acid selected from Val, Ile, Leu, Ala and Gly. In some embodiments, I268 is substituted with an amino acid selected from Leu, Val, Ala and Gly. In some embodiments, G269 is substituted with an amino acid selected from Ala, Val, Ile, and Leu. In some embodiments, C275 is substituted with an amino acid selected from Gln, Asn, Ala, Gly, and Val. In some embodiments, G279 is substituted with an amino acid selected from Ala, Val, Ile, and Leu. In some embodiments, F292 is substituted with an amino acid selected from Ile, Leu, Val, and Ala. In some embodiments, K327 is substituted with a negatively charged amino acid selected from Glu DB1 / 156198702.2 8 Attorney Docket No.: MAN-042PC / 107590-5041 and Asp. In some embodiments, G365 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His. In some embodiments, T369 is substituted with an amino acid selected from Ile, Leu, Val, Ala, and Gly. In some embodiments, F385 is substituted with an amino acid selected from Leu, Ile, Val, and Ala. In some embodiments, R391 is substituted with an amino acid selected from Leu, Ile, Val, and Ala. In some embodiments, N394 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp. In some embodiments, I409 is substituted with an amino acid selected from Met, Leu, and Val. In some embodiments, D412 is substituted with a polar amino acid selected from Asn, Gln, Ser, and Thr. In some embodiments, S427 is substituted with an amino acid selected from Ile, Leu, Val, and Ala. In some embodiments, L428 is substituted with an amino acid selected from Val, Ile, Ala and Gly. In some embodiments, T434 is substituted with an amino acid selected from Ile, Leu, Val, and Ala. In some embodiments, A438 is substituted with an amino acid selected from Ile, Leu, Val, and Ala. In some embodiments, T471 is substituted with Ala, Gly, and Val. In some embodiments, E489 is substituted with an amino acid selected from Gly, Ala, Ile, Leu, and Val. In some embodiments, Q492 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His. In some embodiments, C510 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln. In some embodiments, the TPS enzyme comprises one or more mutations (e.g., 2, 3, 4, 5, 6, 7.8, 9, 10, or more mutations) with respect to SEQ ID NO: 21 selected from N14D, I21V, K35E, S67L, N79E, R83G, F100G, S112G, D126E, I135S, L152V, Y168H, V173A, S180P, K204R, L213S, N215T, V241A, T261V, I268L,G269A, C275Q, G279A, F292I, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions with respect to SEQ ID NO: 21 selected from: (i) K35 is substituted with a negatively charged amino acid selected from Glu and Asp; (ii) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (iii) I409 is substituted with an amino acid selected from Met, Leu, and Val; and (iv) T471 is substituted with Ala, Gly, and Val. In some embodiments, the TPS enzyme comprises one or more substitutions selected from K35E, Y168H, I409M, and T471A. In some embodiments, the TPS enzyme comprises K35E, Y168H, I409M, and T471A substitutions. DB1 / 156198702.2 9 Attorney Docket No.: MAN-042PC / 107590-5041 In some embodiments, the TPS enzyme comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO: 167. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions with respect to SEQ ID NO: 21 selected from: (i) K35 is substituted with a negatively charged amino acid selected from Glu and Asp; (ii) S112 is substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val; (iii) I135 is substituted with an amino acid selected from Ser, Thr, Tyr, and Cys, (iv) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (v) V173 is substituted with an amino acid selected from with Ala and Gly; (vi) S180 is substituted with a non-polar amino acid selected from Pro, Ala, Gly and Val; (vii) V241 is substituted an amino acid selected from with Ala and Gly; (viii) K327 is substituted with a negatively charged amino acid selected from Glu and Asp; (ix) F385 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (x) R391 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (xi) I409 is substituted with an amino acid selected from Met, Leu, and Val; (xii) T471 is substituted with Ala, Gly, and Val; and (xiii) Q492 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His. In some embodiments, the TPS enzyme comprises one or more substitutions selected from K35E, S112G, I135S, Y168H, V173A, S180P, V241A, K327E, F385L, R391L, I409M, T471A, and Q492R. In some embodiments, the TPS enzyme comprises K35E, S112G, I135S, Y168H, V173A, S180P, V241A, K327E, F385L, R391L, I409M, T471A, and Q492R. In some embodiments, the TPS enzyme comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO: 168. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions with respect to SEQ ID NO: 21 selected from: (i) N14 is substituted with a charged amino acid selected from Asp, Glu, Arg, Lys, and His; (ii) I21 is substituted with an amino acid selected from Val, Leu, Ala, and Gly; (iii) K35 is substituted with a negatively charged amino acid selected from Glu and Asp; (iv) S67 is substituted with a non-polar amino acid selected from Leu, Ile, and Val; (v) R83 is DB1 / 156198702.2 10 Attorney Docket No.: MAN-042PC / 107590-5041 substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val; (vi) F100 is substituted with an amino acid selected from Gly, Ala, Ile, Leu, and Val; (vii) S112 is substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val; (viii) D126 is substituted with Glu; (ix) I135 is substituted with an amino acid selected from Ser, Thr, Tyr, and Cys, (v) (x) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (xi) V173 is substituted with an amino acid selected from with Ala and Gly; (xii) S180 is substituted with a non-polar amino acid selected from Pro, Ala, Gly and Val; (xiii) N215 is substituted with an amino acid selected from Thr, Ser, and Gln; (xiv) V241 is substituted an amino acid selected from with Ala and Gly; (xv) G269 is substituted with an amino acid selected from Ala, Val, Ile, and Leu; (xvi) K327 is substituted with a negatively charged amino acid selected from Glu and Asp; (xvii) G365 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His; (xviii) T369 is substituted with an amino acid selected from Ile, Leu, Val, Ala, and Gly; (xix) F385 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (xx) R391 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (xxi) N394 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (xxii) I409 is substituted with an amino acid selected from Met, Leu, and Val; (xxiii) D412 is substituted with a polar amino acid selected from Asn, Gln, Ser, and Thr; (xxiv) S427 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; (xxv) L428 is substituted with an amino acid selected from Val, Ile, Ala and Gly; (xxvi) T434 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; (xxvii) A438 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; (xxviii) T471 is substituted with Ala, Gly, and Val; (xxvxi) E489 is substituted with an amino acid selected from Gly, Ala, Ile, Leu, and Val; (xxx) Q492 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His; and (xxxi) C510 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln. In some embodiments, the TPS enzyme comprises one or more substitutions with respect to SEQ ID NO: 21 selected from N14D, I21V, K35E, S67L, R83G, F100G, S112G, D126E, I135S, Y168H, V173A, S180P, N215T, V241A, G269A, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S. In some embodiments, the TPS enzyme comprises N14D, I21V, K35E, S67L, R83G, F100G, S112G, D126E, I135S, Y168H, V173A, S180P, N215T, V241A, DB1 / 156198702.2 11 Attorney Docket No.: MAN-042PC / 107590-5041 G269A, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S. In some embodiments, the TPS enzyme comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO: 169. In some embodiments, the TPS enzyme comprises one or more substitutions with respect to SEQ ID NO: 21 selected from N14D, I21V, K35E, S67L, R83G, F100G, S112G, D126E, I135S, Y168H, V173A, S180P, N215T, V241A, G269A, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S. In embodiments, the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions with respect to SEQ ID NO: 21 selected from: (i) N79 is substituted with a charged amino acid selected from Glu, Asp, Arg, Lys, and His; (ii) L152 is substituted with an amino acid selected from Val, Ile, Ala and Gly; (iii) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (iv) K204 is substituted with an amino acid selected from Arg and His; (v) L213 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln; (vi) T261 is substituted with an amino acid selected from Val, Ile, Leu, Ala and Gly; (vii) I268 is substituted with an amino acid selected from Leu, Val, Ala and Gly; (viii) C275 is substituted with an amino acid selected from Gln, Asn, Ala, Gly, and Val; (ix) G279 is substituted with an amino acid selected from Ala, Val, Ile, and Leu; (x) F292 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; and (xi) I409 is substituted with an amino acid selected from Met, Leu, and Val. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme that comprises one or more (e.g., at least 2, 3, 4, 5, 6, or all) substitutions with respect to SEQ ID NO: 21 selected from N79E, L152V, Y168H, K204R, L213S, T261V, I268L, C275Q, G279A, F292I, and I409M. In some aspects, the present disclosure provides an engineered terpene synthase (TPS) enzyme as described above, comprising one or more mutations with respect to SEQ ID NO: 21, such as TPS enzymes comprising an amino acid sequence of SEQ ID NO: 167, 168, or 169, and their variants as described above. In embodiments, one more of such TPS enzymes is expressed in a host cell for production of oud or cypriol oil sesquiterpenoids according to this disclosure. DB1 / 156198702.2 12 Attorney Docket No.: MAN-042PC / 107590-5041 In some embodiments, the heterologous biosynthesis pathway produces elemol, γ- eudesmol, agarospirol, α-guaiene and / or α-bulnesene. In some embodiments, the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NOs: 5 or SEQ ID NOs: 6. In some embodiments, the TPS enzyme comprises the amino acid sequence of SEQ ID NOs: 5 or SEQ ID NOs: 6, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. In some embodiments, the heterologous biosynthesis pathway synthesizes oxidized components of oud oil (e.g., agarofuran). In these embodiments, the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes. In some embodiments, the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes comprising an amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 45-163. In some embodiments, the one or more CYP enzymes comprises a CYP enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO: 133 or SEQ ID NO: 135. In some embodiments, the CYP comprises the amino acid sequence selected of SEQ ID NO: 133 or SEQ ID NO: 135, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. In some aspects, the present disclosure provides host cells and methods for producing one or more sesquiterpene components of oud oil. In some embodiments, the method comprises providing a host cell producing farnesyl diphosphate, and expressing a heterologous oud oil sesquiterpene biosynthesis pathway as described herein. In some embodiments, the heterologous biosynthesis pathway synthesizes unoxidized components of oud oil (e.g., dihydroagarofuran, elemol, γ-eudesmol and agarospirol). In some embodiments, the heterologous biosynthesis pathway further synthesizes oxidized components of oud oil (e.g., agarofuran). In these embodiments, the heterologous DB1 / 156198702.2 13 Attorney Docket No.: MAN-042PC / 107590-5041 biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes as described. In some embodiments, the oxidized components of oud oil (e.g., agarofuran) is prepared via semisynthesis. Thus, in some embodiments, the method further comprises extracting a sesquiterpene compound from the culture and subjecting the sesquiterpene compound to a chemical reaction. In some embodiments, the chemical reaction converts the sesquiterpene compound to an oxidized sesquiterpene components of oud oil. In some embodiments, the oxidized sesquiterpene components of oud oil is agarofuran. In some embodiments, the chemical reaction comprises reaction with a strong acid optionally a strong organic acid. In some embodiments, the strong acid an aryl sulfonic acid. In some embodiments, the aryl sulfonic acid is p-toluene sulfonic acid. In some embodiments, the strong acid (e.g., p-toluene sulfonic acid) is used at a concentration of about 5 mM, or about 10 mM, or about 20 mM, or about 30 mM, or about 40 mM, or about 50 mM, or about 60 mM, or about 75 mM, or about 100 mM. In some embodiments, the reaction with the strong acid (e.g., p-toluene sulfonic acid) is carried about 1 hour, or about 2 hour, or about 4 hours, or about 8 hours, or about 12 hours, or about 24 hours, or about 48 hours, or about 72 hours, or about 100 hours. The similarity of nucleotide and amino acid sequences, i.e. the percentage of sequence identity, can be determined via sequence alignments. Such alignments can be carried out with several art-known algorithms, such as with the mathematical algorithm of Karlin and Altschul (Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5877), with hmmalign (HMMER package, http: / / hmmer.wustl.edu / ) or with the CLUSTAL algorithm (Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994) Nucleic Acids Res. 22, 4673-80). The grade of sequence identity (sequence matching) may be calculated using e.g. BLAST, BLAT or BlastZ (or BlastX). A similar algorithm is incorporated into the BLASTN and BLASTP programs of Altschul et al (1990) J. Mol. Biol.215: 403-410. BLAST protein searches may be performed with the BLASTP program, score=50, word length=3. To obtain gapped alignments for comparative purposes, Gapped BLAST is utilized as described in Altschul et al (1997) Nucleic Acids Res.25: 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs are used. Sequence matching analysis may be supplemented by established homology mapping techniques like DB1 / 156198702.2 14 Attorney Docket No.: MAN-042PC / 107590-5041 Shuffle-LAGAN (Brudno M., Bioinformatics 2003b, 19 Suppl 1:154-162) or Markov random fields. In some embodiments, the microbial host cell is also engineered to express or overexpress one or more enzymes in the methylerythritol phosphate (MEP) and / or the mevalonic acid (MVA) pathway to catalyze isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) from glucose or other carbon source. In some embodiments, the microbial host cell is engineered to express or overexpress one or more enzymes of the MEP pathway. In some embodiments, the MEP pathway is increased and balanced with downstream pathways by providing duplicate copies of certain rate-limiting enzymes. The MEP (2-C-methyl-D-erythritol 4-phosphate) pathway, also called the MEP / DOXP (2-C-methyl-D-erythritol 4-phosphate / l-deoxy-D-xylulose 5- phosphate) pathway or the non-mevalonate pathway or the mevalonic acid-independent pathway refers to the pathway that converts glyceraldehyde-3-phosphate and pyruvate to IPP and DMAPP. The pathway typically involves action of the following enzymes: 1-deoxy-D- xylulose-5-phosphate synthase (Dxs), 1-deoxy-D-xylulose-5-phosphate reductoisomerase (IspC), 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase (IspD), 4-diphosphocytidyl- 2-C-methyl-D-erythritol kinase (IspE), 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF), 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase (IspG), and isopentenyl diphosphate isomerase (IspH). The MEP pathway, and the genes and enzymes that make up the MEP pathway, are described in US 8,512,988, which is hereby incorporated by reference in its entirety. For example, genes that make up the MEP pathway include dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, and ispA. In some embodiments, the microbial host cell expresses or overexpresses of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA, or modified variants thereof, which results in the increased production of IPP and DMAPP. In some embodiments, one or more sesquiterpene components of cypriol oil or oud oil are produced at least in part by metabolic flux through an MEP pathway, and wherein the microbial host cell has at least one additional gene copy of one or more of dxs, ispC, ispD, ispE, ispF, ispG, ispH, idi, ispA, or modified variants thereof. In some embodiments, the microbial host cell is engineered to express or overexpress one or more enzymes of the MVA pathway. The MVA pathway refers to the biosynthetic DB1 / 156198702.2 15 Attorney Docket No.: MAN-042PC / 107590-5041 pathway that converts acetyl-CoA to IPP. The mevalonate pathway typically comprises enzymes that catalyze the following steps: (a) condensing two molecules of acetyl-CoA to acetoacetyl-CoA (e.g., by action of acetoacetyl-CoA thiolase); (b) condensing acetoacetyl- CoA with acetyl-CoA to form hydroxymethylglutaryl-CoenzymeA (HMG-CoA) (e.g., by action of HMG-CoA synthase (HMGS)); (c) converting HMG-CoA to mevalonate (e.g., by action of HMG-CoA reductase (HMGR)); (d) phosphorylating mevalonate to mevalonate 5- phosphate (e.g., by action of mevalonate kinase (MK)); (e) converting mevalonate 5- phosphate to mevalonate 5-pyrophosphate (e.g., by action of phosphomevalonate kinase (PMK)); and (f) converting mevalonate 5-pyrophosphate to isopentenyl pyrophosphate (e.g., by action of mevalonate pyrophosphate decarboxylase (MPD)). The MVA pathway, and the genes and enzymes that make up the MVA pathway, are described in US 7,667,017, which is hereby incorporated by reference in its entirety. In some embodiments, the microbial host cell expresses or overexpresses one or more of acetoacetyl-CoA thiolase, HMGS, HMGR, MK, PMK, and MPD or modified variants thereof, which results in the increased production of IPP and DMAPP. In some embodiments, one or more sesquiterpene components of cypriol oil or oud oil are produced at least in part by metabolic flux through an MVA pathway, and wherein the microbial host cell has at least one additional gene copy of one or more of acetoacetyl-CoA thiolase, HMGS, HMGR, MK, PMK, MPD, or modified variants thereof. In some embodiments, the microbial host cell is engineered to increase production of IPP and DMAPP from glucose as described in US Patent Nos.10,662,442 and 10,480,015, the contents of which are hereby incorporated by reference in their entireties. For example, in some embodiments the microbial host cell overexpresses MEP pathway enzymes, with balanced expression to push / pull carbon flux to IPP and DMAPP. In some embodiments, the microbial host cell is engineered to increase the activity of Fe-S cluster proteins (including by heterologous expression of one or more oxidoreductases), so as to support higher activity of IspG and IspH, which are Fe-S enzymes. In some embodiments, the host cell is engineered to overexpress IspG and IspH, so as to provide increased carbon flux to 1-hydroxy-2-methyl- 2-(E)-butenyl 4-diphosphate (HMBPP) intermediate, but with balanced expression to prevent accumulation of HMBPP at an amount that reduces cell growth or viability, or at an amount that inhibits MEP pathway flux. In some embodiments, the host cell is engineered DB1 / 156198702.2 16 Attorney Docket No.: MAN-042PC / 107590-5041 to downregulate the ubiquinone biosynthesis pathway, e.g., by reducing the expression or activity of IspB, which uses IPP and FPP substrate. In still other embodiments, microbial cells expressing FPPS, TPS, and CYP co- express an isoprenol utilization pathway as described in US 2019 / 0367950, which is hereby incorporated by reference in its entirety. Such cells can produce IPP and DMAPP precursors from prenol and / or isoprenol substrate provided to the culture. In some embodiments, the microbial host cell is a bacterium selected from Escherichia spp., Bacillus spp., Corynebacterium spp., Rhodobacter spp., Zymomonas spp., Vibrio spp., and Pseudomonas spp. For example, in some embodiments, the bacterial host cell is a species selected from Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis, Vibrio natriegens, or Pseudomonas putida. In some embodiments, the bacterial host cell is E. coli. In some embodiments, the microbial host cell is a species of Saccharomyces, Pichia, or Yarrowia, including, but not limited to, Saccharomyces cerevisiae, Pichia pastoris, and Yarrowia lipolytica. Manipulation of the expression of genes and / or proteins, including gene modules, can be achieved through various methods. For example, expression of genes or operons can be regulated through selection of promoters, such as inducible or constitutive promoters, with different strengths (e.g., strong, intermediate, or weak). Several non-limiting examples of promoters of different strengths include Trc, T5 and T7. Additionally, expression of genes or operons can be regulated through manipulation of the copy number of gene or operon in the cell. In some embodiments, expression of genes or operons can be regulated through manipulating the order of the genes within a module, where the genes transcribed first are generally expressed at a higher level. In some embodiments, expression of genes or operons is regulated through integration of one or more genes or operons into the chromosome. Optimization of protein expression can also be achieved through selection of appropriate promoters and ribosomal binding sites. In some embodiments, this may include the selection of high-copy number plasmids, or single-, low- or medium-copy number DB1 / 156198702.2 17 Attorney Docket No.: MAN-042PC / 107590-5041 plasmids. The step of transcription termination can also be targeted for regulation of gene expression, through the introduction or elimination of structures such as stem-loops. Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA. The heterologous DNA is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell. In some embodiments, endogenous genes of the microbial host cell are edited. Editing can modify endogenous promoters, ribosomal binding sequences, or other expression control sequences, and / or in some embodiments modifies trans-acting and / or cis- acting factors in gene regulation. Genome editing can take place using CRISPR / Cas genome editing techniques, or similar techniques employing zinc finger nucleases and TALENs. In some embodiments, the endogenous genes are replaced by homologous recombination. In some embodiments, genes are overexpressed at least in part by controlling gene copy number. While gene copy number can be conveniently controlled using plasmids with varying copy number, gene duplication and chromosomal integration can also be employed. For example, a process for genetically stable tandem gene duplication is described in US 2011 / 0236927, which is hereby incorporated by reference in its entirety. In various embodiments, the microbial host cell is cultured at a temperature between 22° C and 37° C. While commercial biosynthesis in bacteria such as E. coli can be limited by the temperature at which overexpressed and / or foreign enzymes (e.g., enzymes derived from plants) are stable, recombinant enzymes (including the terpenoid synthase) may be engineered to allow for cultures to be maintained at higher temperatures, resulting in higher yields and higher overall productivity. In some embodiments, the host cell is a bacterial host cell, and culturing is conducted at about 22° C or greater, about 23° C or greater, about 24° C or greater, about 25° C or greater, about 26° C or greater, about 27° C or greater, about 28° C or greater, about 29° C or greater, about 30° C or greater, about 31° C or greater, about 32° C or greater, about 33° C or greater, about 34° C or greater, about 35° C or greater, about 36° C or greater, or about 37° C. DB1 / 156198702.2 18 Attorney Docket No.: MAN-042PC / 107590-5041 The sesquiterpene components of cypriol oil or oud oil can be extracted from media and / or whole cells, and the sesquiterpene components of cypriol oil or oud oil recovered. In some embodiments, both the oxidized and / or unoxidized sesquiterpene components of cypriol oil or oud oil product are recovered and optionally enriched by fractionation (e.g. fractional distillation). The oxidized and / or unoxidized sesquiterpene components of cypriol oil or oud oil can be recovered by any suitable process, including partitioning the desired product into an organic phase. The production of the desired product can be determined and / or quantified, for example, by gas chromatography (e.g., GC-MS). The desired product can be produced in batch or continuous bioreactor systems. Production of product, recovery, and / or analysis of the product can be done as described in US 2012 / 0246767, US 10,501,760, US 10,934,564, which are hereby incorporated by reference in its entirety. For example, in some embodiments, oxidized and / or unoxidized sesquiterpene components of cypriol oil or oud oil are extracted from aqueous reaction medium, which may be done by partitioning into an organic phase, followed by fractional distillation. Sesquiterpene and sesquiterpenoid components of fractions may be measured quantitatively by GC / MS, followed by blending of the fractions. In some embodiments, the microbial host cells and methods disclosed herein are suitable for commercial production of sesquiterpene components of cypriol oil or oud oil, that is, the microbial host cells and methods are productive at commercial scale. In some embodiments, the size of the culture is at least about 100 L, at least about 200 L, at least about 500 L, at least about 1,000 L, at least about 10,000 L, at least about 100,000 L, or at least about 1,000,000 L. In some embodiment, the culturing may be conducted in batch culture, continuous culture, or semi-continuous culture. In some aspects, the present disclosure provides methods for making a product comprising the sesquiterpene components of cypriol oil or oud oil, including flavor and fragrance compositions or products. In some embodiments, the method comprises producing the sesquiterpene components of cypriol oil or oud oil as described herein through microbial culture, recovering the sesquiterpene components of cypriol oil or oud oil, and incorporating the one or more components into the flavor or fragrance composition, or a consumable product (e.g., a food product, aroma therapy product or a fragrance). DB1 / 156198702.2 19 Attorney Docket No.: MAN-042PC / 107590-5041 In various embodiments, the amino acid modifications to the terpene synthase are guided by a structural model of the terpene synthase. In some embodiments, the structural model is a homology model. An exemplary homology model can be based on structural coordinates for 5-epi-aristolochene synthase. See, US 6,645,762, US 6,495,354, and US 6,645,762, which are hereby incorporated by reference in their entireties. As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. For example, reference to “a cell” includes a combination of two or more cells, and the like. As used herein, the term “about” in reference to a number is generally taken to include numbers that fall within a range of 10% in either direction (greater than or less than) of the number. EXAMPLES Example 1. Microbial Strains Expressing a Terpene Synthase (TPS) and Cytochrome P450 (CYP) Enzymes Produce Sesquiterpenoids that are Present in Cypriol Oil Cypriol oil, which is an essential oil extracted from Cyperus scariosus plant, has a unique aroma. A sample of cypriol oil was analyzed using gas chromatography-mass spectrometry (GC–MS). A total ion chromatogram indicated the presence of multiple peaks. This includes unoxidized sesquiterpene compounds, e.g., cyprene, and a oxidized sesquiterpene compounds, e.g., α-cyperone. See FIG.1 (bottom left) and FIG.2A. Apathway for the microbial biosynthesis of various components of cypriol oil wasconstructed. See FIG. 1 (top and right). In this pathway, the methylerythritol pathway (MEP), mevalonate pathway (MVA), or a combination of them is engineered in microbial cells to produce the isopentenyl diphosphate (IPP) / dimethylallyl diphosphate (DMAPP). A farnesyl diphosphate synthase (FPPS) is engineered in the microbial cells to convert the IPP / DMAPP precursors to farnesyl diphosphate (FPP). A terpene synthase (TPS) is engineered in the microbial cells to convert the FPP to unoxidized cypriol oil sesquiterpene compounds. One or more cytochrome P450 enzymes (CYP) is engineered in the microbial cells to convert the unoxidized cypriol oil sesquiterpene compounds to oxidized cypriol oil sesquiterpene compounds. DB1 / 156198702.2 20 Attorney Docket No.: MAN-042PC / 107590-5041 As described in greater detail below, an E. coli strain that is capable of producing farnesyl diphosphate and expressing a TPS was produced. The strain was cultured and a whole cell extract was analyzed using gas chromatography-mass spectrometry (GC–MS). The total ion chromatogram of the whole cell extract showed peaks corresponding to several unoxidized sesquiterpene compounds that superimpose with those with the peaks in the total ion chromatogram for cypriol oil, e.g., cyprene. See FIG. 1 (bottom left). Another E. coli strain that is capable of producing farnesyl diphosphate and expressing a TPS and a CYP was produced. The strain was cultured and a whole cell extract was analyzed using gas chromatography-mass spectrometry (GC–MS). A total ion chromatogram showed the absence of peaks corresponding to the unoxidized sesquiterpene compounds, e.g., cyprene, and appearance of new peaks corresponding to oxidized sesquiterpene compounds. See FIG. 1 (bottom left). Yet another E. coli strain that is capable of producing farnesyl diphosphate and expressing a TPS and two CYP enzymes was produced. The strain was cultured and a whole cell extract was analyzed using gas chromatography-mass spectrometry (GC–MS). A total ion chromatogram showed peaks corresponding additional oxidized sesquiterpene compounds, e.g., α-cyperone. See FIG.1 (bottom left). Example 2. Microbial Strains Expressing a Terpene Synthase (TPS) Unoxidized Sesquiterpene Compounds Found In Cypriol Oil A number of terpene synthase (TPS) genes were screened for the production of major sesquiterpene constituents of cypriol oil. Briefly, E. coli strain that is capable of producing farnesyl diphosphate and expressing the recombinant TPS enzymes were grown in overnight seed cultures at 30°C, which were used to inoculated fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with a dodecane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. These data showed that each strain showed a unique signature of abundance of various sesquiterpene compounds. FIG.2A shows a comparison of a total ion current (TIC) chromatogram of cypriol oil, an extracted-ion chromatogram (EIC) cypriol oil and TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing the Cyperus rotundus CroTPS2 (TPS2, SEQ ID NO: 2) enzyme. The total ion chromatogram of the whole cell extract showed peaks corresponding to several unoxidized sesquiterpene compounds that superimpose with those with the peaks in the total DB1 / 156198702.2 21 Attorney Docket No.: MAN-042PC / 107590-5041 ion chromatogram for cypriol oil. Compounds from peaks labeled 1-9 in in FIG.2A were purified and analyzed by mass spectrometry. FIG.2B shows the mass spectrometry data for the compounds identified at various retention time. Some of these compounds were identified as α-copaene, elemene, cyprene, caryophyllene, humulene, and rotundene (FIG. 2B). These results indicated, inter alia, that TPS2 produces the majority of unoxidized (MW 204) sesquiterpene compounds found in cypriol oil. Example 3. In vivo Production of Alpha & Beta Selinene in Cypriol Oil A number of terpene synthase (TPS) genes were screened for the production of cypriol oil constituents of β-selinene and α-selinene. Briefly, E. coli strain that is capable of producing farnesyl diphosphate and expressing the recombinant TPS enzymes were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with a dodecane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. FIG.3A shows a comparison of a total ion current (TIC) chromatogram of cypriol oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing one of CroTPS1 (TPS1, SEQ ID NO: 1), Zingiber zerumbet ZSS2 (TPS36, SEQ ID NO: 36), Zea mays ZmTPS21 (TPS41, SEQ ID NO: 41) and Leucophylum frutescens LfTPS12a (TPS43, SEQ ID NO: 43) enzymes. Interestingly, each strain showed a unique signature of abundance of various sesquiterpene compounds. As shown in FIG.3A, each of the whole cell extracts showed two prominent peaks labelled as 10 and 11. Compounds from these peaks were isolated and subjected to GC-MS. FIG.3B shows a mass spectrometry profile for compound 11. Based on the profile, compound 10 was identified to be β-selinene. FIG.3C shows a mass spectrometry profile for compound 11. Based on the profile, compound 11 was identified to be α-selinene. The compound marked by the number 4 and 6 in FIG. 3A were caryophyllene and humulene, respectively (See FIG.2B). These results indicated, inter alia, that E. coli strains expressing TPS1 produced both β-selinene and α-selinene, along with minor cypriol oil compounds caryophyllene and humulene; E. coli strains expressing TPS36 produced both β-selinene and α-selinene as DB1 / 156198702.2 22 Attorney Docket No.: MAN-042PC / 107590-5041 minor products; and E. coli strains expressing TPS41 or TPS43 produced β-selinene and α- selinene in opposite ratios compared to TPS1. Example 4. In vivo Production of Oxidized Sesquiterpenoids Found in Cypriol Oil A number of cytochrome P450 (CYP) genes were screened for the production of oxidized sesquiterpene constituents of cypriol oil. Briefly, E. coli strain that is capable of producing farnesyl diphosphate and expressing a recombinant TPS2 enzyme and a CYP enzyme were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C over 72 hours. Cells were grown in 96-well plates with a dodecane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. FIG.4A shows a comparison of a total ion current (TIC) chromatogram of cypriol oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing TPS2 (SEQ ID NO: 2), without a cytochrome P450 enzyme (CYP), or one of Cyperus rotundus CroCYP1 (CYP15, SEQ ID NO: 59), Cyperus rotundus CroCYP14 (CYP28, SEQ ID NO: 72), and Aquilaria sinensis WT-AsCYP21 (CYP49, SEQ ID NO: 93) enzymes. As shown in FIG.4A, a new peak, labeled 12, that is found in cypriol oil was formed in each of the strains. This compound in this peak was isolated and subjected to GC-MS. FIG.4B shows a mass spectrometry profile of compound in the peak 12. These results indicated, inter alia, that E. coli strains coexpressing TPS1 and one of CYP15, CYP28, and CYP49 produced an oxidized product 11 which is found in cypriol oil. Example 5. Microbial Strains Expressing a Terpene Synthase (TPS) and Cytochrome P450 (CYP) Enzymes Produce Sesquiterpenoids that are Present in Oud Oil Oud oil, which is an essential oil extracted from a resin secreted by Aquilaria trees infected with Phialophora parasitica mold, has a unique aroma. To understand the components of oud oil that present the unique aroma, different oud oil samples were analyze to identify major compounds common / unique between them. Oud oils were diluted 10,000- fold in hexanes and analyzed by GC-MS. FIG.5A and FIG.5B (bottom left) show the GC- MS analysis of three different oud oil samples to identify major compounds common / unique between them. These results showed, inter alia, that oud oil comprises a mixture of sesquiterpenes, including agarofuran, dihydroagarofuran, γ-eudesmol, agarospirol, α- DB1 / 156198702.2 23 Attorney Docket No.: MAN-042PC / 107590-5041 guaiene and α-bulnesene. A mass spectral library was built containing 109 unique sesquiterpenoid compounds. Apathway for the microbial biosynthesis of various components of oud oil wasconstructed. See FIG. 5B (bottom left). In this pathway, the methylerythritol pathway (MEP), mevalonate pathway (MVA), or a combination of them is engineered in microbial cells to produce the isopentenyl diphosphate (IPP) / dimethylallyl diphosphate (DMAPP). A farnesyl diphosphate synthase (FPPS) is engineered in the microbial cells to convert the IPP / DMAPP precursors to farnesyl diphosphate (FPP). A terpene synthase (TPS) is engineered in the microbial cells to convert the FPP to unoxidized oud oil sesquiterpene compounds. One or more cytochrome P450 enzymes (CYP) is engineered in the microbial cells to convert the unoxidized oud oil sesquiterpene compounds to oxidized oud oil sesquiterpene compounds. Shown on bottom left are GC-MS chromatograms of oud oil. Total ion chromatogram is shown on top, with three extracted ion chromatograms below showing representative fragment ions of sesquiterpenes (product of a TPS), sesquiterpenoids with one oxidation (TPS + one monooxygenase), and sesquiterpenoids with two oxidations (TPS + two oxidative enzymes), respectively. Four examples compounds are highlighted above the TIC. As described in greater detail below, an E. coli strain that is capable of producing farnesyl diphosphate and expressing a TPS was produced. The strain was cultured and a whole cell extract was analyzed using gas chromatography-mass spectrometry (GC–MS). The total ion chromatogram of the whole cell extract showed peaks corresponding to several unoxidized sesquiterpene compounds that superimpose with those with the peaks in the total ion chromatogram for oud oil, e.g., agarofuran, γ-eudesmol and agarospirol. See FIG. 5B (bottom left). Another E. coli strain that is capable of producing farnesyl diphosphate and expressing a TPS and a CYP was produced. The strain was cultured and a whole cell extract was analyzed using gas chromatography-mass spectrometry (GC–MS). A total ion chromatogram showed the reduction in heights of some of peaks corresponding to the oxidized sesquiterpene compounds, and appearance of new peaks corresponding to oxidized sesquiterpene compounds. See FIG. 5B (bottom left). Yet another E. coli strain that is DB1 / 156198702.2 24 Attorney Docket No.: MAN-042PC / 107590-5041 capable of producing farnesyl diphosphate and expressing a TPS and two CYP enzymes was produced. The strain was cultured and a whole cell extract was analyzed using gas chromatography-mass spectrometry (GC–MS). A total ion chromatogram showed peaks corresponding additional oxidized sesquiterpene compounds. See FIG.5B (bottom left). Example 6. In vivo Production of Major Sesquiterpenes in Oud Oil A number of terpene synthase (TPS) genes were screened for the production of major sesquiterpene constituents of oud oil. Briefly, E. coli strain that is capable of producing farnesyl diphosphate and expressing the recombinant TPS enzymes were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with a dodecane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. These data showed that each strain showed a unique signature of abundance of various sesquiterpene compounds. FIG.6A shows a comparison of a total ion current (TIC) chromatogram of oud oil, an extracted-ion chromatogram (EIC) oud oil and TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing the Aquilaria sinensis AsTPS10 (TPS21, SEQ ID NO: 21) enzyme. The total ion chromatogram of the whole cell extract showed peaks corresponding to several unoxidized sesquiterpene compounds that superimpose with those with the peaks in the total ion chromatogram for oud oil. Characteristic molecular weight and fragment ions of hydroxylated sesquiterpene TPS products are shown in the EIC (with molecular weights of 222, 207 and 204). Compounds from peaks labeled 1-9 in FIG. 6A were purified and analyzed by mass spectrometry. FIG. 6B shows the mass spectrometry data for the compounds identified at various retention time. Some of these compounds were identified as dihydroagarofuran, elemol, γ-eudesmol and agarospirol (FIG.6B). These results indicated, inter alia, that TPS21 produces the majority of unoxidized (MW 222) sesquiterpene compounds found in oud oil. Example 7. Engineering of Aquilaria sinensis Terpene Synthase for Improvement in Activity A number of derivatives of TPS21 (SEQ ID NO: 21) were screened for the production of oud oil constituents. Briefly, E. coli strains that are capable of producing farnesyl diphosphate and expressing the mutant derivatives of TPS21 were grown in DB1 / 156198702.2 25 Attorney Docket No.: MAN-042PC / 107590-5041 overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with an isopropyl myristate overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. Titer was calculated by comparing the total titers of the whole cell extract for all major TPS products involved using TPS21 as the reference. The Table below shows the results with all mutant derivatives of TPS21 that showed at least 1.1-fold increase in activity compared to the strain expressing TPS21. Fold increase in activity Variant th t e Based on these r (SEQ ID NO: 167), TPS46 (SEQ ID NO: 168), and TPS47 (SEQ ID NO: 169) were constructed. FIG. 6D shows a sequence alignment of Aquilaria sinensis AsTPS10 (TPS21, SEQ ID NO: 21) enzyme or one of its engineered variants TPS45 (SEQ ID NO: 145), TPS46 (SEQ ID NO: 146) and TPS47 (SEQ ID NO: 147). TPS45 has the following mutations with respect to TPS21: K35E, Y168H, I409M, and T471A. TPS46 has the following mutations with respect to TPS21: K35E, S112G, I135S, Y168H, V173A, S180P, V241A, K327E, F385L, R391L, I409M, T471A, and Q492R. TPS47 has the following mutations with respect to TPS21: N14D, I21V, K35E, S67L, R83G, F100G, S112G, D126E, I135S, Y168H, V173A, S180P, N215T, DB1 / 156198702.2 26 Attorney Docket No.: MAN-042PC / 107590-5041 V241A, G269A, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S. The production of oud oil constituents by cells expressing TPS45, TPS46, or TPS47 was studied in comparison with cells expressing TPS21. Briefly, E. coli strains that are capable of producing farnesyl diphosphate and expressing TPS45, TPS46, TPS47 or TPS21 were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with an isopropyl myristate overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. As shown in FIG. 6C, these data showed that each strain showed a unique signature of abundance of various sesquiterpene compounds. The total ion chromatogram of the whole cell extract showed peaks corresponding to several unoxidized sesquiterpene compounds that superimpose with those with the peaks in the total ion chromatogram for oud oil. Characteristic molecular weight and fragment ions of hydroxylated sesquiterpene TPS products are shown in the EIC (with molecular weights of 222, 207 and 204). Specifically, the heights of the peaks corresponding to elemol, γ-eudesmol, and agarospirol and other unoxidized sesquiterpene compounds changed between TPS45, TPS46, TPS47 and TPS21. These results indicated, inter alia, that E. coli strains expressing TPS45, TPS46, or TPS47 produced varying levels of elemol, γ-eudesmol, and agarospirol and other unoxidized sesquiterpene compounds compared to E. coli strains expressing TPS21. Example 8. Improved In vivo Production of γ-Eudesmol A number of terpene synthase (TPS) genes were screened for the improved production of oud oil constituent γ-eudesmol. Briefly, E. coli strain that is capable of producing farnesyl diphosphate and expressing the recombinant TPS enzymes were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with a dodecane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. FIG.7A shows a comparison of a total ion current (TIC) chromatogram of oud oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing one of the TPS21 (SEQ ID NO: 21), Zea DB1 / 156198702.2 27 Attorney Docket No.: MAN-042PC / 107590-5041 mays ZmEDS (TPS35, SEQ ID NO: 35), Zingiber zerumbet ZSS2 (TPS36, SEQ ID NO: 36), and Salvia miltorrhiza SmSTPS1 (TPS42, SEQ ID NO: 42) enzymes. Interestingly, each strain showed a unique signature of abundance of various sesquiterpene compounds. As shown in FIG. 6A, each of the whole cell extracts showed a peaks labelled as 3. The compound from this peak was isolated and subjected to GC-MS. FIG. 6B shows a mass spectrometry profile for compound 3. Based on the profile, compound 3 was identified to be γ-eudesmol. These results indicated, inter alia, that TPS35, TPS36 and TPS42 produce γ- eudesmol. Example 9. Production of α-Guaiene and α-Bulnesene Constituents of Oud Oil by an Engineered Microbial Strain A number of terpene synthase (TPS) genes were screened for the production of oud oil constituents of α-guaiene and α-bulnesene. Briefly, E. coli strain that is capable of producing farnesyl diphosphate and expressing the recombinant TPS enzymes were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with a dodecane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. FIG.8A shows a comparison of a total ion current (TIC) chromatogram of oud oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing one of the Aquilaria sinensis AsTPS1 (TPS5, SEQ ID NO: 5) and Aquilaria malaccensis AmTPS1 (TPS6, SEQ ID NO: 6) enzymes. As shown in FIG.8A, each of the whole cell extracts showed two prominent peaks labelled as 10 and 11. Compounds from these peaks were isolated and subjected to GC-MS. FIG. 8B shows a mass spectrometry profile for compound 11. Based on the profile, compound 10 was identified to be α-guaiene. FIG. 8C shows a mass spectrometry profile for compound 11. Based on the profile, compound 11 was identified to be α-bulnesene. These results indicated, inter alia, that E. coli strains expressing TPS5 or TPS6 produced both α-guaiene and α-bulnesene as minor products. DB1 / 156198702.2 28 Attorney Docket No.: MAN-042PC / 107590-5041 Example 10. Production of Agarofuran by an Engineered Microbial Strain A number of cytochrome P450 (CYP) genes were screened for the production of oxidized sesquiterpene constituents of oud oil, including agarofuran. Briefly, E. coli strain that is capable of producing farnesyl diphosphate and expressing a recombinant TPS21 enzyme and a CYP enzyme were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 96-well plates with a dodecane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude whole cell extracts were analyzed by GC-MS. FIG. 9A shows a comparison of a total ion current (TIC) chromatogram of oud oil, with the TIC of whole cell extract of an E. coli strain that is capable of producing farnesyl diphosphate and expressing TPS21 (SEQ ID NO: 21), without a cytochrome P450 enzyme (CYP), or one of Aquilaria sinensis AsCYP18 (CYP89, SEQ ID NO: 133) and Aquilaria sinensis AsCYP20 (CYP91, SEQ ID NO: 135) enzymes. As shown in FIG.9A, a new peak, labeled 12, that is found in oud oil was formed in each of the strains. In addition, new peaks, labeled 13 and 14, that are not found in oud oil were also formed in the strains expressing CYP89 or CYP91 (FIG.9A). Compounds from these peaks were isolated and subjected to GC-MS. As shown in FIG.9B, mass spectrometry profile of compound in the peak 12 in the strains expressing CYP89 or CYP91 shows that the peak corresponds to agarofuran. There was a smaller peak at a position corresponding to peak 12 in the strain that did not express a CYP. Mass spectrum of this peak did not match that for agarofuran. As shown in FIG.9C and FIG.9D, mass spectrometry profile of compounds in the peaks 13 and 14 in the strains expressing CYP89 or CYP91 are different compounds. These results indicated, inter alia, that E. coli strains coexpressing TPS21 and one of CYP89, and CYP91 produced an oxidized product agarofuran which is found in oud oil. Example 11. Semi-Synthetic Production of Agarofuran A semi-synthetic route was created for the production of agarofuran from the compound of peak 14, which was formed by an E. coli strain capable of producing farnesyl diphosphate and expressing TPS21 (SEQ ID NO: 21) and CYP89 (SEQ ID NO: 133), or TPS21 (SEQ ID NO: 21) and CYP91 (SEQ ID NO: 135) enzymes. FIG. 10A shows a schematic representation of a proposed path of in vitro conversion of compound 14 (See DB1 / 156198702.2 29 Attorney Docket No.: MAN-042PC / 107590-5041 FIG.9A and FIG.9D) to agarofuran. Briefly, an E. coli strain that is capable of producing farnesyl diphosphate and expressing the recombinant TPS21 and CYP89 / CYP91 enzymes were grown in overnight seed cultures at 30°C, which were used to inoculate fresh media for fermentation at 30°C for 72 hours. Cells were grown in 3 L flasks with an octane overlayer, and extraction was carried out with two equivalent volumes of ethyl acetate. Crude extract was clarified with brine, concentrated on a rotary evaporator, and the compound in peak 14 was purified on a silica column with a mobile phase of 3:1 EtOAc:hexanes. Purified product (“Starting Material” in FIG. 10B) was resuspended in ethyl acetate and incubated with stirring at room temperature for 2.5 hours with and without 40 mM para-toluene sulfonic acid. An additional reaction with 40 mM para-toluene sulfonic acid was carried out under the same conditions for 22 hours. Products were analyzed by GCMS. As shown in FIG. 10B, agarofuran (compound from peak 12) was formed synthetically upon addition of a strong acid to biosynthetically-produced compound from peak 14. Another rearrangement product (having the same molecular weight as agarofuran also (238) also formed (FIG. 10B). The abundance of agarofuran increased and the compound from peak 14 decreased over 22 hours (FIG.10B). These results indicated, inter alia, that agarofuran may be semi-synthetically prepared from a compound made by E. coli strains co-expressing TPS1 and one of CYP89, and CYP91. DB1 / 156198702.2 30 Attorney Docket No.: MAN-042PC / 107590-5041 SEQUENCES Terpene Synthase (TPS) Enzymes SEQ ID NO: 1 Cyperus rotundus CroTPS1 (TPS1) MENTNNTKGFVVVNKLGRKTANYTPSRWSEFFIDYVPPLVNVSEEWLVEGAAKMKEEIRAMITTAT DTVEMIKLIDTLEHLCVDYHFEAEINDKLQFLNRTKFDSDDLYQVALRFRLLRQHGFYVPPDVFNK FKDEFGNFKTTLIGDTKGLLSLYNAAHLLFLNETVLEDAIKFAGDNLKKTVHDVKSPLAKQVLRAL KSPLPRFMQKLEARFYIDEYGDEENSNNTILEFAKLDFIAVQREHCKELKALSLWWKDLRITETLP YARDRIVECYFWILGVYFEPCYSRARIITTKCISLLSVLDDTYDVYATLDECRLITAAFKRWDKGA VDMLPEYIRSFYLKFINSCDEIESELEPSEKFRVKYFQSQTVMMVENYLKEAEWYAQDMFPEVDIR KEVSFRSSGYIELACMSFIGMGEVATKEAFDWVTGIPKILWASAEVCRFTDDIYSNEREHKVGQCA STFDCYMKQYNATSEETTERFTSWIEDAWRTINEECIVETVPRPLIERIVNWNKTIQVIYMHCDNG YSMCENLKDYIALLFEEPLPF SEQ ID NO: 2 Cyperus rotundus CroTPS2 (TPS2) MENTNNTKDFVVVNKMGRRTANYTPSRWSEFFIDYVPPLVNVSEEWLVEGAAKMKEEIRAMITTAT DTVEMMKLIDTLEHLCVDYHFEAEINDKLQFLNRTKFDSDDLYQVALRFRLLRQHGFYVPPDVFNK FKDEFGNFKTTLIGDTKGLLSLYNAAHLLFLNETVLEDAIKFAGDNLKKVVHDLKSPLAEQVSRAL KSPLPRFMQKLEARFYIDEYGDEEDSNDTILKFAKLDFIAVQREHCKELKALSLWWKDLRITETLP YARDRIVECYFWILGVYFEPCYSRARIITTKYITLLSVLDDTYDIYATLDECRLLTIAFKRWDKGA VDMLPEYIRSFYLKFINSCNEIESELEPSEKFRLSYFKSQTEIMVDAYLQEASWYAQDIIPEVDAR KEVSVVRSSGYPELTCVSFIGMGEVATKEAFDWVTSIPKIVRASAEICRFTDDIYSSEREHKVGQC ASTFDCYMKQYNATSEETTERFTSWIEDAWRTINEECIVETVPRPLIERVVNWAKIMHVLYTHCDN GYSMCENIKDYIAVLFEEPLPF SEQ ID NO: 3 Cyperus rotundus CroTPS3d29 (TPS3) MQLEQSSATERRSANYNPTIWQDKFIQSVNVRDQHVDKNRENIYKLKREVSKMVYKEELLRDKLEL VDAIQQLGVAYHFKDEINSIIDESMDQISSVTLRGDLYETSILFRLLRNHGFSVHEDIFKSFFDDK GHCRPELASDIKGMLNLYEASYHAKEGEELLETARNFTTKHLTEFLESSNMKYNDSSLKKHVAHAL DLPLHWRMERLHTRWFIDQYKTDEHVKPALWELAILDFNVVQQVYQKELKHVSRWWTDLELYNKLP FIRDRLVENFLWTVGCSYIPDHSSYRIALTQANCMITTIDDVYDVYGSLDELEIFTDAIEQWDISV AEGLPENLRICILALFNTVKDQGDKVLRENGNIITPYLRRTWQDLCKSYLVEARWYHNGYAPTLEE DB1 / 156198702.2 31 Attorney Docket No.: MAN-042PC / 107590-5041 YLDNAWISIGGNLLLSYAYCINNYVTAEDLEKFSSGYPDIVRYSLMHLRLYNDLATSSDELQRGDI DKSIQCYMRDKNVTESVARQGIKELIWKYWRALNGEVIGNSDFEKYFRTVAFNLSRITQVIYGHDD GYAKPDGDTKDVITSLFFTPIN SEQ ID NO: 4 Cyperus rotundus CroTPS3 (TPS4) MALVLGLPSIIHVHQTHRGRPLRRLVPCAQLEQSSATERRSANYNPTIWQDKFIQSVNVRDQHVDK NRENIYKLKREVSKMVYKEELLRDKLELVDAIQQLGVAYHFKDEINSIIDESMDQISSVTLRGDLY ETSILFRLLRNHGFSVHEDIFKSFFDDKGHCRPELASDIKGMLNLYEASYHAKEGEELLETARNFT TKHLTEFLESSNMKYNDSSLKKHVAHALDLPLHWRMERLHTRWFIDQYKTDEHVKPALWELAILDF NVVQQVYQKELKHVSRWWTDLELYNKLPFIRDRLVENFLWTVGCSYIPDHSSYRIALTQANCMITT IDDVYDVYGSLDELEIFTDAIEQWDISVAEGLPENLRICILALFNTVKDQGDKVLRENGNIITPYL RRTWQDLCKSYLVEARWYHNGYAPTLEEYLDNAWISIGGNLLLSYAYCINNYVTAEDLEKFSSGYP DIVRYSLMHLRLYNDLATSSDELQRGDIDKSIQCYMRDKNVTESVARQGIKELIWKYWRALNGEVI GNSDFEKYFRTVAFNLSRITQVIYGHDDGYAKPDGDTKDVITSLFFTPIN SEQ ID NO: 5 Aquilaria sinensis AsTPS1 (TPS5) MSSAKLGSASEDVSRRDANYHPTVWGDFFLTHSSNFLENNDSILEKHEELKQEVRNLLVVETIDLP SKIQLTDEIIRLGVGYHFEMEIKAQLEKLHDHQLHLNFDLLTTSVWFRLLRGHGFSISSDVFKRFK NTKGEFETEDARTLWCLYEATHLRVDGEDILEEAIQFSRKKLEALLPELSFPLNECVRDALHIPYH LNVQRLAARQYIPQYDAEPTKIESLSLFAKIDFNMLQALHQSELREASRWWKEFDFPSKLPYARDR IAEGYYWMMGAHFEPKFSLSRKFLNRIIGITSLIDDTYDVYGTLEEVTLFTEAVERWDIEAVKDIP KYMQVIYTGMLGIFEDFKDNLINARGKDYCIDYAIEVFKEIVRSYQREAEYFHTGYVPSYDEYMEN SIISGGYKMFIILMLIGRGEFELKETLDWASTIPEMVKASSLIARYIDDLQTYKAEEERGETVSAV RCYMREYGVSEEEACKKMREMIEIEWKRLNKTTLEADEISSSVVIPSLNFTRVLEVMYDKGDGYSD SQGVTKDRIAALLRHAIEI SEQ ID NO: 6 Aquilaria malaccensis AmTPS1(TPS6) MSSAKLGSAPEDVSRRDANYHPTVWGDFFLTHSSNFLENNHSILEKHEELKQEVRNLLVVETSDLP SKIQLTDKIIRLGVGYHFEMEIKAQLEKLQDHQLHLNFDLLTTSVWFRLLRGHGFSISSDVFKRFK NTKGEFETEDARTLWCLYEATHLRVDGEDILEEAIQFSRKKLEALLPELSFPLNECVRDALHIPYH RNVQRLAARQYIPQYDAELTKIESLSLFAKIDFNMLQALHQSELREASRWWKEFDFPSKLPYARDR IAEGYYWMMGAHFEPKFSLSRKFLNRIIGITSLIDDTYDVYGTLEEVTLFTEAVERWDIEAVKDIP DB1 / 156198702.2 32 Attorney Docket No.: MAN-042PC / 107590-5041 KYMQVIYTGMLGIFEDFKDNLINARGKDYCIDYAIEVFKEIVRSYQREAEYFHTGYVPSYDEYMEN SIISGGYKMFIILMLIGRAEFELKETLDWASTIPEMVKASSLIARYIDDLQTYKAEEERGETVSAV RCYMREYGVSEEEACKKMREMIEIEWKRLNKTTLEADEISSSVVIPSLNFTRVLEVMYDKGDGYSD SQGVTKDRIATLLRHAIEI SEQ ID NO: 7 Aquilaria crassna AcTPS1 (TPS7) MSSAKLGSASEDVSRRDANYHPTVWGDFFLTHSSNFLENNDSILEKHEELKQEVRNLLVVETSDLP SKIQLTDEIIRLGVGYHFETEIKAQLEKLHDHQLHLNFDLLTTYVWFRLLRGHGFSISSDVFKRFK NTKGEFETEDAWTLWCLYEATHLRVDGEDILEEAIQFSRKKLEALLPELSFPLNECVRDALHIPYH RNVQRLAARQYIPQYDAEPTKIESLSLFAKIDFNMLQALHQSVLREASRWWKEFDFPSKLPYARDR IAEGYYWMMGAHFEPKFSLSRKFLNRIIGITPLIDDTYDVYGTLEEVTLFTEAVERWDIEAVKDIP KYMQVIHTGMLGIFEDFKDNLINARGKDYCIDYAIEVFKEIVRSYQREAEYFHTGYVPSYDEYMEN SIISGGYKMFIILMLIGRGEFELKETLDWASTIPEMVKASSLIARYIDDLQTYKAEEERGETVSAV RCYMREFGVSEEQACKKMREMIEIEWKRLNKTTLEADEISSSVVIPSLNFTRVLEVMYDKGDGYSD SQGVTKDRIAALLRHAIEI SEQ ID NO: 8 Aquilaria sinensis AsTPS2 (TPS8) MSAAQVSPAPVPAHNAAASKEEVRRSAGYHPSFWGEFFLTHTSEYAKKDDKIQKQHEELKQEVKGM LVDATTEPTKKLELIDAILRLGVGYHFEDEIQAELERIHRLGDLDCDLYNTCIWFRVLRGQGFTVS AEEFEKIKSRDGGFKAKDAKTLLCLYETTQLRIQGEEVLEEALEFSSKQLEALVPELSAPLGDYVK NSLELPYHKGMQRLEARQYIPIYEADMTKNISLLHFAKLDFNLLQALHQSEIREITRWWKDLDFKT RLPYARDRLVECYFWILGVQYEPQYSMSRLFLTKVISLASVFDDTYDIYGTFEELKLLTDAIERWE IEATDSLPSYMQILYRALLDVFDEYTDKLINAEGKDYCLYYGKEAMKGLIRSYHTEAVSFHTGYVQ NFEEYLDNSAVSSGYPMLTVEALIGMGHPYATKEALDWALKVPRVIKASSDICRLVDDLRTYKVEE ERGDAPSGVHCYMRDYNVSEEEACSKINEMIDLAWKAINEEMQKPGHLPLPILLPALNFTRMMEVL YQNIDGYTNSGGRTKDRITSLLVHPITI SEQ ID NO: 9 Aquilaria malaccensis AmTPS2 (TPS9) MSAAQVSPAPVPAHNAAASKEEVRRSAGYHPSFWGEFFLTHTSEYAKKDDKIQKQHEELKQEVKGM LVDATTEPTKKLEMIDAILRLGVGYHFEDEIQAELERIHRLGDLDCDLYNTCIWFRVLRGQGFTVS AEAFEKIKSRDGGFKAKDAKTLLCLYETTQLRIQGEEVLEEALEFSSKQLEALVPELSAPLGDYVK NSLELPYHKGMQRLEARQYIPIYEADMTKNISLLHFAKLDFNLLQALHQSEIREITRWWKDLDFKT DB1 / 156198702.2 33 Attorney Docket No.: MAN-042PC / 107590-5041 RLPYARDRLVECYFWILGVQYEPQYSMSRLFLTKVISLASVFDDTYDIYGTFEELKLLTDAIERWE IEATDSLPSYMQILYRALLDVFDEYKDKLINAQGKDYCLYYGKEAMKGLIRSYHTEAVSFHTGYVQ NFEEYLDNSAVSSGYPMLTVEALIGMGHPYATKEALDWALKVPRVIKASSDICRLVDDLRTYKVEE ERGDAPSGVHCYMRDYNVSEEEACSKIEEMIDLAWKAINEEMQKPGHLQLPILLPALNFTRMMEVL YQNIDGYTNSGGRTKDRITSLLVHPITI SEQ ID NO: 10 Aquilaria sinensis AsTPS3 (TPS10) MSPAQVVLPVSAQTQKAAASEEANRRSAGYHPSFWGEFFLTHSSGYTKSDTKIQQKHEELKQQVRG MILDAAADTSEKLELIDAALRLGVGYHFEAEIQSQLQKIHGQGSFHSDLYTACIWFRVLRGQGFTV SADVFNIMKNKDGGFEARDARTLLCLYETTHLRIQGEQVLEEALEFSRKQLGDLLAELSSPLAEYV NNSLELPYHKGMQRLEARQYIPIYESYVNKNDTLLQFAKLDFNLLQALHQSEIREITRWWKDLDFK ARLPYARDRLVECYFWILGVQYEPQYSISRVFLSKVISLASVFDDTYDIYGTFDELKLLTDAVERW EPEATDSLPGYMQILYGALLKVFEEYKDELINAGGRDYCLYYAKEAMKGLVRSYHTEAVSFHTGYV QNFEEYLDNSAVSSGYPMLTVEALIGMGAPYATRESLDWALKVPKIIKASSDICRLVDDLRTYKVE EERGDAPSGVHCYMRDYNVSEEEACTKIEEMIDLAWKAINEEIQKPNHLPLPILLPALNFARMMEV LYQNIDGYTNSGGRTKERISSLLVHPFTI SEQ ID NO: 11 Aquilaria sinensis AsTPS4a (TPS11) MSPAQVVLPVSAQTQKAAASEEANRRSAGYHPSFWGEFFLTHSSEYAKSDATVQRKHEELQQQVRR MILDAAADTSKKLELIDATLRLGVGYRFEAEIESELEKIHSQGAPDCDLYTACIWFRVLRGQGFAV SADVFTKLKNKNGGFDANDARTLLCLYETTHLRIRGEQVLEEALDFSTKQLEALLPAVSSPLAQYV KNSLELPCHKGMQRLEARQYIPIYEADSTKNDTLLHFAKLDFNLLQALHQSEIREITRWWKDLDFK TRLSYARDRLVECYFWILGVQYGPQYSMSRVFLTKVITLASVFDDTYDIYGTFDELKLLTAAVDRW EPEATESLPRYMQILYGALLEVFEEYKDKLINAEGRDYCLYYGKEAMKGLVRSYHTEAVSFHTGYV QNFEEYLDNSAVSSGYPMLTVEALIGMGAPYATKEALDWALKVPRIIKASSDICRLVDDLRTYKVE EERGDAPSGVHCYMRDYNVSEEEACEKIKEMIDLAWKSINEEIQKPNHLPLPVLLPALNFARMMEV LYQNIDGYTNSGGRTKERITSLLVDHVTI SEQ ID NO: 12 Aquilaria sinensis AsTPS4b (TPS12) MSPAQVVLPVSAQTQNTAASEEANRRSAGYHPSFWGEFFLTHSSEYEKSDATVQRKHEELQQQVRR MVMDPAADTSKKLELIDATLRLGVGYRFEGEIESELEKIHSQGTPDCDLYTACIWFRVLRGQGFTV SADVFTKLKNKDGGFDAKDAQTLLCLYETTHLRIQGEQVLEEALDFSTKQLEALLPELSSPLAEYV DB1 / 156198702.2 34 Attorney Docket No.: MAN-042PC / 107590-5041 KNSLELPYHKGMQRLEARQYIPIYEAYSTKNDALLHFAKLDFNLLQALHQSEIREITRWWKDLDFK TRLSYARDRLVECYFWILGVQYEPQYSMSRIFLTKVISLASVFDDTYDIYGTFDELKLLTAAVDRW EPEATDSLPGYMQILYGALSEVFEEYKDMLINAEGRDYCLYYGKEAMKGLVRSYHTEAVSFHTGHV QNFEEYLDNSAVSSGYPMLTVEALIGMGAPYATKEALDWALKVPRIIKASSDICRLVDDLRTYKVE EERGDAPSGVHCYMKDYNVSEEEACERIKEMIDLAWKAINEEIQKPNHLPLPVLLPALNFARMMEV LYQNIDGYTNSGGRTKERITSLLVHPVTI SEQ ID NO: 13 Aquilaria sinensis AsTPS5 (TPS13) MSCFSGLASAASGPVPVTVSPGAVKPGNYSRPSADFPPDIWGDHFLAYSSTADLGNESDEMLEHKK LKQEVRNMIVAGIEDPARNLDLVDWIQRLGVSYHFQAEIEELFLKMLGKLDEYVEKHADDLHKISL CFRLLRQQGYKVSSEMFTSFKDDEGNFKESLNEDVEGLLSLYEASHLQIHGEDILEQALSFSVTQL EFIIKDLSTCLLSTRVNHALEYPIRKNFPRLGARFYISTYQDMPSHNQKILKFSKLDFNILQKEHQ RELSKISRWWKEMDVKRKFPFARHRIVECYFWILGIYFEPQYAQGREITTKAIALTSILDDIYDAY GTPEELDLLTTAIQGWDSNLGTQLPEYMKTYYLLLLDVYNRIADDLGMQGKSYCVDYVKEEKKKVA KAYNSEAKWYHQNYTPTMEEYMQVALSSSGYPFLSTVSFIGMGKLATRDCYEWVINMPKLILATAT ISRLQDDIVSHEFEQKRGHSASSVECYMKQYGVTRQEAVEQLSKQVNDAWKDVNVECMHPTAVPMQ LLMPLLNLVRVAHVIYNKHDGYTNPHASKDLVASLFLHPIPY SEQ ID NO: 14 Aquilaria malaccensis AmTPS17 (TPS14) MSCFSGLASAASVPVPVTISPGTVNPGNCSRRSADFPPDIWGDHFLAYSSTADLGNESDEMLEHKK LKQEVRNMIVAGIEDPARNLDLVDWIQRLGVSYHFQEEIEELLLKMLEKLDEYVENNADDLHKISL CFRLPRQQGYKVSSEMFNSFKDDEGNFKESLKKDIEGLLSFYEASHLQVHGEDILEEALCFSVSQL KFLIKDLSTCPLSTRVNHALKYPIRKNLSRVGARFYISTYQDMPSHNQKVLKFSKLDFNILQKEHQ RELSQISRWWKEMDIKRKFPFARHRIVECYFWILGIYFEPQYALGREITTKAIALISILDDIYDAY GTPKELELLTTAIEGWDSNLGTQLPEYIKTYYLLLLDVYNRIADDLGMQGKSYCVDYVKEEKKKVA KAYNREVKWYHQNYTPTMEEYMQVALPSSGYPFLSTISFIGMGDVATRDSYEWVVNSPKLILASSR ICRLQDDIIGHEFEQKRGHSASSVECYMKQYGVTRQKAVEQLSKQVNDAWKDINEECMRPTAVEMQ LLMPLLNLVRVIHVLYSNHDGYTNPHASKDLVASLLLHPIPY SEQ ID NO: 15 Aquilaria sinensis AsTPS6 (TPS15) MSCFQALLPAAAPAAFPVPQRAGAATNRSCLRDSELGKTSAVVRNRVRAKAVTQDDQPRRLADFHP DIWGDRFLAPSPNASANEMEILEHEKLKQEVRKMIIAGIEDPSKNMDLVDTIQRLGVSYHFEEEIK DB1 / 156198702.2 35 Attorney Docket No.: MAN-042PC / 107590-5041 ELLERMHRNLDAFVKDNADDLHQISLCFRLLRQQGYKVSSEMFNSFKYDEGNFKQSLTEDGKGLLS LYEATHLRIHGEDILEKAFTFSVAQLKSVALNNASMLLTRQINHALRFPIQRTIPRLVARFYISMY QEKPSHNPRVLKFSKLDFNILQKQYQKELSQISRWWKELDVKTNFPFARDRMVEVYFCMMQIYFEP QYALGRAILSKAIAMASIQDDIYDAYGTPEELEPLTEAIQRWDPDVANQLPGYIKNFYRALLGLYN EIEDEIAAEGKLYKVQYAKEEVKRVAKAYMREVKWFQQNYTPTMDEYMEVGLVTSGCTPILTVAFA GVLGEIVTKTTFEWLVNFPKIVVATSTLGRLYDDLADHVHEIEQVRGHVPSAVECYMKQYGVTEHE AVEELSKLMEGAWKDINEEYLGLSKTIPMSLLTPIINYVRLGPVLYHERDGFTNPHAVKDFVTSIL VDPIPY SEQ ID NO: 16 Aquilaria sinensis AsTPS7 (TPS16) MSQFNALVSTTTSAVLPVRTNRSCFRAPALGTTSVVVPNRVWAKAVNHDDHPRQSAGFHPDIWGDL FLASENEMLEHEKLKQDVRKMIITASEDPARNLGLVDSIQRLGVSYHFEEEIKELLQKMHDNYDRY RKDNADNLSNISLCFRLLRQEGFRISSDMFSRFKDHEGNFNVSQEDIEGLLALHEATQLRVHGENI LDEALVFTLAQLTSILVNNSNSLLSKQIKHYLRYPIRKNIPRLEAKFYISIYKEKPSHSQVLLKFS KLDFNILQKQHNEELTQMSRWWKEELGVERNFPFTRDRIVESYFQVVGFYFEPQYVLGRKFVGKAM AIAWVLDDINDVYEFAAQLPDYTRHFFLVLLDIYKEMEVEMAAQGNLYKAHYAIEEAKRLAKAYYT EAKWHHQNYTPSFKEYMQVACESAACSFLIVTFYVGMGDLATKDTFEWASSFPNLVSAVSYLGRLQ DDIMTHEFEQKRGHLPSSVELYMKDYGVTKQEAVDEFWRQIDRAWKDINEECLNPTPVPFPLLMPI INLLRVVHVVYNDCDGYTNPHVIKDFVTSTFLDPIPY SEQ ID NO: 17 Aquilaria sinensis AsTPS8a (TPS17) MAPETNRPLAQFQADIWEEQFVSSPLLHLETEQASEHQKLKEQVRELLLAGLDKPWEQLDLIDSVQ RLGVAYHFEDEIENLLQGIHKNLDTCLEENDNLHGISLLFRLIRQSGLTVSCDMFNKFKDESGKLK ESLSEDVIGLLSLHGAASVRLHGEDILEQAFDFSTKHLKSVAEDTSSSPKLAAQASQALKYPVQKN FPRLEAKYYISVYPLHNTPVVLTFAKLDFNILQKLHQNELREIARWWKDLDIPRRLPYARDRITEL FFWAIAIYYEPCYALGRKIWAKVIALVSLLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNEFS KELYQILLDVYDEIGDHMAKLGKSYRLDYAVEMMKRQATAYLTEARWFSQNYTPTLEEYLKLGIHT STCPVLTVSSLLGMGDDISRDAFEWVLSTPKIVIASSQIGRLVDDIVSHEFEKKRGHADTAVECYM KEYGATEQEAVKELYKRIENAWKDMNEELLRPTEVPMAVLMQVLNFTRCNHVVYVDTDAYTFPDYL KDFVAALFIHQLPLD SEQ ID NO: 18 Aquilaria sinensis AsTPS8b (TPS18) DB1 / 156198702.2 36 Attorney Docket No.: MAN-042PC / 107590-5041 MALETNRHLAHFQADIWEKHFVSSPLLHLETEQASKHQKLKEQVRELLLAGLDKPWEQLDLIDSIQ RLGIAYHFKDEIENLLLGIHKNLDTCLEENDNLHGISLLFRLLRQYGLTISCDVFNKFKNESEMLK ESLSEDVIGLLSLHEAACVRLHGENILEQALDFTTKHLKSIKEDTSSSPKLAAQASQALKYPVQKN IPRLDAKYYISVYPLHNNPVVLTFAKLDFNMLQKLHQNELREIARWWKDLDIPRRLPYARDRITEL FFGAIAVYYEPCYALGRKIWTKVIALGSLLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNECS KVLYQILLDVYDEIGEDMAKLGKSYRLDYAVEMMKRQATAYLAEARWFSQNYTPTLEEYLKLGIHT SSCPVLIVSSLLGMGDNISRDAFEWVLSTPKIVIASSQIGRLVDDIMSHEFEKKRGHADTAVECYM KKYGATKQEAVKELYMRIESAWKDINEEFLQPTEVPMAVLMRVLNFTRCNHVVYADTDAYTFPDYL KDFVAALFVHQLPLD SEQ ID NO: 19 Aquilaria malaccensis AmTPS8b (TPS19) MALETNRHLAHFQADIWEKHFVSSPLLHLETEQASKHQKLKEQVRELLLAGLDKPWEQLDLIDSIQ RLGIAYHFKDEIENLLLGIHKNLDTCLEENDNLHGISLLFRLLRQYGLTISCDVFNKFKNESEMLK ESLSEDVIGLLSLHEAACVRLHGENILEQALDFTTKHLKSITEDTSSSPKLAAQASQALKYPVQKN IPRLDAKYYISVYPLHNNPVVLTFAKLDFNMLQKLHQNELREIARWWKDLDIPRRLPYARDXITEL FFGAIAVYYEPCYALGRKIWTKVIALGSLLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNECS KVLYQILLDVYDEIGEDMAKLGKSYRLDYAVEMMKRQATAYLAEARWFSQNYTPTLEEYLKLGIHT SSCPVLIVSSLLGMGDNISRDAFEWVLSTPKIVIASSQIGRLVDDIMSHEFEKKRGHADTAVECYM KKYGATKQEAVKELYMRIESAWKDINEEFLQPTEVPMAVLMRVLNFTRCNHVVYADTDAYTFPDYL KDFVAALFVHQLPLD SEQ ID NO: 20 Aquilaria sinensis AsTPS9 (TPS20) MAPETNRPLAQFQADIWKEHFVSSPLLHLETEQASEHQKLKEQVRELLLAGLDKPWEQLDLIDSVQ RLGVAYHFEDEIENLLQGIHKNLDTCLEENDNLRGISLLFRLLRQSGLTVSCDVFNKFKDESGKLK ESLSEDAIGLLSLHEAACVRLRGEDILEQAFDFTTTHLKSIAEDTSSSPKLVAQASQALKYPVPKN IPRLEAKYYISVYPVLNTPVVLTFAKLDFNMLQKLHQNEMREIARWWKDLDIPRRLPYARDRITEL FFWAIAVYYEPCYALGRKILTKLIALTSLLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNECS KELYQILLDVYDEIGDHMAKLGKSYRLNYAVEMIKRQARIYLTEARWFSQNYTPTLEEYLKLGIHT STCPLLIPSSLLGMGDNISRDVFEWFLSTPKILTASSLITRLLDDIMTNEFEKKRGHVDTAVESYM KEYGATKQEAVKELYKRIESAWKDMNEGLLRPTEVPKAVLMRVLNFTRSSQFMYTDTDAYTFPDYL KDFVAALLVHQLPLH SEQ ID NO: 21 DB1 / 156198702.2 37 Attorney Docket No.: MAN-042PC / 107590-5041 Aquilaria sinensis AsTPS10 (TPS21) MAETNRPLAHFQANIWEEHFISSPLLHLETEQASKHQKLKEQVRELLLAGLDKPWEQLDLIDSIQR SGVAYHFEDEIENLLQRIHKNLDTCLEENDNLHFISLLFRLLRQSSLTVSCDVFNKFKDDSGKLKE SLIEDVIGLLSLHEAACMRLHGEDILEQAFDFTTTYLKSIVEDTSSSSKLAAQASQALKYPVRKNI PRLEAKYYISVYPLLNNPVVLTFAKLDFNILQKLHQNELREIVRWWKDLDIPRRLPYARDRITELF FWAIGVYYEPCYALGRKILTKVFALTSFLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNKCSK ELYQILLDVYDEIGEDMAKLGKSYRLNYAVEMMKGQARTYLTEARWFSQNYTPTFEEYLKRGINTS ACPLLTLSSLLGIGDDISRDAFEWILSTPKSLIASSLTGRLADDIMSHEFEKKRGHADTAVECYMK EYGATKQETVKELYKRIESAWKDMNEELLQPTEVPKAVLMRVLNFTRCNQVVYADADAYTFPDYLK DFVAALLVHQLPLD SEQ ID NO: 22 Aquilaria sinensis AsTPS11 (TPS22) MGSEKAAWCEESTQVEELKRAAKEVVVGVEEAPALLCLIDALHRLGIASYFQQEIDRAFCRLLPTV ASDLDLFHTSMQFRLLRQHAFPITPAVFNKFIDSNGKFMDHLAEDAEGLLSLYEASHLGFSGEQVL EEAKDFSSKNLNLLLSQNKLKGNLRGQVQLSLQLPLHWRILRVEARNFIDIYQQDVGMQHLVLLRL AKLEYNLMQSLYLDELKELTKWWTQVKAKYKPGFPREGRLVECYFWAMGAIPEREFSKGRKNLAAY GIIATVLDDMYDIQGSIEDLQKFTHAINLWDIKAVNELPDYMKVIYSAIVENGDQTARHASEHVGL NIDFLPRIKEQWESYCRAYMVEATWVREGYMPSFDDYMNNAWVSVGIVPSMVYTLLAQACAIAKYL PDCLDNWANSELFYWPCVITRLVDDLNSTDDEMERGEPNAMVCYMMERGVPQEEAKVHIRGLLNNA WTRLMELGDPQAPGHIPNSLLGVALSMCRSVQTIFLHGDWFGAQTQPKKDFLTQHLLTPIGD SEQ ID NO: 23 Aquilaria malaccensis AmTPS18 (TPS23) MGSEKADWCEGSGLVEELKQAAKEVVVGVEHAPALLRLIDALHRLGIAHYFRQEIHRAFCRLLPSV ASDLDLFHTSLQFRLLRQHAFPITPVVFDKFIDSNGKFLEHIAEDAEGLLSLYEASHLGFSGEQVL EGAKDFSSKHLNLLLSQNKLKGNLRGQVQLSLQLPLHWRMPRIEARYFIDIYQQDVGMQHLVLLRL AKLDYNLLHSLYLDELKELTEWWTKVKAKYKPGFPRENLLVECYFWAMGSVPEFEFSKGRKNLAAY GIIATILDDMYDIQGSIEDLQKFTHAIKLWDIKAVNGLPDYMKVIYSAIVENGDQTARHALEHLGL NIDFLPYIKEQWASYCRALMMEARWARERYMPSFDDYMNNAWVSIGIVPGMVYALLAQAHEVAEYL PDCLDNWANSELFYWPSFITRLLDDLTSTDDEMERGEANAMVCYMVERGAPQEEAKVHMKGLLNNA WTRLMELGNPQAPGHIPNSLLGVALSMCRSVQKIFLHGDWFGARTQPNQDWSSQVEELKQAAKELA VGVEEAPALLRLIDALHRLEITHISGKRSTAPSAAY SEQ ID NO: 24 DB1 / 156198702.2 38 Attorney Docket No.: MAN-042PC / 107590-5041 Aquilaria malaccensis AmTPS19 (TPS24) MGSGTADWCEGSSQVEELKQAAKGVVVGVEDAPALLRLIDALHRLGIAHYFRPEIHRAFCRLLPSV ASDLDLVYTSLQFRLLRQHAFPVTPVVFDKFIDSNGKFLEHLAEDTEGLLSLYEASHLGFFGEQVL EEAKDFSSKHLNLLLSQNKLKGNLRGQVQLSLQLPLHQRMPRVEARNFIDIYQQDAETQHLVLLRL AKLEYNLMHSLYLDELKELTEWWTQVKAKYKPGFPRDNRLVQCYFWAMGFVPDREFSKGRKNLAAY GIIATALDDMYDTQGSIDDLQMFTHAINLWDIKAVNELPDFMKVIYSTIVENGDQTARDALEHLGL NIDFLPYIKEQWASYCKVLMVEARWAGEGYIPSFDDYMHNARVSIGIVPGMVYAFLAQAHVIAEYL PDCLDNWANSELFFWPGFITRVLDDLMGTDDEMERGEPKAMVCYMAERGVSQEEAKVHMRGLINNA WTRLVELGDPQAPSHIPNSLLGVALSICRTVQTTYLHGDWFDVGTQPNQDCLTQHLFTPIC SEQ ID NO: 25 Aquilaria sinensis AsTPS12d50 (TPS25) MCYSTSRRSANYQPNSWDYDMLQSLADGPRLDDKIYNDRAKLLKEEVRCLIWDEEAKSSDILLLID DIQRLGLRYHFKDDIILALHRILQYEDFSDENCSISSLCYVALKFRLLRQHGFEVSQEVFKKFKGE DGKFKAKLSKDVEGVLSLYEASHFGFEGEDVIDEAKAFTRSHLTHTLKHLETTKALFKRINHALEL PFPRQMRRLEAQWTIETYASQSNANHALLQFAMFDFNFVQSAHQVELRELTRWWRALGLSDKLSFA RDRLMECFFWSVGITPEPQYGKCRKALAKVACFVTVIDDVYDVYGTLDELELFTRAVERWDVNMVD DLPDYMKLCFLALYNTINEIAFEILQERGISVISYLAKAWADLFNTFLQEAKWSSSKYTPSFQEYL GNAWLSSSGPLFMVHAYFFMSHSIKTKELESLQNYHALLRLPSLIFRLCNDYATYKAELEKGDATK GVLCYMKETGKIEEEAQEHIAYLIEEAWKKLNKEATGGSPFSKAFEETALDVARVAQCHYQYGDGH GAPDSRSKNRVSSLFIEPIPLNWLETKVNNKS SEQ ID NO: 26 Aquilaria sinensis AsTPS12 (TPS26) MALPSMSSDFLCLSNSNFSGPKLCLGKSKCPSQKQGQARTSGSGYLNIKVCYSTSRRSANYQPNSW DYDMLQSLADGPRLDDKIYNDRAKLLKEEVRCLIWDEEAKSSDILLLIDDIQRLGLRYHFKDDIIL ALHRILQYEDFSDENCSISSLCYVALKFRLLRQHGFEVSQEVFKKFKGEDGKFKAKLSKDVEGVLS LYEASHFGFEGEDVIDEAKAFTRSHLTHTLKHLETTKALFKRINHALELPFPRQMRRLEAQWTIET YASQSNANHALLQFAMFDFNFVQSAHQVELRELTRWWRALGLSDKLSFARDRLMECFFWSVGITPE PQYGKCRKALAKVACFVTVIDDVYDVYGTLDELELFTRAVERWDVNMVDDLPDYMKLCFLALYNTI NEIAFEILQERGISVISYLAKAWADLFNTFLQEAKWSSSKYTPSFQEYLGNAWLSSSGPLFMVHAY FFMSHSIKTKELESLQNYHALLRLPSLIFRLCNDYATYKAELEKGDATKGVLCYMKETGKIEEEAQ EHIAYLIEEAWKKLNKEATGGSPFSKAFEETALDVARVAQCHYQYGDGHGAPDSRSKNRVSSLFIE PIPLNWLETKVNNKS DB1 / 156198702.2 39 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 27 Aquilaria sinensis AsTPS13d50 (TPS27) MLETSSDDQNLVQQSADDNRASIWSNDYIQSMGSKYSGQANTEHINKLKEDARTMLKKAEDEPLIN QLELIDLLERLGISYHFEDEIQRNLERISQAHSKPAHYKDLYATSLEFKLLRQHGYNVTSDVFKAF KDDKIGQFKASLGKDCKGLLNLYEASFLAVEGENILEEARSFSKKYLSKQKKDGTYLSLLVAHALE LPLHWRMPRMEARWFIDLYEQCQYMNPVLLHFAKLDFNIVQATHQQDLKFVSRWWMNTGLGENLNF IRDKMIEHFLWTIGLMYEPQHGYFRRVVAQLVALITTIDDIYDTYGTLDQLQLFTDAVVRLDINEV DRLSDNYMKMSLFALHNSVSEMAAKHFKDQEVNVLPFIKKAWIDLCEAYLVEAKWYNRGYVPTMQE YINNATISVAAPLTLCYAYVLLSNPLSKDILDNFHEYSIISHCPSLITRLTNDLGTSLAEIRQADV PKSIECYVHENGCSEDEAREHVKGLIEATWKKMNKASLESPLTMPNKTFHQVAVNLARMSQFMYLH SDGHSFQDFTTYKNDMLSLLANPFEI SEQ ID NO: 28 Aquilaria sinensis AsTPS13 (TPS28) MSLSTCSRVPVAVVAVTLSQARPLRSVATNAFARASCGGGHRHKLRSVAPLETSSDDQNLVQQSAD DNRASIWSNDYIQSMGSKYSGQANTEHINKLKEDARTMLKKAEDEPLINQLELIDLLERLGISYHF EDEIQRNLERISQAHSKPAHYKDLYATSLEFKLLRQHGYNVTSDVFKAFKDDKIGQFKASLGKDCK GLLNLYEASFLAVEGENILEEARSFSKKYLSKQKKDGTYLSLLVAHALELPLHWRMPRMEARWFID LYEQCQYMNPVLLHFAKLDFNIVQATHQQDLKFVSRWWMNTGLGENLNFIRDKMIEHFLWTIGLMY EPQHGYFRRVVAQLVALITTIDDIYDTYGTLDQLQLFTDAVVRLDINEVDRLSDNYMKMSLFALHN SVSEMAAKHFKDQEVNVLPFIKKAWIDLCEAYLVEAKWYNRGYVPTMQEYINNATISVAAPLTLCY AYVLLSNPLSKDILDNFHEYSIISHCPSLITRLTNDLGTSLAEIRQADVPKSIECYVHENGCSEDE AREHVKGLIEATWKKMNKASLESPLTMPNKTFHQVAVNLARMSQFMYLHSDGHSFQDFTTYKNDML SLLANPFEI SEQ ID NO: 29 Aquilaria malaccensis AmTPS13d50 (TPS29) MVKTSSDDQNLVQQSADDNRASIWSNDYIQSMGSKYSGQANTEHINKLKEDARTMLKKAEDEPLIN QLELIDLLERLGISYHFEDEIQRNLERISQAHSKPAHYKDLYATSLEFKLLRQHGYNVTSDVFKAF KDDKSGQFKASLGKDCKGLLNLYEASFLAVEGENILEEARSFSKKYLSKQKKDGTYLSLLVAHALE LPLHWRMPRMEARWFIDLYEQCQYMNPVLLHFAKLDFNIVQATHQQDLKFVSRWWMNTGLGENLNF IRDKMIEHFLWTIGLMYEPQHGYFRRVVAQLVALITTIDDIYDTYGSLDQLQLFTDAVVRLDINEV DRLSDNYMKMSLFALHNSVSEMAAKHFKDQEVNVLPFIKKAWIDLCEAYLVEAKWYNRGYVPTMQE YINNATISVAAPLTLCYAYVLLSNPLSKDILDNFHEYSIISHCPSLITRLTNDLGTSLAEIRQADV DB1 / 156198702.2 40 Attorney Docket No.: MAN-042PC / 107590-5041 PKSIECYVHENGCSEDEAHEHVRGLIEATWKKMNKASLESPLTMPNKTFHQVAVNLARMSQFMYLH SDGHSFQDFTTYKNDMLSLLANPFEI SEQ ID NO: 30 Aquilaria malaccensis AmTPS13 (TPS30) MSLSTCSRVPVAVVAVTLSQARPLRSVATNAFARASCGGGHRHKLRSVTAVKTSSDDQNLVQQSAD DNRASIWSNDYIQSMGSKYSGQANTEHINKLKEDARTMLKKAEDEPLINQLELIDLLERLGISYHF EDEIQRNLERISQAHSKPAHYKDLYATSLEFKLLRQHGYNVTSDVFKAFKDDKSGQFKASLGKDCK GLLNLYEASFLAVEGENILEEARSFSKKYLSKQKKDGTYLSLLVAHALELPLHWRMPRMEARWFID LYEQCQYMNPVLLHFAKLDFNIVQATHQQDLKFVSRWWMNTGLGENLNFIRDKMIEHFLWTIGLMY EPQHGYFRRVVAQLVALITTIDDIYDTYGSLDQLQLFTDAVVRLDINEVDRLSDNYMKMSLFALHN SVSEMAAKHFKDQEVNVLPFIKKAWIDLCEAYLVEAKWYNRGYVPTMQEYINNATISVAAPLTLCY AYVLLSNPLSKDILDNFHEYSIISHCPSLITRLTNDLGTSLAEIRQADVPKSIECYVHENGCSEDE AHEHVRGLIEATWKKMNKASLESPLTMPNKTFHQVAVNLARMSQFMYLHSDGHSFQDFTTYKNDML SLLANPFEI SEQ ID NO: 31 Aquilaria sinensis AsTPS14 (TPS31) MDAAASNFAAISKINQLRLQPSILPSATTTTPRKLLRVNFPRPSTVPLITESAGSIHAGRLEYFKH VLRKMGHRRQHGYESLAMVDAVQRVGLDHHFHDEIEEVLHNHHFIASLADGVASPELQSLHEVALS FRLLRQQGYPVPADVFGRFKDKHGRFNQEVGKDVKGLMELYEASQLGVDGEDIIAEAEAYSSQFLR QLEPLLDHHQAIAVRHTLTQPHHKNIARFNALNYLHNYQGANTWVHVLQDLAKLDFDLVQSLYKQE LQQVSKWWWDMGLSKELEHVRDQPVKWYTFGIACIEDPSLSQERVELTKPVAMIYAIDDVFDVYGT IEELTFFTEAVDRWDYALVEKLPDYMRLCFRVLDDMINEISHRVETLHGWNPARSLRKPWGIICKA FLVEAKWFHSKTLPKSEEYLANGIRSSGVPVILVHLFFLLGQNINTNTVEEIDRLPEIISSTATIL RLWNDVGSARVEDREGNDGSFVEVYMKEHGKEGREEAAKAMDEAMRRVSEAWKRLNRENLSPSPFS SSPFSRGSLNLARLVPLLYSFSERRSLPLLEEFINCVIYEPATL SEQ ID NO: 32 Aquilaria sinensis AsTPS15 (TPS32) MASSIKAFFAFPSFTAISRSNQPQLPPIFVPTTKSSQLGLVPKSTESFYCRTIMEKLGSVHTSRVE YFRQVMRKMGDDREQAFEGLAMIDAVQRLALDHYFHDEIQELLHKHHQMLSVNAGVSSPQLHEAAL SFRLLRQHGYNVPAGMLGTFKDMKVNNKQRMDIEGLMELYEASQLGVDGEDILDDAEEFSGQHLRE MEPRLHHHQASAVRNTLRHPYHKNISSLVARNFRHGYQGPNMWIYELQELAKLDFNLVQSLHQTEL HQVSRWWKEVGLSRELELVRDQPLKWYTWSLASIEDPSLSNERVELTKPIAMVYVIDDIFDVYGTL DB1 / 156198702.2 41 Attorney Docket No.: MAN-042PC / 107590-5041 DELILFTQVLDRWDYSVAQQLPEYMKTCFKALDDITNELSDKVKMRHGWNPLCSLRKTWGSLCKAF LMEAKWFNSGTLPGAEEYLENGIVSSGVHVALVHLFFLLGQNLNRNTVDQIDSYPGVVSSSATILR LWDDLGSAKDENQEGNDGSYVECYLKEQDKGGGVGEVERARKHVKHKISNAWKRLNRECLLPNPFS SSSLAKASLNVARMVPLMYDYDEEHRLPSLHEFINSVLYEPAIL SEQ ID NO: 33 Aquilaria sinensis AsTPS16 (TPS33) MDPYSLVNPSAYDTAWLAMIPNPDQQVQPMFQNCLDWVLRSQMEDGFWGGSDGHGLPTIESLPATL ACLVVLTKWNVGKDKIERGLAFLESNTEKLLDGTYGNCPRWFAIIFPGMIELARKTGLYLPFHDHL KVRLIDVFDRRQRILEMEELIGDQCPPLLSFLDALPSSYEITDQVTNTIINKITNGDGSLYQSPSA TAQAFMLTGNSKCSHFLQALVQRCPNGVPPTYPLDEELIRLCWVNQIQRLGLAQHFTHEIETILSQ AYRSMSTWGSEQFEGKSTSLLQLGIQLQKDALAFRLLRMQGYHVSPWRFCWFMRDEEIRQLMEKNH KQLASVMLEIYRATELMFPGEMELKEAMSFSRKLLVKATRRANQARSFEQHHVAFGRLIEHEIGLP WAARMDHLEHRMWIEEKDMNALWMARASFHRLSDVANGKLLQLAMLDYEFRQFIYKNELEEVKRWS RMWGLSEMGFGREKTTYCYFAIASSFSLPYQSDMRLMVAKSAVLITVADDFFDEEGSLHDLTMLTQ SIQRWDGKGLKGHSATIFNALDNFVKETSEKYLQEQGHDITRQIREIWCETFEAWLMEAKWSKSGG MPSTEEYLATGMASIATHTVVLPTSCFLDPSFPISKLRPKEYETLTRLLMLIPRLLNDIQSYQKEK EQGKLNYVLLYLKENPEADIEDSIAHVRNILETKRQELLQHVLLDEFSDLPKLCKLFHLACVKVFQ MFFNTSNRYDSNTDMLEDIGKALYMPLNVGFFSLDSIGRDRSLGSRKEFQQVRSALVSPLILRPK SEQ ID NO: 34 Chicoria hispanica ChTPS1a (TPS34) MASSQVGDMVNGNAEPTRHLAKFPPSLWGDRFTSFTLDKQLWDKYGNEIEVLKEQVRSMVVAGGRK AAEQINLINVLERLGVSYHFEKEIEEQLEQLFAKFEDNEDYDLFTIALHFRIFRQHGYKMSCDVFN KFRDSNGEFKETVSNDVQGMLSLYEATYLKIRGEGFLDEAHAFTIAQLESLVGGPHLSSDLSEQVM HALKQSIHRGFPRLEAKHFISFYEKDASRNETLLRLAKLDFNQLQLSHREELCHIFRWWKELDLIS KVPYARDRAVECFFWSTCAYYEPQHSVGRAVLTKIMLLLSVTDDTYDAYGTYDELKLYTNAVQRWD VSAMDELPDYMKALYRALLNVYDEVERDLAKQGRDYGVHHSKEAFKEIVRSYEIEAEWFKEGYVAS FEEYMKNALVTSTGRLHTTSCFMGLEADVATTEAFEWILTKPKMVAASGAIGRLVDDVMSHDEEQE RGHVATGLDCYMKQRGVSKQEAIVELYKMIENAWRDINEEMLKPTAISMKLLIRVLNLSRISDVVY KYVDGYTHPEIIKDHVISLFEDPIPM SEQ ID NO: 35 Zea mays ZmEDS (TPS35) DB1 / 156198702.2 42 Attorney Docket No.: MAN-042PC / 107590-5041 MAPSNIVVQSSSTPPVAGGDEEFAPSVWGDFFVTYATPVSQASEQRMSERAELLKAQVRQAFDAAS MDVAGLITYVDTLERLGLDNHFRDLIGAALERIGAEELPEHGGGLHIVALRFRLLRQHGIWVSTDV FDAFREDAGGFCSSLCSDDPRGLLSLYNAAHMAVPGEVVLDDAIAFARGRLLDIISKGEVRSPVSE QITRALDIPLPRFTRRLETMHYIAEYEHEEAHDGLLLELARLNFVLVRALHLRELKDLSLWWRELY NTVKLPYARDRMVEIYFWTCGMLHEEEYSLARMFFAKTFGMVSLMDDTFDVHATLDECHKLKEAMQ RWDESEVSILPEYLRLLYIKTLSNFKEFEEILEPNKKYRMAYTKEAYKLCSKNYLKEAIWSNQKYQ PSFKEHEELSIMTSGLPMLTILTLMGFGDEATPEAFEWVSSVPEMVRAGSQVTRFLNDLSSYKLGK NKKDMPGSVETYMVENGLTGDEAAAAIAALLENRWRILNQTRMEIDHTLLPAAQVVLNMARANEII YLHGRDAYTFGADLKDLVTTLFLKQVLPL SEQ ID NO: 36 Zingiber zerumbet ZSS2 (TPS36) MEKQSLTFDGDEEAKIDRKSSKYHPSIWGDYFIQNSSLTHAKESTQRMIKRVEELKVQVKSMFKDT SDLLQLMNLINSIQMLGLDYHFENEIDEALRLIYEVDDKSYGLYETSLRFQLLRQHGYHVSADIFN KFKDDNGSFISSLNGDAKGLLSLYNVSYLGTHGETILDEAKSFTKPQLVSLMSELEQSLAAQVSLF LELPLCRRNKILLARKYILIYQEDAMRNNVILELAKLNFNLLQSLYQEELKKISIWWNDLAFAKSL SFTRDRVVEGYYWVLTIYFEPQHSRARVICSKVFAFLSIMDDIYDNYGILEECTLLTEAIKRWNPQ AIDGLPEYLKDYYLKLLKTFEEFEDELELNEKYRMLYLQDEVKALAISYLQEAKWGIERHVPSLDE HLHNSLISSGSSTVICASFVGMGEVATKEVFDWLSSFPKVVEACCVIGRLLNDIRSHELEQGRDHT ASTVESYMKEHDTNVDVACEKLREIVEKAWKDLNNESLNPTKVPRLMIERIVNLSKSNEEIYKYND TYTNSDTTMKDNISLVLVESCDYFNK SEQ ID NO: 37 Catharanthus roseus CrTPS18 (TPS37) MGREVVIMMASFVDNGVLRPIKKFPPSIWGDTFNSFEWDHEASEKLGKEMKILEKDARNMLQADTR NETVKDIITLINTFERLGLSYKFEKEIEDHLERLVHSFDYDGNQHDLLTVSLLFRILRQHGYEISS GIFKKFMDKNGEFKEEIIGNDVKGVLSLYEASYVRGHGEDILEKALVFTKGHLMRILPEIIESPLG KQVIYALEQPLHRGVPRLEARHYISIYEEDQETKNEALLRLAKLDFNLLQMLHKKEICEITRWWKK SDFMGKLPYLRDRVVECYFWAIGIYFEPKYSLARIMASKVVAMTSIMDDTYDSYGIIEELEVFTSA VERWSIEEIDRLPSYMKIAYMALLNLYEEFDEKLKEQGRSFAVQYSKERMKQLIRSYDKEAKWFYE RSDDVPSFDEYMENAISTSTYLVLMPSLLLGMESASREVFDWVMNNPSIVVASAKVGRCTDDVATY SVEKARGQPACGIEWYMKEHGVSKEETFKKFHEIVEDSWKDINKELVRSSSIPMDILVRALNQARV IDVVYKHDQDGYTHPEKVLKPHIKALLVDPISI SEQ ID NO: 38 DB1 / 156198702.2 43 Attorney Docket No.: MAN-042PC / 107590-5041 Nicotiana tabacum NtEAS (TPS38) MASAAVANYEEEIVRPVADFSPSLWGDQFLSFSIKNQVAEKYAKEIEALKEQTRNMLLATGMKLAD TLNLIDTIERLGISYHFEKEIDDILDQIYNQNSNCNDLCTSALQFRLLRQHGFNISPEIFSKFQDE NGKFKESLASDVLGLLNLYEASHVRTHADDILEDALAFSTIHLESAAPHLKSPLREQVTHALEQCL HKGVPRVETRFFISSIYDKEQSKNNVLLRFAKLDFNLLQMLHKQELAQVSRWWKDLDFVTTLPYAR DRVVECYFWALGVYFEPQYSQARVMLVKTISMISIVDDTFDAYGTVKELEAYTDAIQRWDINEIDR LPDYMKISYKAILDLYKDYEKELSSAGRSHIVCHAIERMKEVVRNYNVESTWFIEGYTPPVSEYLS NALATTTYYYLATTSYLGMKSATEQDFEWLSKNPKILEASVIICRVIDDTATYEVEKSRGQIATGI ECCMRDYGISTKEAMAKFQNMAETAWKDINEGLLRPTPVSTEFLTPILNLARIVEVTYIHNLDGYT HPEKVLKPHIINLLVDSIKI SEQ ID NO: 39 Chrysopogon zizanioides ZS (TPS39) MATTAAFCLTTTPIGEPVCRRQYLPTVWGSFFLTYQPCTPEEVQSMEERALAKKTEVGRMLQEVAA SSNLARKLGLVDELERLGVDYHYKTEINDLLGAIYNGKDDDNGGSDDDLYITSLKFYLLRKHGYAL SSDVFLKFRDEQGNISSDDVKCLIMLYDASHLRIHEEKILDNINSFTKSCLQSVLETNLEPALQEE VRCTLETPRFRRVERIEAKRFISAYEKNIARDDALLEFARLDYNIVQILYCKELKELTVWWKEFHS RTNLTFARDRIVEMYFWVMAIIYEPCYSYSRIWVTKMFLSVALLDDIYDNYTSTEESNIFTTAMER WDVKATEQLPANMRTFYDYLICTTDEVVEELKLQNNKNAELVKKVLIDAAKCYHSEVKWRDDHYVP NDVGEHLQLSMRSIAAMHSINFVFISLGAVCTREAVECAFTYPKIIRGICVHARISNDIASHEREQ ASEHMASTLQTCMKQYGITVEEAAEKLRVINEESWMDIVEECLYKDQYPLALSERVVAFAQSICFM YNGVDKYTIPSKLKDSLDSLYVNLIPV SEQ ID NO: 40 Setaria italica SiTPS25 (TPS40) MAPSRVAAVLDGQGMAKATDSRIDLVVTTGGVDDDEKFAPSVWGDFFITYVPPMSQRSEEWMRERA ELLKGQVHQVFNARMDAMGVADLVTYVDTLERLGLDNHFPEVIEAALNRIRTEEPEPDVFNSLHIV SLRFRLLRQHGIWVSADVFDKFRDEAGSFSTGICSDPRGLLSLYNAAHMAVPGEVALDDTIAFARG HLQAIKGKVRSPIAEQISRALDIALPRFTRRLETMHYIAEYEHEEPHDSLLLELARLNYNLVRTLH LKELKDLSLWWRDLYDTVKLPYARDRMVEIYFWTCGMLHEEEYSRSRMLFAKTFGMVSLLDDTFDV HATLDECHKLNEAMQRWDESEVSILPEYLRLLYIKTLSNFKEFEDSLERDQKYRMSYAKKAYKLSS KNYLREAIWSSQKYQPSFKEHEEVSIMSSGLPMLTIITLMGYGDVATQEVFEWVDAVPEMVRAGSQ VTRFLNDLSSYKLGKHKKDMPSAVETYMVENGLKGEEAVAAIATLLENRWRILNQASMKIDRTLLP AVQVVVNMARTNEIIYLHGRDGYTFGDDLKDLIITLFLKQVPL DB1 / 156198702.2 44 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 41 Zea mays ZmTPS21 (TPS41) MDGDIAAALPPVNQQSKADGTAVAAAAAAAACHGDFEPSVWGDFFVTYTSPPSLSQEPEEQMRERA NFLKGEVRKKFEAAAAMSAINSAMLVDAVVHLGIDHCFREEIATALRSVHKEEGEFGSCDDLHTVA VRFLVLRQHGLWVSADVFDKFRDDTGSLSKSLLCSNPRGLLSLYNAAHMVTPEEKVLDDAIAFARS HLEAMIGELRSPMVEQVSRSLDIPLPRFSRRLESMHYIAEYGQEEGHDAQILELARLEFELVRSLH LRELREICRWWRELYNDVKLPYARDRIVEIYFWACGVIHEEEMSRARMIFAKTFAFTSLIDDTCDV HATLEEVQKFNEAMQSWEEDAVSIVPEYLRTLYSRTIKGFQEFEDMLEPNEKYSMSYVKKAYKLLL QYYLKEATWANENHTPSFKEHVQVSIISSGLPMLVPVLLMGTGLATREAFEWADSAPDMVLASGEV GRFLNDMASYKLGKNKKDVANAHECYMKEYGATGEEAFAFIANMTENAWRKINQACMEMDPAMLPA FKVAVVDLSRSMEIIYLGGKRDAYTFGSNLKDLVTSLFLKPCA SEQ ID NO: 42 Salvia miltorrhiza SmSTPS1 (TPS42) MATTQAQIQRPIANFSPSLWGDQFIKNDPGAKAAEKHCKAVEELKKEVMNMITAAGSNLVEAMNLI DTLERLGISYHFEKEIDQKLKHFFNLNKDYSDESYDLYTVSLHFRLFRQHGHRISSDIFGRWIDES GKFKEGLKTDGKGLLSLYEASYLRTRGETILDDALEFATATLNSIAPHLESPLSKQVVHALIQPLH YGNPRIEAHNFISIYEENQDKNEFLLRFAKLDYNLLQMLHKEELNEVSRWWKELDLVSKLPYARDR VVECFFWAMGVYHEPQYSRARIMLTKTITMTSIIDDTYDAYGVIEELDIFTEAIERWNMEEMKKLP EYIQPFYKALLELYEQFEEELAEEGRSYAAHYAIESLKELVRSYHVEAKWFIQGYLPPFEEYLKNA LITCTYCYHTTTSLLGVESAVEEDFEWLANKPKMLVAGLLICRVIDDIATYEVEKERGQSATGIES YMRDNNATIEEAVAKFFEIATDAWKDINEECLMPSPYSRDVLMRILNLERIIDVTYKGNEDGYTQP EKVLKPHIIALFVDPIKM SEQ ID NO: 43 Leucophylum frutescens LfTPS12a (TPS43) MDLSTAVSINCNKEIVRPVANFSPSLWGDQFIKHNADAQVPTKDSEEVEALKNEAKSMLLAPGNKM VDTMNLIDTIERLGVSYHLEKEIEEKLVQFFNLNTNYGDEAYDLYTVALHFRLFRQHGYRISSDIF GKFVDVNGEFQESLKADARGLLSLYEAAHLRIHGEDIMEKALAFASANLKSIAPNLSSPLKQQVLH ALVQQLHLGNPRIEARNFISFYEQDESRNESLLRFAKLDYNILQMLHKAELHEVSRWWKELDLISK LPYARDRVVECFFWAMGAYHEPQYSRARIMLTKTIAMTSIIDDTYDAYGTIEELDIFTEAIQRWNI SEIHRLPEYIKPFYKAIFELYEQFEEELSKEGRSYATYFAIESLKEIVRSFHVEAKWFIEGYLPPF QEYLNNALITCTYSYHTTTSLLGIESATREEFEWLSKKPKVLVAGLTICRVIDDIATYEVEKERGQ IATGIECYMRDNGVTKEVAMAKFFEIATNAWKDINEECLRPFVHSRDVLMRILNLERVIDVTYKNN EDGYTQPEKVLKPHIIALFVEPIKI DB1 / 156198702.2 45 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 44 Leucophylum frutescens LfTPS12b (TPS44) MASTIVENAPSNCNKEIVRPIANFSPSLWGDEFLKCNVDAQVPRKYSEEIEALKNEARSMLLAPGN KMVDTINLIDTLERLGVSYHFEAEIEEKLEQFFNLNTDYDREAYDLYTVALHFRLFRQHGYRISCD IFGKFKDVNGEFQDRLKTDARGLLSLYEAAHLRVHGEDIMEEALVFSTANLKSMAPNLGSPLKQQV LHALVQQLHLGNPRIEARNFISFYEQDESKNESLLRFAKLDYNLLQMLHKEELREVSRWWKDLDLI SKLPYARDRVVECFFWAMGVYHEPQYSRARIMLTKTIAMTSIIDDTYDAYGTIEELDIFTEAIMRW NLSELERLPEYIRPFYRSLLELYNQFEEELSKEGRSYATYYAIESLKELVRSYHVEAKWFIEGYLP PFEEYLNNALITCTYCYHTTTSMLGTESATKEEFEWLSKKPKMLVAGLTICRVIDDIATYEVEKER GQIATGIECYMRDNGVTKEVAVDKFFEIATNAWKDINEECLRPYAQSRDVLQRILNLERIIDVTYK NNEDGYTQPEKVLKPHIIALFVDPIKI SEQ ID NO: 167 TPS45 MAETNRPLAHFQANIWEEHFISSPLLHLETEQASEHQKLKEQVRELLLAGLDKPWEQLDLIDSIQR SGVAYHFEDEIENLLQRIHKNLDTCLEENDNLHFISLLFRLLRQSSLTVSCDVFNKFKDDSGKLKE SLIEDVIGLLSLHEAACMRLHGEDILEQAFDFTTTHLKSIVEDTSSSSKLAAQASQALKYPVRKNI PRLEAKYYISVYPLLNNPVVLTFAKLDFNILQKLHQNELREIVRWWKDLDIPRRLPYARDRITELF FWAIGVYYEPCYALGRKILTKVFALTSFLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNKCSK ELYQILLDVYDEIGEDMAKLGKSYRLNYAVEMMKGQARTYLTEARWFSQNYTPTFEEYLKRGINTS ACPLLTLSSLLGMGDDISRDAFEWILSTPKSLIASSLTGRLADDIMSHEFEKKRGHADTAVECYMK EYGATKQEAVKELYKRIESAWKDMNEELLQPTEVPKAVLMRVLNFTRCNQVVYADADAYTFPDYLK DFVAALLVHQLPLD SEQ ID NO: 168 TPS46 MAETNRPLAHFQANIWEEHFISSPLLHLETEQASEHQKLKEQVRELLLAGLDKPWEQLDLIDSIQR SGVAYHFEDEIENLLQRIHKNLDTCLEENDNLHFISLLFRLLRQSGLTVSCDVFNKFKDDSGKLKE SLSEDVIGLLSLHEAACMRLHGEDILEQAFDFTTTHLKSIAEDTSSSPKLAAQASQALKYPVRKNI PRLEAKYYISVYPLLNNPVVLTFAKLDFNILQKLHQNELREIARWWKDLDIPRRLPYARDRITELF FWAIGVYYEPCYALGRKILTKVFALTSFLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNECSK ELYQILLDVYDEIGEDMAKLGKSYRLNYAVEMMKGQARTYLTEARWFSQNYTPTLEEYLKLGINTS ACPLLTLSSLLGMGDDISRDAFEWILSTPKSLIASSLTGRLADDIMSHEFEKKRGHADTAVECYMK DB1 / 156198702.2 46 Attorney Docket No.: MAN-042PC / 107590-5041 EYGATKQEAVKELYKRIESAWKDMNEELLRPTEVPKAVLMRVLNFTRCNQVVYADADAYTFPDYLK DFVAALLVHQLPLD SEQ ID NO: 169 TPS47 MAETNRPLAHFQADIWEEHFVSSPLLHLETEQASEHQKLKEQVRELLLAGLDKPWEQLDLIDSIQR LGVAYHFEDEIENLLQGIHKNLDTCLEENDNLHGISLLFRLLRQSGLTVSCDVFNKFKDESGKLKE SLSEDVIGLLSLHEAACMRLHGEDILEQAFDFTTTHLKSIAEDTSSSPKLAAQASQALKYPVRKNI PRLEAKYYISVYPLLNTPVVLTFAKLDFNILQKLHQNELREIARWWKDLDIPRRLPYARDRITELF FWAIAVYYEPCYALGRKILTKVFALTSFLDDMYDAYGTIEELELLTQAIQRWDRNAMDGLNNECSK ELYQILLDVYDEIGEDMAKLGKSYRLNYAVEMMKRQARIYLTEARWFSQNYTPTLEEYLKLGIHTS ACPLLTLSSLLGMGDNISRDAFEWILSTPKIVIASSLIGRLIDDIMSHEFEKKRGHADTAVECYMK EYGATKQEAVKELYKRIESAWKDMNEGLLRPTEVPKAVLMRVLNFTRSNQVVYADADAYTFPDYLK DFVAALLVHQLPLD Cytochrome P450 (CYP) Enzymes SEQ ID NO: 45 Cyperus rotundus WT-CroCYP1 (CYP1) MEPIILTSLPYILSSLLLLLFSILFLWNKVAHSKPNLPPGPWTLPIIGSLHHFARGSLPHHALHNL AQLYGPVMLLRAGEINLVVITSREAAKEVMKTQDANFGNRPPLFAANVFMYGATDIAFSNGPHWRQ LRRICSTELFSLKRVKSFSSVRQNEINSMLKCISLNPENSPVNLSEMTCKLTNDIIIAAAFGGKCK NREIFFKILKEVLELLAGFTLSDLFPSLSWLDVHTRRKFSRLQRKLDLVLEDVLHEHIKQPKKGAE DQELEHDLVDVLLNIMENGDLEIPVKMDTIKAVISDLFFAGTETTSTLIVWAMTELMKNPEVMAKA QAEIRQAQSEDAKLNTNALRYLKLVIKEASRMHPGASLLAPRTCKETCTVLGHTIPSEAKVVINAW SLGRNPEYWDNPEEFKPERFETSEMDFRGQHFEFVPFGAGRRICPGLEFGVAMVEEILASLLLHFD WKLPEGMKLEDIDMTELFGVVAAKKVPLCLIPTMSVPLA SEQ ID NO: 46 Cyperus rotundus WT-CroCYP2 (CYP2) MELPCLVITSVIILLCFFLLEKKVTRLRRNLPPGPWSLPFIGNLRQLATTRLPHHVLHDLAKTYGP IMLLRAGERDLVVVTSREAAKEVMKVQDSNFANRPLTSAADVFMYGGTDVAFSNGPYWRQLRRICI TELLISKRVKSFCSVRREEINSMLKSISTVASKSPVNLSAKAYELSNSIVLRAAFGGLCKDRAAFL EIIGEVMELFSGFNLADLFPSLSWLDLKTRRRFKRLHRKMDSILEGVVQEHLKRRRQQKKEGDDEE MDHDLADVLLNVKERGDLEMPITMDNVKAVILDIFSGGTETSSTTIAWAMTELIRHPAIMVKAQAE DB1 / 156198702.2 47 Attorney Docket No.: MAN-042PC / 107590-5041 TRKAAGKNTSKFEENTVCYLKLVIKETLRLHPAAPLLLPRLCKESCQVLGYTVPSGARVIVNAWAL GRNPDYWNNPEEFNPERFEASGIDYKGQNFEFVPFGAGRRICPGIEFGMTVVEEALARLLLHFYWK LPDGMEPKDVDMTETFGLVSAKKVPLCLVPVLRVPLPDV SEQ ID NO: 47 Cyperus rotundus WT-CroCYP3 (CYP3) MDSLISFPLVLFSLFLCLLICLLFKAKTNHSKGLRFPPGPRPLPLIGNLHNLIGSLLHHAMRDLSR QYGPLMLLHLGETPTVVVSSPDAAREIMKTHDTNFASRPISTTMDIQTYGGKGIAFSPYGEYWRQI RKICALKLLSTTRVQSYRSLREEEVGNLINSIYSSASQCQPVNLNKKLVSLVNDITTRAIMGSRCK NKDVFLRELDTTLKLAAGFNLADMFPSSWLTKLVSMAARKAERSRKARSQLFHDIIEQQREKEITT TEGEVENLLQVLLRSLEEDDTLKNHVDSESVEPVIFDLFGGGTETSSTTIEWAMSELLRNPTAMKK AQSEVRELLKEGTHISESHLDKLNYLRLVIKETLRMHPPIPLILPRQCQETCRIFDYDIAKGMTVL VNAWAMGRDPKYWDDPEEFRPERFFNSSTDFKGTNFEFIPFGAGRRMCPGMTFGVANVELPLASLL YHFDWELPDGLKPEQLDMSESFGITAKRKTPLVLYALPYKTNIQG SEQ ID NO: 48 Cyperus rotundus WT-CroCYP4 (CYP4) MELPTFPYTVPCIHASLLLLLFSIWYLQKKATHSKSNLPPGPWTLPIIGCLHHLATASNVPHRALQ ELARRYGPVMLLRAGKLDLVVITSREAAKEVMRTQDANFAHRPDMHASNVLTYGASDIVFSNGPQW RQMRRVCTIELFSSKRVKSFASIRQEEINSMLKSIIGSIAKKSRVNVSAMASELTTNITIAAAFGR KCTGKAVFLDTLDGMLKLLSGFTLSDFFPSLGWLDVNTERELARVQSKIDMVLEDILQEHLNQPRK RGEDEELQRDAVDVLINVMENGDLETPITKDVIKAVILDLFAGGTETSATTITWAMTELMKKPDAM AKLQAEIRQVQSKEDAMSNHNTLRYLRLVIKETLRMHPPVPLIIRGLCKETSEVLGYTIPSETKVL INAWSLGRNSDYWINPDDFKPERFETSDVDFRGQHFEFVPFGAGRRICPGIEFGMAVVEEALVSLL LHFDWNLPDGMKPEDVDVTETSGITAARKEPLCLIPTLRVPLPDV SEQ ID NO: 49 Cyperus rotundus WT-CroCYP5 (CYP5) MEYIPPWAMNYLAIVLATILLLKSISYVRGRKKYNLPPGPKPWPIIGNLNLIGALPHRSLHELSKK YGPMMFLRFGSFPVVVGSSVELAKYFLKTHDALFIDRPKTAAGKYTTYNYLDITWSQYGPYWRQAR KMCLVELFSAKRLASYEYIRVEEINNLLRDLYRSSGKVVKLNKDYLSTVSLNVISRMVLGKNYLVM SEGAIVTPEEFKAMLDELFLLNGVLNIGDSIPWLDFLDLQGYIKRMKKLAKKFDRFLEHVLDEHNE RRWKEGENFVAKDMVDVLLQLADDPTLEVKLERHGVKAFTQDLIAGGTESSAVTVEWAISEILKRP EIFKRATEELDRVIGRERWVQEKETSKLPYVEAIVKETMRLHPVAPMLVPRLSREDATFNGYDIPA DB1 / 156198702.2 48 Attorney Docket No.: MAN-042PC / 107590-5041 GSRVLINVWTIGRDPDVWENPNEFMPERFLDKSIDVKGQDFELLPFGSGRRMCPGYNLGLKVIQTT LANLLHGFDWKLPEGMKRADLNMDEIFGLSTPRKYPLQVVAEPKLPAHLYGA SEQ ID NO: 50 Cyperus rotundus WT-CroCYP6 (CYP6) MTPEIQAVEILVAVSIFIGIHSIRQSKKQGLAVWPFVGMLPSLLLALRHDMYEWITSVLNERGGTF AFKGPWFTNLQCVVTADPRNLEHLLKTKFTNFPKGPYFRNTVQDLLGDGIFSADDETWRKQRKAAS LEFHSAEFRSLTARSLVELVHSRLLPVLESAHQNDTAVDLQDVLLRLTFDNVCMLAFGIDPGCLSP GLPDIPFAHAFEDATEATIIRFVTPTAIWKALRYADLGNERRLRRSLQQVDDFAFNVIETRRKELQ LEESSKTNTRSDLLTVFMRLRDDNGQPYSEKFLRDICVNFILAGRDTSSVALAWFFWLLNKNPEVE AKIVDEIRRIVKERDETEKEGEELIFHPEEVKKMHYLQAALSEALRLYPSVPVDHKEVVEDEVFPD GTVLKKGTKIIYAMYAMGRMESIWGEDCREYKPERWLKDGQFMSESAYKFTAFNGGPRLCLGKDFA YYQMKFAASSILYRYHVKVVDNHPIAPKLALTMYMKYGLKVTLTKRD SEQ ID NO: 51 Cyperus rotundus WT-CroCYP7 (CYP7) MEIISSLYLHVLNLMHKHYPELLLALLSFLLLRVFYRRAQMPLNFPIFGVIPHVLVRCNEMHEWTA RVLRQRGYTCIMKGPIGTPYDFLLTCDPANVAYVFTSQFANYPKGKEFADIFEVLGNGIFNADFDS WAFQRKKAHMLMTDNKFRNFAYLSTRDKLENGLLPLLGELAKSGQVVDLQDVFLRLSFDITSIFTF GFDPGCLARDFPTVPFAKAMDEAEEILFYRHVMPYPYLRLQQKYNFGTQKRMEKASKVIDQVIAQY VAKRKEILSSQSSEERDRTADLLSAYVDCQNEVGKVGEEFNKFLRDTTFNLMVAGRDTTSSAFTWF FYMLHKNPHVKEKILQELKVRAPANPTFPSVAEIRQLVYLHAALCESLRLYPPVPFNHKTALKPDV LPSGTPVDGSRRILFSVYAMGRMEGIWGKDCLEFKPERWLTESGKIHHEPSYKFMAFNSGPRTCLG KDLAFTQMKAVIAAILTRYHVEVEPGFVARPKFSIILHMQEGLKVRVKPRLSL SEQ ID NO: 52 Cyperus rotundus WT-CroCYP8 (CYP8) MVLLPEMILIPTSMEHLSLLCISLLSIFILYFTLKRRNVSRSTKVSIPSPPKLPFIGNIHQLSPLY HQSLHLLSLKYGPLMLLHLGEVPLLVVSSADLACAIMRTHDLTFATRPSAVVADIIRFGDLAFEPY GEDWRQLKKIFTIHLMGTKKVNSYKTIREEEVANLIAKISGHATISSDSPLELSKLLFQLMTDLVC RVVSGKFIMEERRYKIMREIVDENIHLVGRFSIGDLFPSLTCLEKLIGFSKRASINKEKWDMFLEE LIQAHVQSEENKKESDNFVDILLSLKNDPNSHFDLTTEQMKGLLLDAFGAGIDTSYITIDWAISEL IKNPESMKKLKEEVRGVVKPNDMVRTEDLNQMKYLKYVIKETLRLHPPVPLLLPRESMEQCEINGF DB1 / 156198702.2 49 Attorney Docket No.: MAN-042PC / 107590-5041 TIPKGTKVLINSWAISRDAKFWEAPEKFEPERFIDNQVDFKGNDFQFIPFGAGRRICPGISFATAT TELALANLVHHFDWELPSGMTRENFKLDDSSGLTVKRKDDLCLVVKKV SEQ ID NO: 53 Cyperus rotundus WT-CroCYP9 (CYP9) MQRILSQFGTNSWSLLLGALSLVLLWAAARALEWAWLRPKRLERALRRQGLRGPAYRSALGDLKEN SKLNKEARAKPMPLSHDIVPRVAPLFRRIMQEFGNRSYTWFGPHPRVFIRDPDLVREILSNKFGHF EKQILSPFTQLLVNGVANYEGEKWAKHRRILNPAFHMEKLKMMLPAFSACCDELINRWVNSVGPDG SFELDVWPEMQNLTGDVISRAAFGSSYQEGRRIFQLQAEQAERLIKAFPTIVLPFSWYLPTENNRR MKQNAREVRELLMGIITKRENAIRNGEATKNDLLGLLLESNMSEMGQNGKSDSKLGMTTDEVIEEC KLFYFAGQETTSVLLTWTLIMLSMHPEWQEKAREEVLQHFGTEKPDFDGLSRLKIVTMILYEVLRL YSPVVMLTRSTYKTIQVGDLTLPPGVTLAMLILFIHHDPDIWGPDATEFKPMRFAEGISKATINGK PAFFPFGWGPRICIGQNFALHEAKMGLSMILQHFKFKLSDKYRHAPCTVLTLHPQFDVPIRFHRI SEQ ID NO: 54 Cyperus rotundus WT-CroCYP10 (CYP10) MDFIYVNTFLCIFLLIFFKILLSSINKSKKNLPPGPPALPILGHLHLVKLPFHQWLNKISDRYGPA VFLRLGSRPVVVVSNQTLADQCFTTHDLTFANRVHLPTVQMQPNLIVWANYGPYWRTVRQAAATEL LSSQQLHASSQIRGTLYRDMSRKLFSAHKSQQNKSEESSSFKRLAFKKMLFDLMLDMMLITIAGKN NDDSDDMKEFSKALVAWFELTGAANVEDYLPLLRILDLKGTMKRMKHLTTVNDRMVQKMIEEHRQE GVGRRNTMISSLLELQKKDSEKYNDVLFRGMVISLILGGTETTATTIEWAMAELLNNPDILNKAVA EIDAHLGNERLIQESDMNNLPYLNHIISETLRLHPTVPLLAPHESREEIKLGGYDIPKGTMLLVNT YPIQRDPNIWEEPNKFIPERFEDGNSNGKFMIPFGMGRRRCAGETFAMRMMGALLGSLIQSFEWKR IGSELIDLTEGIGLSTPLVTPLEAMYRPRDAMTKVLSEL SEQ ID NO: 55 Cyperus rotundus WT-CroCYP11 (CYP11) MEATTFYYAFLFTAFVIYTTILLLYKRRSSPPLPPGPIGLPIVGSLPFLDASSLHTYFADLSTKYG PILSLRLGSKLAVVISSPSLARAVLEQHDSIFANHDPTVGGLLSTYDGSDIVWTPNGPTLRMLRRV CVQAMLSPSSLDAVSALRQQEVQSSVRHIHARSGTPVDIGTEVFVNALNILTNTMWGGTLVEGEER ESIGNNLKELVIDTNELWGRPNVSEFLPALARFDLQGVQSKIELLAERFDNIFERIIEKKCTDQGE KTKDLVDFCLRLEREEGNSNTPFTRTHLKALLMDMIMGGTGTTTATVEWAMAEILNKPDILQKLHE ELNQIVGKDSLVRESHIPQLHFLSLVIKETLRLHPPAPFLVPHCPSSPCTIDGYHIPEGSRIFVNV WKIQTDPSQWRDPMEFRPERFLQKGFHRDFTGNNFDYLPFGSGRRKCVAIAMAERVLGHLLATMVH SFDWKLPEGNNIDLSEKFGLLMKKAVPLVAIPTPRLSNNELYY DB1 / 156198702.2 50 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 56 Cyperus rotundus WT-CroCYP12 (CYP12) MEATTFYYAFLFTAFVIYTTILLLRKRRSLPLPPGPVGLPIIGSLPFLDTSSLHTCFADLSTKYGP VLSLRLGSKLAVVISSPSLARAVLQEHDNVFANRDPTVGSLLSTYGGSDIVWTPNGPTLRMLRRVC VQAMLSPSSLDAVSALRQQEVQSSVRHIHARSGTPVDIGTEVFVNALNILTNTMWGGTLVDDGERE SVGNNLKELVADTIELWGRPNVSEFLPALARFDLQGVQSKIELLAERFDNIFERIIEKKCTDQGEK TKDLVDFCLRLEREEGNSNTPFTRTHLKALLMDMIMGGTGTTTATVEWAMAEILNKPDILQKLHEE LNQIVGKDSLVRESHIPQLHFLSLVIKETLRLHPPAPFLVPHCPSSPCTIDGYHIPEGSRIFVNVW KIQTDPSQWRDPMEFRPERFLQKGFHRDFTGNNFDYLPFGSGRRKCVAIAMAERVLGHLLATMVHS FDWKLPEGNNIDLSEKFGLLMKKAVPLVAIPTPRLSNNELYY SEQ ID NO: 57 Cyperus rotundus WT-CroCYP13 (CYP13) MRHGDQELVISVSLIKFLITMPHLSFISTMPHLLFFMLSPLLIILIFHFTVIKQITTTSRKKNLPP EPPSLPLIGHLHLLGRLPHRSLRKLSSSHGPIMLLHLGRVPTIVLSSASAVQEAISLHDLALSNRP HIASADILAYDSTGVIFLEYGQRWRRARQIFMVQLLSVKQVESFQHLRQQETTYLVERIRRDGCSG EKAINLSKLLFDVTNSIVCRAGFGQKYVLEDGRSIQKVLSDAFELLLVVRIGEFIPWLSWIDWLRG IDKRAKATADILDQFLEGVIQKRLEERTICDDAEKTEANFIDHVLDVMENGREISTSQRMEKIKVL LSDLIFGGIDTTYITMEFAMAELISHPEVMERVQQEVRKTVRTCDDINEESISNMSFLKAVISETL RLHPPAPILVPRETTEDIQLLGYQIPSKTRVVINAWAIGRDPQRWGTNAEEFWPERFIGSSIEYNG QDFQFVPFGVGRRGCPGINSATRVIELVLANLMYNFDWMLHDEKGGDSLVDMTEKAGLTVHLKNNL VVLAKPFVN SEQ ID NO: 58 Cyperus rotundus WT-CroCYP14 (CYP14) MSSFYKWCEDFGSMFGVYTPFITAIAVLFVGFVLNFYLPYWKLRKVPGPAPTFLVGHLPLLATHGP DVFRVLAKNYGPIFRFHMGRQPLVMVADADLCKDVGIKKFKDIKNRSSPPPTVGSAIHHEALFLSR DSRWSSMRNAIIPLYQPAHLASLIPTMQSYASSLLLNIANTEKEEYIPFSDLVLRMSIDIIGKTAF GFEFGLLNQVPDLAKNEETERDNDISAFLKEYKLTLEYLKMDLSSSMSTILGLFVSPSIQKICKSV LTKVPGTMDFKIAQNEKKLCQRIDALIARRSKERNPEAVDFLAALLNVRESGASKDLFADNYLRAL TFEHLIAGTKTTAFTISSTVYLVSKHSEVEQKLIQEIDSFGPRDSVPTAEDLQNKFPYLDQVIKEA MRFYFVSPLIARETSQDLKVSGYNLPKGTYVWLAVGVLAKDPTQFPEPDVFRPERFNPTCNEERYR HPYAYIPFGIGPRSCIGQRFALQEIKLTIILLYQHYVFRHSPLMESPLELEYDLVLGFKHGVKLVA IKRGA DB1 / 156198702.2 51 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 59 Cyperus rotundus CroCYP1 (CYP15) MAQDLRLILIIVGAIAIIALLVHGFLWNKVAHSKPNLPPGPWTLPIIGSLHHFARGSLPHHALHNL AQLYGPVMLLRAGEINLVVITSREAAKEVMKTQDANFGNRPPLFAANVFMYGATDIAFSNGPHWRQ LRRICSTELFSLKRVKSFSSVRQNEINSMLKCISLNPENSPVNLSEMTCKLTNDIIIAAAFGGKCK NREIFFKILKEVLELLAGFTLSDLFPSLSWLDVHTRRKFSRLQRKLDLVLEDVLHEHIKQPKKGAE DQELEHDLVDVLLNIMENGDLEIPVKMDTIKAVISDLFFAGTETTSTLIVWAMTELMKNPEVMAKA QAEIRQAQSEDAKLNTNALRYLKLVIKEASRMHPGASLLAPRTCKETCTVLGHTIPSEAKVVINAW SLGRNPEYWDNPEEFKPERFETSEMDFRGQHFEFVPFGAGRRICPGLEFGVAMVEEILASLLLHFD WKLPEGMKLEDIDMTELFGVVAAKKVPLCLIPTMSVPLA SEQ ID NO: 60 Cyperus rotundus CroCYP2 (CYP16) MAQDLRLILIIVGAIAIIALLVHGFWLEKKVTRLRRNLPPGPWSLPFIGNLRQLATTRLPHHVLHD LAKTYGPIMLLRAGERDLVVVTSREAAKEVMKVQDSNFANRPLTSAADVFMYGGTDVAFSNGPYWR QLRRICITELLISKRVKSFCSVRREEINSMLKSISTVASKSPVNLSAKAYELSNSIVLRAAFGGLC KDRAAFLEIIGEVMELFSGFNLADLFPSLSWLDLKTRRRFKRLHRKMDSILEGVVQEHLKRRRQQK KEGDDEEMDHDLADVLLNVKERGDLEMPITMDNVKAVILDIFSGGTETSSTTIAWAMTELIRHPAI MVKAQAETRKAAGKNTSKFEENTVCYLKLVIKETLRLHPAAPLLLPRLCKESCQVLGYTVPSGARV IVNAWALGRNPDYWNNPEEFNPERFEASGIDYKGQNFEFVPFGAGRRICPGIEFGMTVVEEALARL LLHFYWKLPDGMEPKDVDMTETFGLVSAKKVPLCLVPVLRVPLPDV SEQ ID NO: 61 Cyperus rotundus CroCYP3 (CYP17) MAQDLRLILIIVGAIAIIALLVHGFKAKTNHSKGLRFPPGPRPLPLIGNLHNLIGSLLHHAMRDLS RQYGPLMLLHLGETPTVVVSSPDAAREIMKTHDTNFASRPISTTMDIQTYGGKGIAFSPYGEYWRQ IRKICALKLLSTTRVQSYRSLREEEVGNLINSIYSSASQCQPVNLNKKLVSLVNDITTRAIMGSRC KNKDVFLRELDTTLKLAAGFNLADMFPSSWLTKLVSMAARKAERSRKARSQLFHDIIEQQREKEIT TTEGEVENLLQVLLRSLEEDDTLKNHVDSESVEPVIFDLFGGGTETSSTTIEWAMSELLRNPTAMK KAQSEVRELLKEGTHISESHLDKLNYLRLVIKETLRMHPPIPLILPRQCQETCRIFDYDIAKGMTV LVNAWAMGRDPKYWDDPEEFRPERFFNSSTDFKGTNFEFIPFGAGRRMCPGMTFGVANVELPLASL LYHFDWELPDGLKPEQLDMSESFGITAKRKTPLVLYALPYKTNIQG SEQ ID NO: 62 DB1 / 156198702.2 52 Attorney Docket No.: MAN-042PC / 107590-5041 Cyperus rotundus CroCYP4 (CYP18) MAQDLRLILIIVGAIAIIALLVHGFWYLQKKATHSKSNLPPGPWTLPIIGCLHHLATASNVPHRAL QELARRYGPVMLLRAGKLDLVVITSREAAKEVMRTQDANFAHRPDMHASNVLTYGASDIVFSNGPQ WRQMRRVCTIELFSSKRVKSFASIRQEEINSMLKSIIGSIAKKSRVNVSAMASELTTNITIAAAFG RKCTGKAVFLDTLDGMLKLLSGFTLSDFFPSLGWLDVNTERELARVQSKIDMVLEDILQEHLNQPR KRGEDEELQRDAVDVLINVMENGDLETPITKDVIKAVILDLFAGGTETSATTITWAMTELMKKPDA MAKLQAEIRQVQSKEDAMSNHNTLRYLRLVIKETLRMHPPVPLIIRGLCKETSEVLGYTIPSETKV LINAWSLGRNSDYWINPDDFKPERFETSDVDFRGQHFEFVPFGAGRRICPGIEFGMAVVEEALVSL LLHFDWNLPDGMKPEDVDVTETSGITAARKEPLCLIPTLRVPLPDV SEQ ID NO: 63 Cyperus rotundus CroCYP5 (CYP19) MAQDLRLILIIVGAIAIIALLVHGFYVRGRKKYNLPPGPKPWPIIGNLNLIGALPHRSLHELSKKY GPMMFLRFGSFPVVVGSSVELAKYFLKTHDALFIDRPKTAAGKYTTYNYLDITWSQYGPYWRQARK MCLVELFSAKRLASYEYIRVEEINNLLRDLYRSSGKVVKLNKDYLSTVSLNVISRMVLGKNYLVMS EGAIVTPEEFKAMLDELFLLNGVLNIGDSIPWLDFLDLQGYIKRMKKLAKKFDRFLEHVLDEHNER RWKEGENFVAKDMVDVLLQLADDPTLEVKLERHGVKAFTQDLIAGGTESSAVTVEWAISEILKRPE IFKRATEELDRVIGRERWVQEKETSKLPYVEAIVKETMRLHPVAPMLVPRLSREDATFNGYDIPAG SRVLINVWTIGRDPDVWENPNEFMPERFLDKSIDVKGQDFELLPFGSGRRMCPGYNLGLKVIQTTL ANLLHGFDWKLPEGMKRADLNMDEIFGLSTPRKYPLQVVAEPKLPAHLYGA SEQ ID NO: 64 Cyperus rotundus CroCYP6 (CYP20) MAQDLRLILIIVGAIAIIALLVHGFWRQSKKQGLAVWPFVGMLPSLLLALRHDMYEWITSVLNERG GTFAFKGPWFTNLQCVVTADPRNLEHLLKTKFTNFPKGPYFRNTVQDLLGDGIFSADDETWRKQRK AASLEFHSAEFRSLTARSLVELVHSRLLPVLESAHQNDTAVDLQDVLLRLTFDNVCMLAFGIDPGC LSPGLPDIPFAHAFEDATEATIIRFVTPTAIWKALRYADLGNERRLRRSLQQVDDFAFNVIETRRK ELQLEESSKTNTRSDLLTVFMRLRDDNGQPYSEKFLRDICVNFILAGRDTSSVALAWFFWLLNKNP EVEAKIVDEIRRIVKERDETEKEGEELIFHPEEVKKMHYLQAALSEALRLYPSVPVDHKEVVEDEV FPDGTVLKKGTKIIYAMYAMGRMESIWGEDCREYKPERWLKDGQFMSESAYKFTAFNGGPRLCLGK DFAYYQMKFAASSILYRYHVKVVDNHPIAPKLALTMYMKYGLKVTLTKRD SEQ ID NO: 65 Cyperus rotundus CroCYP7 (CYP21) DB1 / 156198702.2 53 Attorney Docket No.: MAN-042PC / 107590-5041 MAQDLRLILIIVGAIAIIALLVHGFVFYRRAQMPLNFPIFGVIPHVLVRCNEMHEWTARVLRQRGY TCIMKGPIGTPYDFLLTCDPANVAYVFTSQFANYPKGKEFADIFEVLGNGIFNADFDSWAFQRKKA HMLMTDNKFRNFAYLSTRDKLENGLLPLLGELAKSGQVVDLQDVFLRLSFDITSIFTFGFDPGCLA RDFPTVPFAKAMDEAEEILFYRHVMPYPYLRLQQKYNFGTQKRMEKASKVIDQVIAQYVAKRKEIL SSQSSEERDRTADLLSAYVDCQNEVGKVGEEFNKFLRDTTFNLMVAGRDTTSSAFTWFFYMLHKNP HVKEKILQELKVRAPANPTFPSVAEIRQLVYLHAALCESLRLYPPVPFNHKTALKPDVLPSGTPVD GSRRILFSVYAMGRMEGIWGKDCLEFKPERWLTESGKIHHEPSYKFMAFNSGPRTCLGKDLAFTQM KAVIAAILTRYHVEVEPGFVARPKFSIILHMQEGLKVRVKPRLSL SEQ ID NO: 66 Cyperus rotundus CroCYP8 (CYP22) MAQDLRLILIIVGAIAIIALLVHGFWLKRRNVSRSTKVSIPSPPKLPFIGNIHQLSPLYHQSLHLL SLKYGPLMLLHLGEVPLLVVSSADLACAIMRTHDLTFATRPSAVVADIIRFGDLAFEPYGEDWRQL KKIFTIHLMGTKKVNSYKTIREEEVANLIAKISGHATISSDSPLELSKLLFQLMTDLVCRVVSGKF IMEERRYKIMREIVDENIHLVGRFSIGDLFPSLTCLEKLIGFSKRASINKEKWDMFLEELIQAHVQ SEENKKESDNFVDILLSLKNDPNSHFDLTTEQMKGLLLDAFGAGIDTSYITIDWAISELIKNPESM KKLKEEVRGVVKPNDMVRTEDLNQMKYLKYVIKETLRLHPPVPLLLPRESMEQCEINGFTIPKGTK VLINSWAISRDAKFWEAPEKFEPERFIDNQVDFKGNDFQFIPFGAGRRICPGISFATATTELALAN LVHHFDWELPSGMTRENFKLDDSSGLTVKRKDDLCLVVKKV SEQ ID NO: 67 Cyperus rotundus CroCYP9 (CYP23) MAQDLRLILIIVGAIAIIALLVHGFRALEWAWLRPKRLERALRRQGLRGPAYRSALGDLKENSKLN KEARAKPMPLSHDIVPRVAPLFRRIMQEFGNRSYTWFGPHPRVFIRDPDLVREILSNKFGHFEKQI LSPFTQLLVNGVANYEGEKWAKHRRILNPAFHMEKLKMMLPAFSACCDELINRWVNSVGPDGSFEL DVWPEMQNLTGDVISRAAFGSSYQEGRRIFQLQAEQAERLIKAFPTIVLPFSWYLPTENNRRMKQN AREVRELLMGIITKRENAIRNGEATKNDLLGLLLESNMSEMGQNGKSDSKLGMTTDEVIEECKLFY FAGQETTSVLLTWTLIMLSMHPEWQEKAREEVLQHFGTEKPDFDGLSRLKIVTMILYEVLRLYSPV VMLTRSTYKTIQVGDLTLPPGVTLAMLILFIHHDPDIWGPDATEFKPMRFAEGISKATINGKPAFF PFGWGPRICIGQNFALHEAKMGLSMILQHFKFKLSDKYRHAPCTVLTLHPQFDVPIRFHRI SEQ ID NO: 68 Cyperus rotundus CroCYP10 (CYP24) MAQDLRLILIIVGAIAIIALLVHGFWNKSKKNLPPGPPALPILGHLHLVKLPFHQWLNKISDRYGP AVFLRLGSRPVVVVSNQTLADQCFTTHDLTFANRVHLPTVQMQPNLIVWANYGPYWRTVRQAAATE DB1 / 156198702.2 54 Attorney Docket No.: MAN-042PC / 107590-5041 LLSSQQLHASSQIRGTLYRDMSRKLFSAHKSQQNKSEESSSFKRLAFKKMLFDLMLDMMLITIAGK NNDDSDDMKEFSKALVAWFELTGAANVEDYLPLLRILDLKGTMKRMKHLTTVNDRMVQKMIEEHRQ EGVGRRNTMISSLLELQKKDSEKYNDVLFRGMVISLILGGTETTATTIEWAMAELLNNPDILNKAV AEIDAHLGNERLIQESDMNNLPYLNHIISETLRLHPTVPLLAPHESREEIKLGGYDIPKGTMLLVN TYPIQRDPNIWEEPNKFIPERFEDGNSNGKFMIPFGMGRRRCAGETFAMRMMGALLGSLIQSFEWK RIGSELIDLTEGIGLSTPLVTPLEAMYRPRDAMTKVLSEL SEQ ID NO: 69 Cyperus rotundus CroCYP11 (CYP25) MAQDLRLILIIVGAIAIIALLVHGFLYKRRSSPPLPPGPIGLPIVGSLPFLDASSLHTYFADLSTK YGPILSLRLGSKLAVVISSPSLARAVLEQHDSIFANHDPTVGGLLSTYDGSDIVWTPNGPTLRMLR RVCVQAMLSPSSLDAVSALRQQEVQSSVRHIHARSGTPVDIGTEVFVNALNILTNTMWGGTLVEGE ERESIGNNLKELVIDTNELWGRPNVSEFLPALARFDLQGVQSKIELLAERFDNIFERIIEKKCTDQ GEKTKDLVDFCLRLEREEGNSNTPFTRTHLKALLMDMIMGGTGTTTATVEWAMAEILNKPDILQKL HEELNQIVGKDSLVRESHIPQLHFLSLVIKETLRLHPPAPFLVPHCPSSPCTIDGYHIPEGSRIFV NVWKIQTDPSQWRDPMEFRPERFLQKGFHRDFTGNNFDYLPFGSGRRKCVAIAMAERVLGHLLATM VHSFDWKLPEGNNIDLSEKFGLLMKKAVPLVAIPTPRLSNNELYY SEQ ID NO: 70 Cyperus rotundus CroCYP12 (CYP26) MAQDLRLILIIVGAIAIIALLVHGFLLRKRRSLPLPPGPVGLPIIGSLPFLDTSSLHTCFADLSTK YGPVLSLRLGSKLAVVISSPSLARAVLQEHDNVFANRDPTVGSLLSTYGGSDIVWTPNGPTLRMLR RVCVQAMLSPSSLDAVSALRQQEVQSSVRHIHARSGTPVDIGTEVFVNALNILTNTMWGGTLVDDG ERESVGNNLKELVADTIELWGRPNVSEFLPALARFDLQGVQSKIELLAERFDNIFERIIEKKCTDQ GEKTKDLVDFCLRLEREEGNSNTPFTRTHLKALLMDMIMGGTGTTTATVEWAMAEILNKPDILQKL HEELNQIVGKDSLVRESHIPQLHFLSLVIKETLRLHPPAPFLVPHCPSSPCTIDGYHIPEGSRIFV NVWKIQTDPSQWRDPMEFRPERFLQKGFHRDFTGNNFDYLPFGSGRRKCVAIAMAERVLGHLLATM VHSFDWKLPEGNNIDLSEKFGLLMKKAVPLVAIPTPRLSNNELYY SEQ ID NO: 71 Cyperus rotundus CroCYP13 (CYP27) MAQDLRLILIIVGAIAIIALLVHGFWVIKQITTTSRKKNLPPEPPSLPLIGHLHLLGRLPHRSLRK LSSSHGPIMLLHLGRVPTIVLSSASAVQEAISLHDLALSNRPHIASADILAYDSTGVIFLEYGQRW RRARQIFMVQLLSVKQVESFQHLRQQETTYLVERIRRDGCSGEKAINLSKLLFDVTNSIVCRAGFG QKYVLEDGRSIQKVLSDAFELLLVVRIGEFIPWLSWIDWLRGIDKRAKATADILDQFLEGVIQKRL DB1 / 156198702.2 55 Attorney Docket No.: MAN-042PC / 107590-5041 EERTICDDAEKTEANFIDHVLDVMENGREISTSQRMEKIKVLLSDLIFGGIDTTYITMEFAMAELI SHPEVMERVQQEVRKTVRTCDDINEESISNMSFLKAVISETLRLHPPAPILVPRETTEDIQLLGYQ IPSKTRVVINAWAIGRDPQRWGTNAEEFWPERFIGSSIEYNGQDFQFVPFGVGRRGCPGINSATRV IELVLANLMYNFDWMLHDEKGGDSLVDMTEKAGLTVHLKNNLVVLAKPFVN SEQ ID NO: 72 Cyperus rotundus CroCYP14 (CYP28) MAQDLRLILIIVGAIAIIALLVHGFNFYLPYWKLRKVPGPAPTFLVGHLPLLATHGPDVFRVLAKN YGPIFRFHMGRQPLVMVADADLCKDVGIKKFKDIKNRSSPPPTVGSAIHHEALFLSRDSRWSSMRN AIIPLYQPAHLASLIPTMQSYASSLLLNIANTEKEEYIPFSDLVLRMSIDIIGKTAFGFEFGLLNQ VPDLAKNEETERDNDISAFLKEYKLTLEYLKMDLSSSMSTILGLFVSPSIQKICKSVLTKVPGTMD FKIAQNEKKLCQRIDALIARRSKERNPEAVDFLAALLNVRESGASKDLFADNYLRALTFEHLIAGT KTTAFTISSTVYLVSKHSEVEQKLIQEIDSFGPRDSVPTAEDLQNKFPYLDQVIKEAMRFYFVSPL IARETSQDLKVSGYNLPKGTYVWLAVGVLAKDPTQFPEPDVFRPERFNPTCNEERYRHPYAYIPFG IGPRSCIGQRFALQEIKLTIILLYQHYVFRHSPLMESPLELEYDLVLGFKHGVKLVAIKRGA SEQ ID NO: 73 Aquilaria sinensis WT-AsCYP1 (CYP29) MTTKERFKPFLSNSLMDHQFLSLPMLFSSILFMLLLLKFWRNRKLSPKLPPGPRKLPLIGNLHQLV GDMPHRRLRDLASKYGPLMHLQLGEVPFIIISSPKTAEQVMKVHDINFASRPNSLGAEIVLYNSSD IAFAPYGDHWRQMRKICIMELLSTKRVLQFRSIREEEILNFCRAIGSSAGFPVNLSKMLYSCSYGI IARALIGRKAKDDERYIEITGRIIKLFAGFSIVDAFPSSKLLQVMSGVKSKFESIRQEADEFLDNI IKEHKAVKGSSGSTETEDDLMHVLLNLQEHWDLEFPLTTDSIKAVIQDLILGGMETSATTVDWAIS EMLKTPRVLHKVQAEVRQVFEKEGRISETEFHKLEYLRLVIKESLRLHPPLPLLVPRQGDRCEING YEIPAKAQVMVNAWAIGRDPKYWSDPEIFIPERFLESSVDFRGTHFELIPFGAGRRTCPGISFGLA NVELTLVHLLYHFDWKLPDGKAYEDLDMTEAFGVSMRRKWDLFVVPTMNSASYLQ SEQ ID NO: 74 Aquilaria sinensis WT-AsCYP2 (CYP30) MTTPERYETFLSTCTSLMEHQSLSVPMLLTSILFLLLLLMVWRNRNLRPKGPPGPRKLPLIGNLHQ LNGDMPHRRLRDLASKYGPLMHLQLGEVHFIIISSPETAEQIMKVHDINFASRPRTLAAEIVMYNC KAVVFGPYGDLWRQLRKICVTGLLTAKRVQQFGSIRGEEVSNIVRAISSSAGLPINLSKMFHSSAY NIIIKALIGGKAKDSERYIEITERAVELFGGFSIVDAFPSSKLLQVMSGMKSKLEILDQEADEILE NIIKEHKAVRDNSDSTKIEEDLVHVLLNLQEHGNLEHSLEADSIKGVIQDLIFGGIETSSTAVEWT FSEMLKNPRVLQKAQAEVREVFETEGKINEAEFHKLKYLRLVIKESLRLHPPLPLLLPRQGDGCEI DB1 / 156198702.2 56 Attorney Docket No.: MAN-042PC / 107590-5041 NGYEIPAKSQVIVNAWAIGSDPRYWSDPETFNPERFIESSVDFRGTHFQLVPFGSGRRVCPGISFG LANVELPLVHLLYHFDWKLPDGKANEELDMTETFGVAVSRKSDLYVVPSMHGAS SEQ ID NO: 75 Aquilaria sinensis WT-AsCYP3 (CYP31) MTTKERFKPFLSNSLMDHQFLSLPILFSSILFMLLLLKFWRNRKLSPKLPPGPRKLPLIGNLHQLV GDMPHRRLRDLASKYGPLMHLQLGEVPFIIISSPKTAEQVMKVHDINFASRPNSLGAEIVMYNSSD IALAPYGDHWRQMRKICIMELLSTKRVQQFRSIREEEILNFCRAIGCSAGFPVNLSKMLHSSSYSI IARALIGGKAKDDERFIEITSGVAKSFGGFSIVDVFPSSKLLQVMSGVKSKFESIHQEADEILENI IREHKAVRGSSGSTQTDEDLVHVLLNLQEHGDLEFPLTTDSIKAVILDLILGGIETSATSVEWTMS EMLKNPRVLRKAQAEVRQVFGREGRISETEFHKLEYLRLVIKESLRLHPPLPLLIPRQGGRCEING YEVPAKAKVIVNAWAIGRDPKYWSEPETFNPERFSQRSIDFRGAHFELVPFGAGRRICPGVSFGLA NVELTLVHLLYHFDWKLPHGKLHEDLDMIEAIGSAVGRKWDLFVVPSMHSASYLQF SEQ ID NO: 76 Aquilaria sinensis WT-AsCYP4 (CYP32) MTTFLNASLIDNQLFSVPMLLTSILFMLLLLMVRRNRNLTSKLPPGPPRLPLIGNMHQLMGDMPHR RLRDLASKYGPLMHFQLGEVPCIIISSPETAEQIMKVHDVNFASRPRTLVAEIIEYNCNDVVFGAY GDLWRQLRKICVVELLHAKRVQQFGSLREEEVSNLVQAVRSSAGLPINLSKLFYSSSFNIIIKALI GRKSKGSEKYIEIAERAIKLFGGFSIVDAFPSSKLLQVLSGVKSKLESLHQEADEILENIIQEHKA VRKNSGSTKIEDDLVHVLLNVQEQGNLERPLASDSVKGVIQDLIFGGIETSSTTTDWAFSELLKNP RALQKAQAEVREVFETAEKINEAEFHKLKYLRLVIKETVRLHPSLPLLLPRQGDRREVNGYEIPAN AHVIVNAWAIGRDPRYWSDPETFNPERFIDSSVDFKGNHFELVPFGAGRRICPGISFGLANAELSL VHLLYHFDWKLPDGRPTEELDMTEEFAAVVRRKSDLCVVPYVRAA SEQ ID NO: 77 Aquilaria sinensis WT-AsCYP5 (CYP33) MLLPIYILLALLLLFVVRKIFTGARPGRLPPGPSGPPLIGNLFQLDSFGPHRHLWRLSLKYGPLFT LKLGFKTTLVASSARMAREIMKTHDLDCCSRPLQRGSQKLSYNGLDIVFSPYNSYWREIRRICVVH LFNPNRVQLYRPIREEEVSLMIRKLTSQCQDPSKHGAVNLSDAMMCLTSAIICRVGFGKRYEDEGT EKSRFHELLNETQAMFGAFFVSDYFPLMAWFDRLTGLVRRLDRNFRELDEFYVKCINEHLDPMRLR PEHEDIIDVLLHLQKSREFSVHLTLDHIKAVLMNVLVAGTDTGAATVIWAMVFLMKNPNSMQKVQK EIRSSVGRKGFMNEDDLQHLTYFKALIKETYRLQPTVPLLVPRETIKSFKIDSYEIPARTQIFVNA WAIGRDPEIWDNPEEFRPERFIGSSIDYKGLNYELIPFGAGRRVCPGIHMGALTVELALANLLHTF DWEMPLGMKKEEINFEEIPGITMHKKNALCLVPKLVYHY DB1 / 156198702.2 57 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 78 Aquilaria sinensis WT-AsCYP6 (CYP34) MLLPIYILLALLLLFVVRKIFIGARSCRLPPGPPGPPLIGNLFQLDSFGPHRHLWRLSLKYGPLFT LKLGFKTTLVASSARMAREIMKTHDLDCCSRPLSRGAQKLSYNGLDIGFSPYNSYWREIRRICVVH LFNPNRVQLYRPIREEEVSLMIRKLSSQCQDPSKHGAVNLSDAMMCLTSAIICRVGFGKRYEDEGT EKSRFHELLNESQAMFGAFFVSDYFPLMAWFDRLTGLVRRLDRNFRELDEFYEKCINEHLDPMRPR PEHEDIIDVLLHLQKSREFSVHLTFDHIKAVLMNVLIAGTDTGAATVIWAMTFLMKNPNSMQIVQE EIRSSVGKKGLVNENDLQHLPYFKAVIKETYRLQPTVPLLLPREVIKSFKIDNYEIPAKTQIFVNA WAIGRDPKIWDNPKEFLPERFIGSSIDYKGLDYELIPFGAGRRGCPGIHMGALTVELALANLLYAF DWEMPPGMNKEEIDFEEIPGITVHKKNVLCLVPKKIIIGIYVS SEQ ID NO: 79 Aquilaria sinensis WT-AsCYP7 (CYP35) MLLLICILLALLLLFVVRKIFIGARPGHLPPGPPGPPLIGNLFQLDSFGPHRHLWRLSLKYGPLFT LKLGFKTTLVASSARMAREIMKTHDLDCCSRPLQRGAQKLSYNGLDIAFSPYNSYWREIRRICVVH LFNPNRVQLYRPIREEEVSLMIRKLSSQCQDPSKHGTVNLSDAMMCLTSAIICRVGFGKRYEDEGA EKSRFHELLNESQAMFGAFFVSDYFPLIAWFDQLTGLVRRLDRNFRNLDEFYEKCINEHLDPMRPR PEHEDIIDVLLHLQKSREFSVHLTLDHIKAILMNVLIAGTDTGAATVIWAMAFLMKNPNSMQKVQE EIRSSVGKKGLVNENDLQHLPYFKAVIKETYRMQPTAPLLIPREVIKSFKIDNYEIPAKTQIFVNA WAIGRDPEIWDNPEEFMPERFIGSSIDYKGLDYELIPFGAGRRGCPGIHMGALTVELALANMLYAF DWELPPGMNREEIDFEEIPGITIHKKKALCLVPKKIIIGI SEQ ID NO: 80 Aquilaria sinensis WT-AsCYP8 (CYP36) MLLPIYFLLPLLLLFVVRKIFIGARPAGRLPPGPPGPPLIGNLFQLDSFGPHRHLWRLSLKYGPLF TLKLGFKTTLVASSARMAREIMKTHDLDCCSRPLQRGAQKLSYNGLDIAFSPYNSYWREIRRICVV HLFNPNRVQLYRPIREEEVSLMIRNLSSQCQDPSKHGAVNLSDAMMCLTSAIICRVGFGKRYEDEG TEKSRFHELLNESQAMFGAFFVSDYFPLMSWFDRLTGLVRRLDKNFRDLDEFYQNCINEHLDPMRP MPEQEDIIDVLLHLQKNREFSVHLTLDHIKAILMNVLIAGTDTGAATVIWAMAFLMKNPNSMQKVQ EEIRSSVGKKGFVNEDDLQYLPYFKAVIKETYRLQTTVPLLVPREVIKSFKIDKYEIPAKTQIFIN AWAIGRDPEMWDNPEEFLPERFIGSSIDYKGLDYELIPFGAGRRGCPGIHMGALTVELALANILYA FDWEMPPGMNREDIDFEEIPGITMHKKNALCLVPKKIIIGI SEQ ID NO: 81 DB1 / 156198702.2 58 Attorney Docket No.: MAN-042PC / 107590-5041 Aquilaria sinensis WT-AsCYP9 (CYP37) MESLPILFTSLSFLLVLLVLWTKSRSKKLPPGPRKLPIIGNLHNFSGPLLPHQTITELAKKYGPIM HLQLGQVCAIVMSSPEMAREVMKTHDLHFASRPQPVGGDILFYNYTNMVFVPYGDYARQLRKICVM ELLSPKRVLSFRPIREEEVAKLVAEVSSQAREVVNLRKVIGSNSYRVISRIIIGRMVDPKGRYLGL TKEIIEVLGGFTLSDVFPSLKFLQVLTGVRSKFKRIRQEADAILNNLISEHVAARKSNTKYEEDIL HVLLDLQERDQLGFPLTTDNIKAFMQDLIIGGIETSATITEWGMAELLKNPTVLAKATKEVRGVFG KEGKVTEAGLQQIEYLKLVVKETLRLHPSSPLLLPRENQEKIEINGYEIPAKAKVFVNAWGIVRDP KYWKKAETFWPERFIDNENNADYNGTQFEYVPFGAGRRMCPGISMGLVNVELALANLLFNFDWVLP NGQKNEDLSLAEAHGIAVGRKEPLQAIPIPYNP SEQ ID NO: 82 Aquilaria sinensis WT-AsCYP10 (CYP38) MESLPILFTSLSFLLVLLVLWTKSRSKKLPPGPRKLPIIGNLHNFAGPLLPHQTITELAKKYGPIM HLQLGQVCAIVMSSPEMAREVMKTHDLHFASRPQPVGGDILFYNYTNMVFVPYGDYARQLRKICVM ELLSPKRVLSFRPIREEEVAKLVAEVSSHARELVDLRKVIYSSSYRVISRIIIGKMVDAEGRYIVL TKEIMEVLGGFTLSDVFPSLKFLQVLTGLRSRVKRIGKEVDAILNNFISDHMAARKINTEGLEGDI LHFLLNLQEQGQLRFPLTTDHIKACLQILMLAGIETSAITTEWAMAELLKNPTLLAKATKEVRDVF GKEGKVTEAGLQQIEYLKLVVKETLRLHPAGPLLLPRETQEKIEINGYEIPAKAKVFVNVWAIVRD PKYWKNPETFSPERFIENENHADYNGTNFEYLPFGAGRRMCPGVSMGLANVELALANLLFNFDWVL PNGQRNGDLSLAEAHGISAGRKEPLRAIPIPYTP SEQ ID NO: 83 Aquilaria malaccensis WT-AmCYP11 (CYP39) MESLPILFTSLSFLLVLLVLWTKPRSKKLPPGPRKLPIIGNLHNLAGPLLPHQTIAELAKKYGPIM HLQLGQVCTIVMSSPEMAREVMKTHDLHFASRPQPVGGDILFYNFTDMVFMPYGDYARQLRKICVM ELLSPKRVLSFRPIREAEVAKLVAEVSSHARELVDLRKVVYSSSYRVISRIIIGKMVDAEGRYVEL TKEIMEVLGGFTLSDVFPSLKFLQVLTGVRSRFKRIGKEVDAILNNLISDHMAARKTNTEGHEGDI LHFLLNLQEQGQLRFPLTTDNIKACLQILILGGIETSAITTEWAMAELLKNPTLLAKATKEVRDVF SKEGKVTEAGLQQIEYLKLVVKETLRLHPTSPLLLPRENQEKIEINGYEIPAKAKVFVNVWAIVRD PKCWKNPETFWPERFIENENHADYNGTKFEYLPFGAGRRMCPGVSMGLANVELALANLLFNFDWVL PNGQRNGDLSLAEAHGISVGRKEPLRAIPIPYTP SEQ ID NO: 84 Aquilaria sinensis WT-AsCYP12 (CYP40) DB1 / 156198702.2 59 Attorney Docket No.: MAN-042PC / 107590-5041 MEQFQLPSLSILLTFLSFLILLLKLWTKPRTKNLPPGPPKLPVIGNIHTLAAGGPLPHRTLARLAK KYGPIMHLQLGQISTVVVSSPEMAKEVMKTHDINFAQRPQSIASHVVFYNCTDMVFTQQVEYGKEL RKICVTELLSQKRVLSFRPVRQEESVNLIREITSNAGKPINVRSAIRSMSYKVIARALIGRRAERE ERYIKLTKEVVELLGGFSLSESFPGIKFLPTVTGLRSKLNRIQNEINGILDRIITEHKEFRKQSPS SNGIGQEEDILHVLLNLQEANQLEFPLTRENIKANLQALILAGIDTASTAVEWGMVELLKNPSLLE KATKELRDVFGKQGKVDEAEFHRLHYLKLVIKETLRKHPSAPLLIPRESIDECEINGYKIPAKTRI IINAWAISSDPKYWKDPETFNPERFLEDERTFDYRGNQFEYLPFGSGRRMCPGVAMGLINVELGLA NLLYNFDWKMPEGQRNEDLSLTENFGLSVGRKEDFYAVPYPYKP SEQ ID NO: 85 Aquilaria malaccensis WT-AmCYP13 (CYP41) MLQAALDGIGDHKDALVTKAVFTFLVAAFALYFWILWSVKRSKQSSAPPLPPGPRGLPLLGYLPFL SGKLQLDFTQLSYLYGPILSLWLGKKLCVIITSPEVAKEVVRDHDIIFSNRDPPAVADIITYSGND IAFGSYGPKWRDMRKMFVREMLSNTNLDACYDLRREEVINAVKDLYKKVGQPIDLGQLAFLTEVNA ILSLLWGGKVSGQKGASLWVTFRGLVGDIMDLLGKPDISDFFPALRRFDLQGLQKKMRKIQEYCDK LFDEAIEERLGMGNDDKEITNKKGPTDFLQFLLDLNKSEDPANNISHNQLKAMLVDVVVGGTDTTS TMVEWGMAELLCNPSKMEKLKSELAAVVGLDKFVEESDLPKLRYLEAVFKETLRLHPPLALLIPRS PSESTTVSGYYIPKGSRVFLNVYGIHRNSKYWESPSDFKPERFLDGPESFDFYGNDFRYMPFGSGR RFCAGRPLGEKMVLYLLATLVHSFDWKVPDGKKVDLDEHFGIVLRKGNPLVAIPTPRLTNLGLYKE SEQ ID NO: 86 Aquilaria malaccensis WT-AmCYP14 (CYP42) MLQAALDGASHQKDALPNKSIFTFIVAAFALYFWILWSVKRSKKSSAPPLPPGPRGLPLVGYLPYL GDQLQHDYTQLSSLYGPILSLWLGKKLCVVITSPEVAKEVVRDHDIIFSNRDPPAVADIITYSGND IAFGSYGPKWRNMRKMFVREMLSNTNLDACYDLRREEVINAVKDLYKKVGQPVDIGQLAFLTEVNA ILSLLWGGKVSGQKGASLWVTFRGLVGDIMDLLGKPDISDFFPALRRFDLQGLQKKMRKIQEYCDK LFDEAIEERLGMGNDEEIANKKGPTDFLQFLLDLNKSEDPTNNISHNQLKAMLVDVVVGGTDTTST MVEWGMAELLCNPSKMEKLKGELAAVVGVDNFVEESHLPKLPYLEAVLKETLRLHPPLPFLVPRSP SESTIVAGYSIPKGSRVFLNVYGIHRNSKYWESPCDFKPERFLEGPEKFDFLGNDFRYMPFGSGRR FCAGRPLGEKMVLYLLATLVHSFDWNVPEGKKVDLDEHFGIVLRKSNPLVAVPTPRLTDASLYKT SEQ ID NO: 87 Aquilaria sinensis WT-AsCYP15 (CYP43) MDQNLQIIVALALVLLTVLITLAKLTSSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHRRFRELAQK YGPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMAAVKAITYDHTDIGFSPYGSYWRQLR DB1 / 156198702.2 60 Attorney Docket No.: MAN-042PC / 107590-5041 KICATELLSANCVRSYRSIREEEVANMVASIHSAHGQLPVNLTQKIFSLTFGITARAAFGKKCKDQ EGFIKQVTKLSWLAGGFSMADLYPSLTMLHRIDGSSDEMERVHKEMDRILQEIVREHREERKSITK TEEESEDLVDVLLRLQEQGEFPAGDSNVKAVILDVFTGGGDTSSSTVAWAMSEMLRNPRVMREAQT EVRRVCAGKGTVDEEAIGQMTYLKALETMRLRPVLPLLVPRECSQTCEVGGYTIPAKSRIIVNAWA IGRDPKNWDKAEDFLPERFINGQYDFTGRNMEYIPFGGGRRICPGILFALPNVELPLAQLLFHFDW KLPNGARGEDLEMSEKFGLGVQRMNDLMVIATPYRPM SEQ ID NO: 88 Aquilaria sinensis WT-AsCYP16 (CYP44) MDQNLQIIVALALVLLTVLITMAKLTSSSKRSAKLPPGPRPLPLIGNLHNLVRGLPHHRFRELAQK YGPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMAAVKAITYDHTDIGFSPYGSYWRQLR KICATKLLSANCVRSYRSIREEEVANMVASIHSVHGQLPVNLTQKIFSLTFGITARAAFGKKCKDQ EEFIKQVTKLSWLAGGFSVADLYPSLTMMHRIDGSSDEMEKVHKEMDRILQEIVREHREERKSGTK TEGEAEDLVDVLLRLQEQGEFPADDSNVKAVILDVFAGGSETSSSTVDWAMSELLRNPRVMREAQA EVRRVCAGKGTVDEEAIGQMTYLKVLVKETMRLHPSLPLLVPRECSQTCEVGGYTIPAKSRIIVNA WAIGRDPKNWDKAEDFLPERFIDGQYDFIGRNMEYIPFGGGRRICPGILFALPNVELPLAQLLFHF DWKLPNGAKGEDLEMSEKFGLDVKRMNDLMVIATPCRPM SEQ ID NO: 89 Aquilaria sinensis WT-AsCYP17 (CYP45) MDQNLQIIVALALVLLTTLVTLAKLTSSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHRRFREMAQK YGPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAIVALKSITYDHIDIGFSPYGSYWRQLR KICATELLSANCVLSYRSIREEEVANMVASIHSAQGQLPVNLTQKLFSLTFGITARAAFGKRCKDQ EEFINQVTEFSWLAGGFSMADLYPSLTMLHRIGGSSNQMERVHKEMDRILQEIVREHRKETKTEGE VEDLVDVLLRLQEEAEFPADDSNVKAVILDVFAGGGETSSSTMEWAMSEMLRNPRVMREAQAEVRR VCAGKGTVDEEAIRQMTYLKALVKETLRLHPPIPLLLPRECSQTCEVDGYTIPAKSRIIVNAWAIG RDPKNWDKAEDFLPERFIDGQYDFSGRNMEYIPFGGGRRICPGILFALPNVELPLAQLLFNFDWKL PKGARGEDLEMSEKFGIGVKRMNDLMVIATPYRPLL SEQ ID NO: 90 Aquilaria sinensis WT-AsCYP18 (CYP46) MDQNLQIIVALALVLLTVLVTLAKLTSSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHHRFRELAQK YGPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMVAVKAITYGHTDIGFSPYGSYWRQLR KICATELLSANCVRSYRSIREEEVANMVASIHSAQGQLPVNLTQKIFSLTFGITARAAFGKKCKDQ EEFIKQVTQLSRLAGGFSMADLYPSLTMLHHIGGSSDEMERVHKEMDRILQEIVREHREERKSGTK DB1 / 156198702.2 61 Attorney Docket No.: MAN-042PC / 107590-5041 TEGEAEDLVDVLLRLQEQGEFPADDSNVKAVILDVFAGGSETSSSTVEWAMSEMLRNPRVMREAQA EVRRVCAGKGTVDEEAIGQMTYLKALVKETLRLHPAIPLLLPRECSQTCEVNGYTIPAKSRIIINA WAIGRDPKNWDKAEDFLPERFIDGQYDFTGRNTEYIPFGGGRRICPGILFAQPNVELPLAQLLFHF DWKLPSGARGEDLEMSEKFGAGVKRLNDLMVIATPYRSL SEQ ID NO: 91 Aquilaria sinensis WT-AsCYP19 (CYP47) MDQNLQVIVALALVLLTVLVTLAKLTSSSKSGKLPPGPRPLPLTGNLHNLVGGLPHHRFRELAQKY GPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMVAVKAITYDHTDIGFSPYGSYWRQLRK ICATELLSANCVRSYRSIRKEEVANMVASIRSAHGQLPVNLTQKIFSLTFGITARAAFGKKCKDQE EFIKQVTELSRLAGGFSMADLYPSLRMLHRIGGSSDEMERVHKEMDRILQEIVREHREERKSGTKT EGEAEDLVAVLLRLQEQGEFPADDSNVKAVILDVFAGGSETSSSTVEWAMSEMLRNPRVMREAQAE VRRVCAGKGTVDEEAIGQMTYLKALVKETLRLHPAIPLLLPRECSQTCEVDGYTIPAKSRIIVNAW AIGRDPKNWDKAEDFLPERFIDGQYDFTGRNTEYIPFGGGRRICPGILFAQPNVELPLAQLLFHFD WKLPSGARGEDLEMSEKFGAGVKRLNDLMVIAEPYGAM SEQ ID NO: 92 Aquilaria sinensis WT-AsCYP20 (CYP48) MDQNLQIIVALAVVLLSVLVTLAKLTSSSKRSPKLPPGPRPLPLIGNLHNLVGGLPHRRFRELAQK YGPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPALVAMKAITYDHTDVGFSPYGSYWRQLR KICATELLSANCVRSYRSIREEEVANMVTSIRSAQGQLAVNLTQKILSLTFGITARAAFGKKCKDQ EEFIKRVTELSRLAGGFTMADLYPSLTILHRIDGTRDEMERVHKEMDRILQEIVREHREERKSGTK TEGEAEDLVDVLLRLQEQGEFPADDSNVKAVILDVFVAGSDTSSSTVEWAMSEMLKNPRVMREALA EVRRVCAGKGTVDEEAIGQMTYLKALVKETLRLHPAIPLLLPRECSQACEVDGYTIPAKSRIIVNA WAIGRDPKNWDKAEDFLPERFIDSMYDFTGRNTEYIPFGGGRRICPGILFALPNVELPLAQLLFHF DWKLPNGAKGEDLEMSEKFGAGVKRMNDLMVIATPYRPL SEQ ID NO: 93 Aquilaria sinensis WT-AsCYP21 (CYP49) MDQNLQIIVALALVLLTVLVTLAKLTSSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHRRFRELAQK YGPLIHLKLGEVSTIVASSPEMAREVLKTHDSIFAYRPAMVAVKAITYDHTDIAFSPYGSYWRQLR KICATELLSANCVRSYRSIREEEVANMVTSIRSAQGQLPVNLTQKIFSLTFGITARAAFGKKCKDQ EEFIKLVTELSRLAGGFTMADLYPSLTMLHRIDGSRDEMERVHMEMDRILQEIIREHREERKSGTK TEGEAEDLVDVLLRLQEQGEFPANDSNVKAVILDVFVAGSETSSSTVEWAMSEMLRNPRVMREAQG ELRRVCAGKGTVDEEAIGQMTYLTALVKETLRLHPAVPLLLPRECSKTCEVDGYTIPAKSRIIVNT DB1 / 156198702.2 62 Attorney Docket No.: MAN-042PC / 107590-5041 WAIGRDPKNWDKAEDFLPERFIDGKYDFTGRSTEYIPFGGGRRICPGILFALPNVELSLAQLLFHF DWKLPNGAKGEDLEMSEKFGVDVKRMNNLMVIGTPYRPV SEQ ID NO: 94 Aquilaria sinensis WT-AsCYP22 (CYP50) MDISFPILLSLVAFLLFLLVILKARRKPSPTFPPGPSKLPIIGSMHHLAGALPHRILADLAKKYGP LMHLQLGEVSTIVVSSPELAKQVMKTHDIIFSSRPYIPSQGIFSYGNKDIAVAPYGEYWRQLRKIC MVELLSLKRVQSYGPIRERVVSNTIQTIASGAGSPVNLSNMIYSTTIGVVLRAAFGETCRFQEKFI QVVKKSTQLAGGLSLPDVFPSRNSLFVLSGRKYRCEKVHKEIDKILSGIIEEHKARKREGKGISDQ QEAEDLVQVLLDIQDRGDLQFSLTTSDIKGVIQDIFVAGSDTSSSTVEWAMSEMLRNPRTLEKAQV EVRDVFGRKGKVDDEGLQELKYMKSVIKETLRTHPPLALLIPRESMDECELNGYNIPSKTQVIVNA WAIGRDPDYWTEPDKFFPERFLESSVDFKGNHFEFIPFGAGRRICPGMPFGLANAERLLAELLFHF DWKLPSGKRPQELDMTEKFGAVVARKNKLYLTPVPYRK SEQ ID NO: 95 Aquilaria sinensis WT-AsCYP23 (CYP51) MDISFPILPSLVAFLLFLLVILKTRRKPSPNFPPGPSKLPLIGSMHHLAGALPHRILADLAKKYGP LMHLQLGEVPTIVVSSPELAKQVMKTHDIIFSSRPYIPSQGIFTYGNKDIAAAPYGEYWRQLRKIC IVELLSLKRVQSYGPIRERVLSNTIQTIASGAGSPVNLSNMIYSTTIGVVLRAAFGETCKFQEEFI QVVKKSTQLAGGLSLPDVFPSRNSLFVLTGRKYRCEKVHKEMDKILSGIIEEHRARKREGKGISDQ QEAEDLVQVLLDIQDRGDLQFSLTTRDIKGVIMDVFVAGSDTSSSTVEWAMSEMLRNPRTLEKAQV EVRDVFGRKGKVDDEGLQELKYMKSVIKETLRTHPPLALLIPRESMDKCELNGYNIPSKTQVIVNA WAIGRDPDYWTEPDKFFPERFLESSVDFKGNHFEFIPFGAGRRICPGMPFGLANAERLLAELLFHF DWKLPNGKRPQELDMKEKFGIVVARKNNLYLTPIPYRK SEQ ID NO: 96 Aquilaria sinensis WT-AsCYP24 (CYP52) MDFSFPILSSILASLLFLLMILKAARKSKSQIVSPNLPPGPPKLPIIGNMHHLFGSLPHRILGDLA KKYGPLMHMQLGEVSTIIVSSPEIAKEVMKTHDIIFSSRPFIPSQGIISYNCEDIACAPYGEYWRQ LRKICIVELLSVKRVQSFGSIRERVVSDMVQTIASGADSPVNLSKLIYSATIGITLKAAFGEKCQY QEEFIQVVKKSTELTGGLSLADVFPSRRSLFVLTARKYRCEKVHKEVDKILNDIIKEHRSGKREGK GIGDQQEAEDLVQVLLDIQDRGDLQFPLTANNIKGVIQDIFVAGGDTSSTTVEWAMSEMLRNPITM EKAQAEVRAVFGKKGKVEEARLQELKYMKSVMKETFRIHPPLALLVPRESIDECEVSGFCIPAKTQ VILNAWAIGRDPNHWNEPEKFCPERFLETPVDYKGNHFEFIPFGAGRRICPGMPFGIANVELLLAE LLYHFDWKLPNGMRPEDLDMTEMFGIVVRRKKELYLTPISYAN DB1 / 156198702.2 63 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 97 Aquilaria sinensis WT-AsCYP25 (CYP53) MDISLPIFPTILALLIFLPMILKASRRKSGAEKLSPNLLPGPPKLPIIGNLHQLFGSLPHHVLGEM ANKYGPIFHLQLGEASTVVVSTPELAQEVMRTHDVIFANRPSVPSQNVISYNGRDIVSAPYGDHWR QLRKLCTIQLLSHKRIQSYEPIRERVVSDMVQTIASRAGSVVNLSKLIYSAAIQIIMKSAFGEKCQ VREDFIQVVHRTTEVTEGMSLSDHFPSKKFLFTLTGMKSQCEKVLNDIDNILNGVIEEHRSRKREG KGSRDEHEAEDLLQILMDIQEKGDPEIPLTMDDIKGVVMDVFVAGAGTSASTVEWTMSELMRNPRI MEKAQAEVRAVFGKKGKVDEAGLEELTYVKSVIKEDLRVHIPLPLLIPRESTEECELGGFKLPPKT RVIINGWSTGRDPNYWKEPEKFYPERFLGSPVDYKGHHFEFVPFGAGRRICPGVSFGIMNVELLLS NLLYHFDWKLPYGMKPEELDMTEKAGLTVMRKHELFITPTPHLK SEQ ID NO: 98 Aquilaria sinensis WT-AsCYP26 (CYP54) MDISFPIFPTILALLIFLPMILKASRRKSGAGKLSPKLLPGPPKLPIIGNLHQLSGSLPHHILGDM AKKYGPIFHLQLGEASTVVVSTPELAQEVMKTHDVIFANRPSLPSQYVISYNGQDIVSTPYGDRWR QLRKLCTIQLLSQKRIQSYEPIRERVVSDMVQTIASGAGSVTNLSKFIYSAAIQIIMKSAFGEKCQ VRDDFIQVVHRTTEATEGMSLSDHFPSKKFLFMLTGMKPRCEKILNDIDNILNEIIEEHRSRKREG KGSRDEHEAEDLLQILMDIQEKGDPEIPLTMDDIKGVVMDVFVAGAGTSASTVEWTMSELMRNPRI MEKAQAEVRAVFGKKGKVDEAGLEELTYVKSVIKEDLRVHIPLPLLIPRESTEECELGGFKLPPKT RVIINGWSTGRDPNYWKEPEKFYPERFLGSPVDYKGHHFEFVTFGAGRRICPGVSFGIMNVELLLS NLLYHFDWKLPYGMKPEELDMTEKAGLTVMRKHELFITPTLHLK SEQ ID NO: 99 Aquilaria sinensis WT-AsCYP27 (CYP55) MDISFPIFPTILALLIFLPMILKASRRKSGAGKLSPKLLPGPPKLPIIGNLHQLSGSLPHHILGDM AKKYGPIFHLQLGEASTVVVSTPELAQEVMKTHDVIFANRPSLPSQYVISYNGQDIVSTPYGDRWR QLRKLCTIQLLSQKRIQSYEPIRERVVSDMVQTIASGAGSVTNLSKFIYSAAIQIIMKSAFGEKCQ VRDDFIQVVHRTTEATEGMSLSDHFPSKKFLFMLTGMKPRCEKILNDIDNILNEIIEEHRSRKREG KGSGDEQEAVDLLQILLDVQEKGDPEIALTMGNIKGVVMDVFVAGAGTSASTVEWTMSELMRNPRI MEKAQAEVRAVFGKKGKVDEAGLEELTYLKALIREDLRVHIPLPIIIPRESTEECELGGFNLPPKT RVIINARAMARDPNYWEEPEKFYPERFLGSPIDYKGHHFEYVPFGAGRRICPGLSFGIMNVEIILS NLLYHFDWKLPNGMKPEELDMTEKAGLTVTRKNELFVTPTLYRE SEQ ID NO: 100 DB1 / 156198702.2 64 Attorney Docket No.: MAN-042PC / 107590-5041 Aquilaria sinensis WT-AsCYP28 (CYP56) MDVSFPTIPSILAFAFFLLMILKAIWRKSEAKKFTKNLPPGPPKLPIIGNVHQLFAPLPHHVLGDM AKKYGPLVHLQLGEASTVLVSSPELAQEVMKTHDLIFANRPYVPSQDVISYHSGDIVTAPYGEFWR LLRKICVVQLLSVKRIQSYEPIRERVVSDMVQTIASGAGSSVNLSKMIYASTIQIIMKSAFGEKCQ VREDFIQVVHKTTEVTEGMALADLFPSRKFLFSLTGLKRRCEKVLKEIDMILDEIIEEHRSRKREG KANGDGQEAEDLVQILLNLQDQGDPEMSLTTDNIKAVIMDVFVAGAGTSASTVEWTMSELLRNPRV MEKAQAEVRAVFGNKGKVDEAGLQELKYLKLVIKENLRTHTPLPLLIPRESTDKCELNGFHIPPKT RVIINAWAMARDPKYWNEPEKFYPERFSDSSRDYKGNHFELIPFGAGRRICPGLSFGIMNVELLLA QLLYHFDWKLPNGMRPEALDMTEKPGLTVMRNSELFVTPIPYLK SEQ ID NO: 101 Aquilaria sinensis WT-AsCYP29 (CYP57) MASTFITLLAFAFVFVAWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAPKYGPIMHL RLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNMRKMCTLEL LSNLKINSFRRMRKEELNVFIESIKEASQRGGVVNLSEKVTTLIAGMACRMIFGKKYEVNDIDEKG FKDLIQEGMHLFAKPNIGDYIPQISRLDLQGMTKKMKIISEKFDDFLEIIIDEHVEMRRSSIGHMR KTQDFVDVMLEIMGSKEAEYPLERGNVKAIILDMFVAASDTSASIIDWALSELIRHPKVMKKVQKE LEDVVGLERMVEESHLEKLNYLEMVVKETLRLHPVGPLLLPHASIEDCTIDGFYIPKKSLLMVNVW AIGRDPTVWLEAEKFWPERFEGCKVDLRGRDFELLPFGSGRRSCPGMQLGLTMVWLVLGQLVHCFD WELPNGILASELDMTKKFGLVTSRAKPLLAMPSYRLNL SEQ ID NO: 102 Aquilaria sinensis WT-AsCYP30 (CYP58) MAWTFITLLALVFVFVAWLLKPKASPKKLPPGPRGLPVFGSLHLLGELPHQDLHRLAQKYGPIMHL RLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNMRKMCTLEL LSNLKINSFRRMRKEELNVFIESIKEASQRGGVVNLSEKVTTLIAGMACRMIFGKKYEVNDIDEKG FKDLIQEGMHLFAKPNIGDYIPQIKGFDMQGITKKMKIVAKKFDDFLEMIVDEHVEMRRSSTGNKQ NTQDFVDVMLDIMGSREAEYVLERDNVKAIILDMFVAASDTSASIIDWALSELIRHPTVMKKVQKE LEDVVGLERMVEESDLEKLNYLEMVVKETFRLHPAGPLLLPHASIEDCTIDGFHIPKKSHLMVNTW AIGRDPMVWPEAEKFWPERFEGSKVDLRGKDFELLPFGYGRRSCPGMQLGLTVVPLVLGQLVHCFD WKLPNGMLVSELDMMEKFGLVTSRAKPLLAMPSYRLNL SEQ ID NO: 103 Aquilaria sinensis WT-AsCYP31 (CYP59) DB1 / 156198702.2 65 Attorney Docket No.: MAN-042PC / 107590-5041 MVWTFITLLAFAFVFVAWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAQKYGPIMHL RLGLVHTIVVSSPRAAELFLKAHDLVFASRQPRKAAKHLSYGQKNLTFAPYGSYWRNMCKMCTLEL LSNLKINSFRWMRKEELNVFIESVKEASQCGGVVNLSEKVTTLIAGVSCRMIFGNKYEIKGIDEKG FKDLIREGMHLSAKPNTGDYIPQISRLDLQGMTKKMKIISEKFNDLLEMIVDEHVEMKRSSIGRMR KTQDFVDVMLEIMGCKDAEYPLERDNVKAIILDMFVAATDTSASVIDWALSELIRHPRVMKKVQKE LEDVVGLERMVEESYLEKLNYLEMVVKETFRLHPVGPLLAPHASIEDCTIDGFYIPKKSLLMVNVW AIGRDPTVWLEAEKFWPERFEGCKVDLRGRDFELLPFGSGRRSCPGMQLGLTMVWLVLGQLVHCFD WELPNGILASELDMTKKFGLVTSRAKDLHAVPSYRLNL SEQ ID NO: 104 Aquilaria sinensis WT-AsCYP32 (CYP60) MVWTFITLLAFAFVFVAWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAQKYGPIMHL RLGLVHTIVVSSPRAAKLFLKDHDLVFASRPPREAAKHLSYDQKNLTFAPYGSYWRNMRKMCTLEL LSNLKINSFRLMREEELNVFIESIKEASQRGGVVNLSEKVTTLIAGMSCRMIFGKKYKIKEIDDKG FKDLIQEGLHLSAKPNIGDYIPQISRLDLQGMTKKMKIISEKFDDFLEIIIDEHVEMRRSSIGHMR KTQDFVDVMLEIMGSKEAEYPLERGNVKAIILDMFVAATDTSASVIDWALSELIRHPKVMKKVQKE LEDVVGLERMVEESHLEKLNYLEMVVKETLRLHPVGPLLLPHASIEDCTIDGFYIPKKSQLMVNVW AIGRDPTVWLEAEKFWPERFEGCKVDLHGRDFELLPFGSGRRSCPGMQLGLTVVRLVLGQLVHCFD WELLNGMLVSELDMTEKFGLVTSRAKDLHAMPSYRLNL SEQ ID NO: 105 Aquilaria sinensis WT-AsCYP33 (CYP611) MASTFITLLAFAFVFVAWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAPKYGPIMHL RLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNMRKMCTLEL LSNPKINSFRWMRKEELDTLIKSIKKASQCGGMVNLTEKIASLITSMSCRMIFGKKYEDKDIDERG FKDLIQECMHLLAKPSIGNYVPQISRLDIQGMTKKIKIIREKLDVFLEMIVDEHVEMRSSSTGDMS KMQDFVDVMLEIMGSKKAEYPLERDNIKAITLDMFVSALDTSSTTIEWAFSELIRHPMMMEKVKKE LEDVVGLERMVEESDLEKLNYLEMVVKETQRLHAVVPLLLPHASMEDCNVDGFNIPKKSRVLVNAW AIGRDPLAWPKAEKFWPERFEGSQVDVHGRYFELLPFGSGRRRCPGMQLGLTVVRLVLAQLVHCFD WELPDGMLPSELDMTEEFGLVISRANHLHAIPSYRLNM SEQ ID NO: 106 Aquilaria malaccensis WT-AmCYP34 (CYP62) MAWTFITLLAFAFVFAAWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAQKYGPIMHL RLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNVRKMCTLEL DB1 / 156198702.2 66 Attorney Docket No.: MAN-042PC / 107590-5041 LSNPKINSFRWMRKEELDTLIKSIKKASQCGGMVNLTEKVASLITSMSCRMIFGKKYEDKDIDERG FKDLIQECMHLLAKPSIGNYVPQISRLDIQGMTKKIKIIREKLDVFLEMIVDEHVEMRSSSTGDMS KMQDFVDVMLEIMGSREAAYLLDRDSVKAIILDMFVAATDTSATVINWALSELIRHPRVMKKVQKE LKDVVGLKRMVEESDLEKLNYLEIVVKETLRLHPAGPLLLPHESIEDCTIDGFHIPKKSQLLVNVW AIGRDPTVWLEGEKFWPERFEGCKVDLHGRNFKLLPFGFGRRSCPGMQLGLTMVRLVLGQLVHCFD WELPNGMLVSELDMTEEFRFVTSRAKHLHAMPSYRLNL SEQ ID NO: 107 Aquilaria malaccensis WT-AmCYP35 (CYP63) MAWAFMTILALAFLFVACLLKPKARAKKLPPGPTGLPLIGSLHLLGKHPHRDLHRLAQKYGPIMHL KLGLVPTIVISSPRAAELFLKDNDLIFADRPPHEAAKHISYGQKNLTFAPYGSYWRDMRKLCTLEL LSNLKINSFRWMRKEELDLLIQSIKEASRRQGVVNLSEKVASLSANMSCRMVFGKKYEGKDIDERG FKGLIQEGMHLFATPNIGDYIPHLSRLDLQGLTKKMKIINKKTDDFIEMIIDEHIEIRRSSTGDMG RGQDFVDVMLEIMGSKKAEYPLERDNIKAITLDMFVSALDTSSTTIEWALSELIRHPMMMEKVKKE LEDVVGLERMVEESDLEKLNYLEIVVKETLRLHPAGPLLLPHESIEDCTIDGFHIPKKSQLLVDVW AIGRDPTVWLEGEKFWPERFEGCKVDLHGRNFKLPPFGFGRRSCPGMQLGLTMVRLVLGQLVHCFD WELPNGMLVSELDMTEEFRFVTSRAKHLHAMPSYRLNL SEQ ID NO: 108 Aquilaria sinensis WT-AsCYP36 (CYP64) MEQLTLILYSSLSLLFLLLAFHLTRRRNNLPPAPPSLPIIGHLHLLKPPIHRVYHLLSHKYGPIFS LHFGSRHVVVVASSALAEECFTKNDIVLANRPRTIGGKHLNYNHTTMGSSSYGDHWRNLRRIGAVE IFSSARLNAFLTVRTDEIQRLLLRLSRDSRDKFERVELRPLLTDLTFNNIMRMVAGKRYYGNDVPG EEEEARKFRDMITEVFLLGGAVNRGELLPSLNWIGKRRYEKRIKNLAGTFDGLLQGLVDEHRRGQR KNTMIDHLLSLQQSQPDYYTDQIIKGLILVLVLAGTDTSAVTLEWAMSNLLNHPEVLEKVRAELDA EIGQEKLLEEQDVNKLPDLQNVIWETLRLYPPGPMLLPHVASADCRIGGYDVPRDTMVLVNAWAIH RDPKVWEDAESFKPERFEKEGRQSHKMMPFGLGRRACPGEGLAHRVVALALGSMVQCFDWEKINED QIEMSEGTGTTMPKAQPLEALCRARPIVHQVFYAAA SEQ ID NO: 109 Aquilaria sinensis WT-AsCYP37 (CYP65) MEQLTLILYSSLSLLFLLLAFHLTRRRNNLPPAPPSLPIIGHLHLLKPPIHRVYHLLSHKYGPIFS LRFGSRHVVVVASSALAEECFTKNDIVLANRPLTIGGKHLSYNHTTIVSSSYGDHWRNLRRIGAVE IFSSARLNTFLTVRTDEIQRLLLRLSRDSKDKFARVELRPLLTDLTFNNIMRMVAGKRYYGNDVPG EEEEARKFRDMITEVFLLGGAVNPGELLPLLNWIGKRRYEKRIKNLAGTFDGLLQGLVDEHRRGER DB1 / 156198702.2 67 Attorney Docket No.: MAN-042PC / 107590-5041 KNTMIDHLLSLQQSQPDYYTDQIIKGLILVLVLAGTDTSAVTLEWAMSNLLNHPQVLEKVRAELES EIGQEKLLEEQDVNKLPYLQNVIWETLRLYPAAPMLLPHVASADCRIGGYDVPRDTMVLVNAWAIH RDPKVWEDAESFKPERFEKEGRQSHKMMPFGLGRRACPGEGLAHRVVALALGSMVQCFDWEKINED QIEMSEGTGTTMPKAQQLEALCRARPIVHQVFYAAA SEQ ID NO: 110 Aquilaria malaccensis WT-AmCYP38 (CYP66) MEQLTLILYSALSLLFLVLAFHLTRRRNNLPPAPPSLPIIGHLHLLKPPIHRVYHLLSHKYGPIFS LRFGSRHVVVVASSALAEECFTKNDIVLANRPLTIGGKHLSYNHTTMASSSYGDHWRNLRRIGAVE IFSSARLNAFLTVRTDEIQRLLLRLSRDSREKFARVELRPLLTDLTFNNIMRMVAGKRYYGNDVPG EEEEARKFRDLITEVFMLGGAVNPGEFLPLLNWIGKLRHEKRIKNLAESFDGLLQGLVDEHRRGER KNTMIDHLLSLQQSQPDYYTDQIIKGLILVLVLAGTDTSAVTLEWAMSNLLNHPQVLKKVRAELDA EIGQEKLLEEHDVNKLPYLQNVIWETLRLYPPAPMLLPHVASADCKIGGYDVPHDTMVLVNAWAIH RDPKVWEDAESFKPERFEKEGRQSHKMMPFGLGRRACPGEGLAHRVVALALGSMVQCFDWEKINED QIEMSEGTGTTMPKAQPLEALCRARPIVHQVFYAAA SEQ ID NO: 111 Aquilaria sinensis WT-AsCYP39 (CYP67) MQETTVMYSCLSALVILLALKLLLPSKTRRKNLPPGPPSLPFIGHLHLVRPPVHRILLNISQKYGP IISLRFGSRPVVVISSASLAEECFTKHDIALANRPRLLAGKHVGYNYTTMVNSPYGDHWRNLRRIG AIEIFSASRLNAFLEVRKDEIRRLLLRLSTNSRCVFARVELKSMLTDLTFNNIIRMVAGKRYYGHE AHDVKDQAEAEEFKGLIRELLMSGGAANPGDFLPIVKWLGKLEKKLIGLAKRMDRFMQGLIDEQRS KRGANTMIDHLLSLQEQDPEYYSDNIIKGIVMVLVIAGTDTTSVTLEWAMTNLLNHPDVLRKAREE MDAVVGQETLVDEPDVTNLPYLQNIVSETLRLHPAAPLLVPHMPSNDCNIGGYDVPCGTIVLVNAW AIHRDPKLWEDPTSFKPERFEKEEKEGHKMLPFGLGRRACPGAPLAQRLVSLALGSLIQCFEWERL GEEAIDITEVKVGIAHKAIPLEAMCKARPIVDKLFNAENN SEQ ID NO: 112 Aquilaria sinensis WT-AsCYP40 (CYP68) MEETTIIYSSLSALVFFLALKVLLRSKTSRKNLPPGPPSLPFIGHLHLIKPPVHRLFHSLSLKYGP IFSLRFGSRPVVVISSAALAEECFTKHDIVLANRPRLLFGKYIGYDYTTMVNSPYGDHWRNLRRIG AIEIFSASRLNALLGVRKDEIRLLLLRLSTNSRGGFARVELKSMFTDLTFNNIMRMVAGKRYYGED VKDKAQAEEFKRLVKELVMTGGAGNPSDFLPMVKWFGFEKKLKGLSNRLDRFMQGLIDEQRSNRGA NTMIDHLLYLQESDPEYYSDKIIKGIIMVLLLAGTDTTSVTLEWAMSNLLNNPEVLKKAREEMDAI VGQETLIDEPDAANLPHLQNIVTETLRLHPAAPLLVPHTPSSDCTIGGYDVPRDTIVLVNAWGIHR DB1 / 156198702.2 68 Attorney Docket No.: MAN-042PC / 107590-5041 DPNLWEDPTSFKPERFEKEEKEGHKMLPFGLGRRACPGAPLAQRMLGLVLGSLIQCFEWERVSEEA IDMAEARGGIAHKAVPVEAMCRARPIVDKVLHA SEQ ID NO: 113 Aquilaria malaccensis WT-AmCYP41 (CYP69) MEETTIIYSFSALLLLLALKLLLRSKIRHKNLPPGPRSLPIIGHLHLIKPPVHGLFHNLSQKYGPI LSLRFGSRPVVVISSAALAEECFTKHDIVLANRPRLLFGKYIGYDYTTMVHSPYGDHWRNLRRVGA IEIFSASRLNAFLGVREDEIRRLLLRLSTRARGGLARVELKPMFTDLTFNNIMRMVAGKRYYGDEV KDKAEAEEFKGLIKELVKTGGAGNPADFLPMVKWLGFEKKLKGLSNGLDRFMQRLIDEKRRNRGAN TMIDHLLSLQESDPEYYSDKIIKGILMVLLLAGTDTTSVTLEWAMSNLLNNPEILKKAREEMDAIV GHETLINESDVANLPYLQNIVSETLRLHPAAPLLVPHTPSTDCTIGGYDVPRDTIVLVNSWGIHRD PNLWENPTSFKPERFEKEEKEGHKMLPFGLGRRACPGAPLAQRMLGLVLGSLIQCFEWERVSEEAV DLTEARGGVAHKAVPLEAMCRARPVVDRVLYAKK SEQ ID NO: 114 Aquilaria malaccensis WT-AmCYP42 (CYP70) MEQVNVIILYSSLSVLFLLLSFKLTRRRYNLPPAPPSLPIIGHLNILKPPIHRLYHRLSHKYGPIF SLRFGSRLVLVVSSSTLAEDCFTTNDIVLANRPRLFASRCLGYNGTVLSTASYGDHWRNLRRIGAV EIFSSVRLNAFLAIRTDEIRRLLLRLSQDSREQFARVQLRHMLTDLTFNNIMRMMAGKRYYGNDVP GEEEEARKFRDLISEAFRAGGVPNPRDYLPILNWFGEGSFQKKIKNLAKSLDGLLQGLLEEHRRGE RRNTMIDHLLSLQQSEPDYYTDQIIKGLVLVLVLAGTDTSAVTLEWAMSNLLNYPRVLQKLKVELD EQIGQEKLLEEQDLSKLPYLENVIWETLRLYPPAPLLLPHVASADCRIGGYDVPRDTMVIVNVWAI HRDPDVWEDAESFKPERFETEARESHKLMPFGLGRRACPGAGLAHRVVALALGSMVQCFEWERVGE DPIDMSEGTGSVMPKDQPLEVLCRARPIVHKVFYVL SEQ ID NO: 115 Aquilaria sinensis WT-AsCYP43 (CYP71) MSQPYIIILYSSVSLLFLLAIFKLTRRRSNLPPGPPSLPIVGHLHLLKPPIHRFYHRLSHKYGSIF SLRFGSRLVVVLSSSALAEECFTKNDVVLANRPRLIATKYLGYNSTTVSTSSYGDHWRNLRRIGAV EIFSSARLNAFLAVRTDEVRRLLLRLSLDSRDTFARVELKPMLTDLTLNNIVRMVAGRRYYGNDER GDEDEGREFRKLIAGIFRVGGSANPGDYSPVLKWADRGRFEKRIKNLSERLDRVLQGLVDEHRQGE TKNTMIDHLLTLQKSQPDYYTDQIIKGLVLVLLLAGTDTSAVTLEWAMANLLNNPRVLQKLKAEID EQIGHEKLLEEEDAPKLPYLQNVIWETLRLNPALPLLLPHVASDDCSIGGYNVPRDTMVVVNAWAI HRDPQVWEDAESFKPERFEREEIKESRKLMPFGLGRRACPGAGLAHRVVALALGSMIQCFEWRKVG EDPVDMSEGIGSTMPKAQPLEALCRARPVVHRVFYGVSK DB1 / 156198702.2 69 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 116 Aquilaria sinensis AsCYP1 (CYP72) MAQDLRLILIIVGAIAIIALLVHGFWRNRKLSPKLPPGPRKLPLIGNLHQLVGDMPHRRLRDLASK YGPLMHLQLGEVPFIIISSPKTAEQVMKVHDINFASRPNSLGAEIVLYNSSDIAFAPYGDHWRQMR KICIMELLSTKRVLQFRSIREEEILNFCRAIGSSAGFPVNLSKMLYSCSYGIIARALIGRKAKDDE RYIEITGRIIKLFAGFSIVDAFPSSKLLQVMSGVKSKFESIRQEADEFLDNIIKEHKAVKGSSGST ETEDDLMHVLLNLQEHWDLEFPLTTDSIKAVIQDLILGGMETSATTVDWAISEMLKTPRVLHKVQA EVRQVFEKEGRISETEFHKLEYLRLVIKESLRLHPPLPLLVPRQGDRCEINGYEIPAKAQVMVNAW AIGRDPKYWSDPEIFIPERFLESSVDFRGTHFELIPFGAGRRTCPGISFGLANVELTLVHLLYHFD WKLPDGKAYEDLDMTEAFGVSMRRKWDLFVVPTMNSASYLQ SEQ ID NO: 117 Aquilaria sinensis AsCYP2 (CYP73) MAQDLRLILIIVGAIAIIALLVHGFWRNRNLRPKGPPGPRKLPLIGNLHQLNGDMPHRRLRDLASK YGPLMHLQLGEVHFIIISSPETAEQIMKVHDINFASRPRTLAAEIVMYNCKAVVFGPYGDLWRQLR KICVTGLLTAKRVQQFGSIRGEEVSNIVRAISSSAGLPINLSKMFHSSAYNIIIKALIGGKAKDSE RYIEITERAVELFGGFSIVDAFPSSKLLQVMSGMKSKLEILDQEADEILENIIKEHKAVRDNSDST KIEEDLVHVLLNLQEHGNLEHSLEADSIKGVIQDLIFGGIETSSTAVEWTFSEMLKNPRVLQKAQA EVREVFETEGKINEAEFHKLKYLRLVIKESLRLHPPLPLLLPRQGDGCEINGYEIPAKSQVIVNAW AIGSDPRYWSDPETFNPERFIESSVDFRGTHFQLVPFGSGRRVCPGISFGLANVELPLVHLLYHFD WKLPDGKANEELDMTETFGVAVSRKSDLYVVPSMHGAS SEQ ID NO: 118 Aquilaria sinensis AsCYP3 (CYP74) MAQDLRLILIIVGAIAIIALLVHGFWRNRKLSPKLPPGPRKLPLIGNLHQLVGDMPHRRLRDLASK YGPLMHLQLGEVPFIIISSPKTAEQVMKVHDINFASRPNSLGAEIVMYNSSDIALAPYGDHWRQMR KICIMELLSTKRVQQFRSIREEEILNFCRAIGCSAGFPVNLSKMLHSSSYSIIARALIGGKAKDDE RFIEITSGVAKSFGGFSIVDVFPSSKLLQVMSGVKSKFESIHQEADEILENIIREHKAVRGSSGST QTDEDLVHVLLNLQEHGDLEFPLTTDSIKAVILDLILGGIETSATSVEWTMSEMLKNPRVLRKAQA EVRQVFGREGRISETEFHKLEYLRLVIKESLRLHPPLPLLIPRQGGRCEINGYEVPAKAKVIVNAW AIGRDPKYWSEPETFNPERFSQRSIDFRGAHFELVPFGAGRRICPGVSFGLANVELTLVHLLYHFD WKLPHGKLHEDLDMIEAIGSAVGRKWDLFVVPSMHSASYLQF SEQ ID NO: 119 DB1 / 156198702.2 70 Attorney Docket No.: MAN-042PC / 107590-5041 Aquilaria sinensis AsCYP4 (CYP75) MAQDLRLILIIVGAIAIIALLVHGFWLMVRRNRNLTSKLPPGPPRLPLIGNMHQLMGDMPHRRLRD LASKYGPLMHFQLGEVPCIIISSPETAEQIMKVHDVNFASRPRTLVAEIIEYNCNDVVFGAYGDLW RQLRKICVVELLHAKRVQQFGSLREEEVSNLVQAVRSSAGLPINLSKLFYSSSFNIIIKALIGRKS KGSEKYIEIAERAIKLFGGFSIVDAFPSSKLLQVLSGVKSKLESLHQEADEILENIIQEHKAVRKN SGSTKIEDDLVHVLLNVQEQGNLERPLASDSVKGVIQDLIFGGIETSSTTTDWAFSELLKNPRALQ KAQAEVREVFETAEKINEAEFHKLKYLRLVIKETVRLHPSLPLLLPRQGDRREVNGYEIPANAHVI VNAWAIGRDPRYWSDPETFNPERFIDSSVDFKGNHFELVPFGAGRRICPGISFGLANAELSLVHLL YHFDWKLPDGRPTEELDMTEEFAAVVRRKSDLCVVPYVRAA SEQ ID NO: 120 Aquilaria sinensis AsCYP5 (CYP76) MAQDLRLILIIVGAIAIIALLVHGFTGARPGRLPPGPSGPPLIGNLFQLDSFGPHRHLWRLSLKYG PLFTLKLGFKTTLVASSARMAREIMKTHDLDCCSRPLQRGSQKLSYNGLDIVFSPYNSYWREIRRI CVVHLFNPNRVQLYRPIREEEVSLMIRKLTSQCQDPSKHGAVNLSDAMMCLTSAIICRVGFGKRYE DEGTEKSRFHELLNETQAMFGAFFVSDYFPLMAWFDRLTGLVRRLDRNFRELDEFYVKCINEHLDP MRLRPEHEDIIDVLLHLQKSREFSVHLTLDHIKAVLMNVLVAGTDTGAATVIWAMVFLMKNPNSMQ KVQKEIRSSVGRKGFMNEDDLQHLTYFKALIKETYRLQPTVPLLVPRETIKSFKIDSYEIPARTQI FVNAWAIGRDPEIWDNPEEFRPERFIGSSIDYKGLNYELIPFGAGRRVCPGIHMGALTVELALANL LHTFDWEMPLGMKKEEINFEEIPGITMHKKNALCLVPKLVYHY SEQ ID NO: 121 Aquilaria sinensis AsCYP6 (CYP77) MAQDLRLILIIVGAIAIIALLVHGFIGARSCRLPPGPPGPPLIGNLFQLDSFGPHRHLWRLSLKYG PLFTLKLGFKTTLVASSARMAREIMKTHDLDCCSRPLSRGAQKLSYNGLDIGFSPYNSYWREIRRI CVVHLFNPNRVQLYRPIREEEVSLMIRKLSSQCQDPSKHGAVNLSDAMMCLTSAIICRVGFGKRYE DEGTEKSRFHELLNESQAMFGAFFVSDYFPLMAWFDRLTGLVRRLDRNFRELDEFYEKCINEHLDP MRPRPEHEDIIDVLLHLQKSREFSVHLTFDHIKAVLMNVLIAGTDTGAATVIWAMTFLMKNPNSMQ IVQEEIRSSVGKKGLVNENDLQHLPYFKAVIKETYRLQPTVPLLLPREVIKSFKIDNYEIPAKTQI FVNAWAIGRDPKIWDNPKEFLPERFIGSSIDYKGLDYELIPFGAGRRGCPGIHMGALTVELALANL LYAFDWEMPPGMNKEEIDFEEIPGITVHKKNVLCLVPKKIIIGIYVS SEQ ID NO: 122 Aquilaria sinensis AsCYP7 (CYP78) DB1 / 156198702.2 71 Attorney Docket No.: MAN-042PC / 107590-5041 MAQDLRLILIIVGAIAIIALLVHGFIGARPGHLPPGPPGPPLIGNLFQLDSFGPHRHLWRLSLKYG PLFTLKLGFKTTLVASSARMAREIMKTHDLDCCSRPLQRGAQKLSYNGLDIAFSPYNSYWREIRRI CVVHLFNPNRVQLYRPIREEEVSLMIRKLSSQCQDPSKHGTVNLSDAMMCLTSAIICRVGFGKRYE DEGAEKSRFHELLNESQAMFGAFFVSDYFPLIAWFDQLTGLVRRLDRNFRNLDEFYEKCINEHLDP MRPRPEHEDIIDVLLHLQKSREFSVHLTLDHIKAILMNVLIAGTDTGAATVIWAMAFLMKNPNSMQ KVQEEIRSSVGKKGLVNENDLQHLPYFKAVIKETYRMQPTAPLLIPREVIKSFKIDNYEIPAKTQI FVNAWAIGRDPEIWDNPEEFMPERFIGSSIDYKGLDYELIPFGAGRRGCPGIHMGALTVELALANM LYAFDWELPPGMNREEIDFEEIPGITIHKKKALCLVPKKIIIGI SEQ ID NO: 123 Aquilaria sinensis AsCYP8 (CYP79) MAQDLRLILIIVGAIAIIALLVHGFIGARPAGRLPPGPPGPPLIGNLFQLDSFGPHRHLWRLSLKY GPLFTLKLGFKTTLVASSARMAREIMKTHDLDCCSRPLQRGAQKLSYNGLDIAFSPYNSYWREIRR ICVVHLFNPNRVQLYRPIREEEVSLMIRNLSSQCQDPSKHGAVNLSDAMMCLTSAIICRVGFGKRY EDEGTEKSRFHELLNESQAMFGAFFVSDYFPLMSWFDRLTGLVRRLDKNFRDLDEFYQNCINEHLD PMRPMPEQEDIIDVLLHLQKNREFSVHLTLDHIKAILMNVLIAGTDTGAATVIWAMAFLMKNPNSM QKVQEEIRSSVGKKGFVNEDDLQYLPYFKAVIKETYRLQTTVPLLVPREVIKSFKIDKYEIPAKTQ IFINAWAIGRDPEMWDNPEEFLPERFIGSSIDYKGLDYELIPFGAGRRGCPGIHMGALTVELALAN ILYAFDWEMPPGMNREDIDFEEIPGITMHKKNALCLVPKKIIIGI SEQ ID NO: 124 Aquilaria sinensis AsCYP9 (CYP80) MAQDLRLILIIVGAIAIIALLVHGFWTKSRSKKLPPGPRKLPIIGNLHNFSGPLLPHQTITELAKK YGPIMHLQLGQVCAIVMSSPEMAREVMKTHDLHFASRPQPVGGDILFYNYTNMVFVPYGDYARQLR KICVMELLSPKRVLSFRPIREEEVAKLVAEVSSQAREVVNLRKVIGSNSYRVISRIIIGRMVDPKG RYLGLTKEIIEVLGGFTLSDVFPSLKFLQVLTGVRSKFKRIRQEADAILNNLISEHVAARKSNTKY EEDILHVLLDLQERDQLGFPLTTDNIKAFMQDLIIGGIETSATITEWGMAELLKNPTVLAKATKEV RGVFGKEGKVTEAGLQQIEYLKLVVKETLRLHPSSPLLLPRENQEKIEINGYEIPAKAKVFVNAWG IVRDPKYWKKAETFWPERFIDNENNADYNGTQFEYVPFGAGRRMCPGISMGLVNVELALANLLFNF DWVLPNGQKNEDLSLAEAHGIAVGRKEPLQAIPIPYNP SEQ ID NO: 125 Aquilaria sinensis AsCYP10 (CYP81) MAQDLRLILIIVGAIAIIALLVHGFWTKSRSKKLPPGPRKLPIIGNLHNFAGPLLPHQTITELAKK YGPIMHLQLGQVCAIVMSSPEMAREVMKTHDLHFASRPQPVGGDILFYNYTNMVFVPYGDYARQLR DB1 / 156198702.2 72 Attorney Docket No.: MAN-042PC / 107590-5041 KICVMELLSPKRVLSFRPIREEEVAKLVAEVSSHARELVDLRKVIYSSSYRVISRIIIGKMVDAEG RYIVLTKEIMEVLGGFTLSDVFPSLKFLQVLTGLRSRVKRIGKEVDAILNNFISDHMAARKINTEG LEGDILHFLLNLQEQGQLRFPLTTDHIKACLQILMLAGIETSAITTEWAMAELLKNPTLLAKATKE VRDVFGKEGKVTEAGLQQIEYLKLVVKETLRLHPAGPLLLPRETQEKIEINGYEIPAKAKVFVNVW AIVRDPKYWKNPETFSPERFIENENHADYNGTNFEYLPFGAGRRMCPGVSMGLANVELALANLLFN FDWVLPNGQRNGDLSLAEAHGISAGRKEPLRAIPIPYTP SEQ ID NO: 126 Aquilaria malaccensis AmCYP11 (CYP82) MAQDLRLILIIVGAIAIIALLVHGFWTKPRSKKLPPGPRKLPIIGNLHNLAGPLLPHQTIAELAKK YGPIMHLQLGQVCTIVMSSPEMAREVMKTHDLHFASRPQPVGGDILFYNFTDMVFMPYGDYARQLR KICVMELLSPKRVLSFRPIREAEVAKLVAEVSSHARELVDLRKVVYSSSYRVISRIIIGKMVDAEG RYVELTKEIMEVLGGFTLSDVFPSLKFLQVLTGVRSRFKRIGKEVDAILNNLISDHMAARKTNTEG HEGDILHFLLNLQEQGQLRFPLTTDNIKACLQILILGGIETSAITTEWAMAELLKNPTLLAKATKE VRDVFSKEGKVTEAGLQQIEYLKLVVKETLRLHPTSPLLLPRENQEKIEINGYEIPAKAKVFVNVW AIVRDPKCWKNPETFWPERFIENENHADYNGTKFEYLPFGAGRRMCPGVSMGLANVELALANLLFN FDWVLPNGQRNGDLSLAEAHGISVGRKEPLRAIPIPYTP SEQ ID NO: 127 Aquilaria sinensis AsCYP12 (CYP83) MAQDLRLILIIVGAIAIIALLVHGFWTKPRTKNLPPGPPKLPVIGNIHTLAAGGPLPHRTLARLAK KYGPIMHLQLGQISTVVVSSPEMAKEVMKTHDINFAQRPQSIASHVVFYNCTDMVFTQQVEYGKEL RKICVTELLSQKRVLSFRPVRQEESVNLIREITSNAGKPINVRSAIRSMSYKVIARALIGRRAERE ERYIKLTKEVVELLGGFSLSESFPGIKFLPTVTGLRSKLNRIQNEINGILDRIITEHKEFRKQSPS SNGIGQEEDILHVLLNLQEANQLEFPLTRENIKANLQALILAGIDTASTAVEWGMVELLKNPSLLE KATKELRDVFGKQGKVDEAEFHRLHYLKLVIKETLRKHPSAPLLIPRESIDECEINGYKIPAKTRI IINAWAISSDPKYWKDPETFNPERFLEDERTFDYRGNQFEYLPFGSGRRMCPGVAMGLINVELGLA NLLYNFDWKMPEGQRNEDLSLTENFGLSVGRKEDFYAVPYPYKP SEQ ID NO: 128 Aquilaria malaccensis AmCYP13 (CYP84) MAQDLRLILIIVGAIAIIALLVHGFWILWSVKRSKQSSAPPLPPGPRGLPLLGYLPFLSGKLQLDF TQLSYLYGPILSLWLGKKLCVIITSPEVAKEVVRDHDIIFSNRDPPAVADIITYSGNDIAFGSYGP KWRDMRKMFVREMLSNTNLDACYDLRREEVINAVKDLYKKVGQPIDLGQLAFLTEVNAILSLLWGG KVSGQKGASLWVTFRGLVGDIMDLLGKPDISDFFPALRRFDLQGLQKKMRKIQEYCDKLFDEAIEE DB1 / 156198702.2 73 Attorney Docket No.: MAN-042PC / 107590-5041 RLGMGNDDKEITNKKGPTDFLQFLLDLNKSEDPANNISHNQLKAMLVDVVVGGTDTTSTMVEWGMA ELLCNPSKMEKLKSELAAVVGLDKFVEESDLPKLRYLEAVFKETLRLHPPLALLIPRSPSESTTVS GYYIPKGSRVFLNVYGIHRNSKYWESPSDFKPERFLDGPESFDFYGNDFRYMPFGSGRRFCAGRPL GEKMVLYLLATLVHSFDWKVPDGKKVDLDEHFGIVLRKGNPLVAIPTPRLTNLGLYKE SEQ ID NO: 129 Aquilaria malaccensis AmCYP14 (CYP85) MAQDLRLILIIVGAIAIIALLVHGFWILWSVKRSKKSSAPPLPPGPRGLPLVGYLPYLGDQLQHDY TQLSSLYGPILSLWLGKKLCVVITSPEVAKEVVRDHDIIFSNRDPPAVADIITYSGNDIAFGSYGP KWRNMRKMFVREMLSNTNLDACYDLRREEVINAVKDLYKKVGQPVDIGQLAFLTEVNAILSLLWGG KVSGQKGASLWVTFRGLVGDIMDLLGKPDISDFFPALRRFDLQGLQKKMRKIQEYCDKLFDEAIEE RLGMGNDEEIANKKGPTDFLQFLLDLNKSEDPTNNISHNQLKAMLVDVVVGGTDTTSTMVEWGMAE LLCNPSKMEKLKGELAAVVGVDNFVEESHLPKLPYLEAVLKETLRLHPPLPFLVPRSPSESTIVAG YSIPKGSRVFLNVYGIHRNSKYWESPCDFKPERFLEGPEKFDFLGNDFRYMPFGSGRRFCAGRPLG EKMVLYLLATLVHSFDWNVPEGKKVDLDEHFGIVLRKSNPLVAVPTPRLTDASLYKT SEQ ID NO: 130 Aquilaria sinensis AsCYP15 (CYP86) MAQDLRLILIIVGAIAIIALLVHGFWSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHRRFRELAQKY GPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMAAVKAITYDHTDIGFSPYGSYWRQLRK ICATELLSANCVRSYRSIREEEVANMVASIHSAHGQLPVNLTQKIFSLTFGITARAAFGKKCKDQE GFIKQVTKLSWLAGGFSMADLYPSLTMLHRIDGSSDEMERVHKEMDRILQEIVREHREERKSITKT EEESEDLVDVLLRLQEQGEFPAGDSNVKAVILDVFTGGGDTSSSTVAWAMSEMLRNPRVMREAQTE VRRVCAGKGTVDEEAIGQMTYLKALETMRLRPVLPLLVPRECSQTCEVGGYTIPAKSRIIVNAWAI GRDPKNWDKAEDFLPERFINGQYDFTGRNMEYIPFGGGRRICPGILFALPNVELPLAQLLFHFDWK LPNGARGEDLEMSEKFGLGVQRMNDLMVIATPYRPM SEQ ID NO: 131 Aquilaria sinensis AsCYP16 (CYP87) MAQDLRLILIIVGAIAIIALLVHGFWSSKRSAKLPPGPRPLPLIGNLHNLVRGLPHHRFRELAQKY GPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMAAVKAITYDHTDIGFSPYGSYWRQLRK ICATKLLSANCVRSYRSIREEEVANMVASIHSVHGQLPVNLTQKIFSLTFGITARAAFGKKCKDQE EFIKQVTKLSWLAGGFSVADLYPSLTMMHRIDGSSDEMEKVHKEMDRILQEIVREHREERKSGTKT EGEAEDLVDVLLRLQEQGEFPADDSNVKAVILDVFAGGSETSSSTVDWAMSELLRNPRVMREAQAE VRRVCAGKGTVDEEAIGQMTYLKVLVKETMRLHPSLPLLVPRECSQTCEVGGYTIPAKSRIIVNAW DB1 / 156198702.2 74 Attorney Docket No.: MAN-042PC / 107590-5041 AIGRDPKNWDKAEDFLPERFIDGQYDFIGRNMEYIPFGGGRRICPGILFALPNVELPLAQLLFHFD WKLPNGAKGEDLEMSEKFGLDVKRMNDLMVIATPCRPM SEQ ID NO: 132 Aquilaria sinensis AsCYP17 (CYP88) MAQDLRLILIIVGAIAIIALLVHGFWSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHRRFREMAQKY GPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAIVALKSITYDHIDIGFSPYGSYWRQLRK ICATELLSANCVLSYRSIREEEVANMVASIHSAQGQLPVNLTQKLFSLTFGITARAAFGKRCKDQE EFINQVTEFSWLAGGFSMADLYPSLTMLHRIGGSSNQMERVHKEMDRILQEIVREHRKETKTEGEV EDLVDVLLRLQEEAEFPADDSNVKAVILDVFAGGGETSSSTMEWAMSEMLRNPRVMREAQAEVRRV CAGKGTVDEEAIRQMTYLKALVKETLRLHPPIPLLLPRECSQTCEVDGYTIPAKSRIIVNAWAIGR DPKNWDKAEDFLPERFIDGQYDFSGRNMEYIPFGGGRRICPGILFALPNVELPLAQLLFNFDWKLP KGARGEDLEMSEKFGIGVKRMNDLMVIATPYRPLL SEQ ID NO: 133 Aquilaria sinensis AsCYP18 (CYP89) MAQDLRLILIIVGAIAIIALLVHGFWSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHHRFRELAQKY GPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMVAVKAITYGHTDIGFSPYGSYWRQLRK ICATELLSANCVRSYRSIREEEVANMVASIHSAQGQLPVNLTQKIFSLTFGITARAAFGKKCKDQE EFIKQVTQLSRLAGGFSMADLYPSLTMLHHIGGSSDEMERVHKEMDRILQEIVREHREERKSGTKT EGEAEDLVDVLLRLQEQGEFPADDSNVKAVILDVFAGGSETSSSTVEWAMSEMLRNPRVMREAQAE VRRVCAGKGTVDEEAIGQMTYLKALVKETLRLHPAIPLLLPRECSQTCEVNGYTIPAKSRIIINAW AIGRDPKNWDKAEDFLPERFIDGQYDFTGRNTEYIPFGGGRRICPGILFAQPNVELPLAQLLFHFD WKLPSGARGEDLEMSEKFGAGVKRLNDLMVIATPYRSL SEQ ID NO: 134 Aquilaria sinensis AsCYP19 (CYP90) MAQDLRLILIIVGAIAIIALLVHGFWSSKSGKLPPGPRPLPLTGNLHNLVGGLPHHRFRELAQKYG PLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPAMVAVKAITYDHTDIGFSPYGSYWRQLRKI CATELLSANCVRSYRSIRKEEVANMVASIRSAHGQLPVNLTQKIFSLTFGITARAAFGKKCKDQEE FIKQVTELSRLAGGFSMADLYPSLRMLHRIGGSSDEMERVHKEMDRILQEIVREHREERKSGTKTE GEAEDLVAVLLRLQEQGEFPADDSNVKAVILDVFAGGSETSSSTVEWAMSEMLRNPRVMREAQAEV RRVCAGKGTVDEEAIGQMTYLKALVKETLRLHPAIPLLLPRECSQTCEVDGYTIPAKSRIIVNAWA DB1 / 156198702.2 75 Attorney Docket No.: MAN-042PC / 107590-5041 IGRDPKNWDKAEDFLPERFIDGQYDFTGRNTEYIPFGGGRRICPGILFAQPNVELPLAQLLFHFDW KLPSGARGEDLEMSEKFGAGVKRLNDLMVIAEPYGAM SEQ ID NO: 135 Aquilaria sinensis AsCYP20 (CYP91) MAQDLRLILIIVGAIAIIALLVHGFWSSKRSPKLPPGPRPLPLIGNLHNLVGGLPHRRFRELAQKY GPLIHLKLGEVSTIVASSPEMAREVLKTHDSVFAYRPALVAMKAITYDHTDVGFSPYGSYWRQLRK ICATELLSANCVRSYRSIREEEVANMVTSIRSAQGQLAVNLTQKILSLTFGITARAAFGKKCKDQE EFIKRVTELSRLAGGFTMADLYPSLTILHRIDGTRDEMERVHKEMDRILQEIVREHREERKSGTKT EGEAEDLVDVLLRLQEQGEFPADDSNVKAVILDVFVAGSDTSSSTVEWAMSEMLKNPRVMREALAE VRRVCAGKGTVDEEAIGQMTYLKALVKETLRLHPAIPLLLPRECSQACEVDGYTIPAKSRIIVNAW AIGRDPKNWDKAEDFLPERFIDSMYDFTGRNTEYIPFGGGRRICPGILFALPNVELPLAQLLFHFD WKLPNGAKGEDLEMSEKFGAGVKRMNDLMVIATPYRPL SEQ ID NO: 136 Aquilaria sinensis AsCYP21 (CYP92) MAQDLRLILIIVGAIAIIALLVHGFWSSKRSAKLPPGPRPLPLIGNLHNLVGGLPHRRFRELAQKY GPLIHLKLGEVSTIVASSPEMAREVLKTHDSIFAYRPAMVAVKAITYDHTDIAFSPYGSYWRQLRK ICATELLSANCVRSYRSIREEEVANMVTSIRSAQGQLPVNLTQKIFSLTFGITARAAFGKKCKDQE EFIKLVTELSRLAGGFTMADLYPSLTMLHRIDGSRDEMERVHMEMDRILQEIIREHREERKSGTKT EGEAEDLVDVLLRLQEQGEFPANDSNVKAVILDVFVAGSETSSSTVEWAMSEMLRNPRVMREAQGE LRRVCAGKGTVDEEAIGQMTYLTALVKETLRLHPAVPLLLPRECSKTCEVDGYTIPAKSRIIVNTW AIGRDPKNWDKAEDFLPERFIDGKYDFTGRSTEYIPFGGGRRICPGILFALPNVELSLAQLLFHFD WKLPNGAKGEDLEMSEKFGVDVKRMNNLMVIGTPYRPV SEQ ID NO: 137 Aquilaria sinensis AsCYP22 (CYP93) MAQDLRLILIIVGAIAIIALLVHGFWILKARRKPSPTFPPGPSKLPIIGSMHHLAGALPHRILADL AKKYGPLMHLQLGEVSTIVVSSPELAKQVMKTHDIIFSSRPYIPSQGIFSYGNKDIAVAPYGEYWR QLRKICMVELLSLKRVQSYGPIRERVVSNTIQTIASGAGSPVNLSNMIYSTTIGVVLRAAFGETCR FQEKFIQVVKKSTQLAGGLSLPDVFPSRNSLFVLSGRKYRCEKVHKEIDKILSGIIEEHKARKREG KGISDQQEAEDLVQVLLDIQDRGDLQFSLTTSDIKGVIQDIFVAGSDTSSSTVEWAMSEMLRNPRT LEKAQVEVRDVFGRKGKVDDEGLQELKYMKSVIKETLRTHPPLALLIPRESMDECELNGYNIPSKT DB1 / 156198702.2 76 Attorney Docket No.: MAN-042PC / 107590-5041 QVIVNAWAIGRDPDYWTEPDKFFPERFLESSVDFKGNHFEFIPFGAGRRICPGMPFGLANAERLLA ELLFHFDWKLPSGKRPQELDMTEKFGAVVARKNKLYLTPVPYRK SEQ ID NO: 138 Aquilaria sinensis AsCYP23 (CYP94) MAQDLRLILIIVGAIAIIALLVHGFWILKTRRKPSPNFPPGPSKLPLIGSMHHLAGALPHRILADL AKKYGPLMHLQLGEVPTIVVSSPELAKQVMKTHDIIFSSRPYIPSQGIFTYGNKDIAAAPYGEYWR QLRKICIVELLSLKRVQSYGPIRERVLSNTIQTIASGAGSPVNLSNMIYSTTIGVVLRAAFGETCK FQEEFIQVVKKSTQLAGGLSLPDVFPSRNSLFVLTGRKYRCEKVHKEMDKILSGIIEEHRARKREG KGISDQQEAEDLVQVLLDIQDRGDLQFSLTTRDIKGVIMDVFVAGSDTSSSTVEWAMSEMLRNPRT LEKAQVEVRDVFGRKGKVDDEGLQELKYMKSVIKETLRTHPPLALLIPRESMDKCELNGYNIPSKT QVIVNAWAIGRDPDYWTEPDKFFPERFLESSVDFKGNHFEFIPFGAGRRICPGMPFGLANAERLLA ELLFHFDWKLPNGKRPQELDMKEKFGIVVARKNNLYLTPIPYRK SEQ ID NO: 139 Aquilaria sinensis AsCYP24 (CYP95) MAQDLRLILIIVGAIAIIALLVHGFWILKAARKSKSQIVSPNLPPGPPKLPIIGNMHHLFGSLPHR ILGDLAKKYGPLMHMQLGEVSTIIVSSPEIAKEVMKTHDIIFSSRPFIPSQGIISYNCEDIACAPY GEYWRQLRKICIVELLSVKRVQSFGSIRERVVSDMVQTIASGADSPVNLSKLIYSATIGITLKAAF GEKCQYQEEFIQVVKKSTELTGGLSLADVFPSRRSLFVLTARKYRCEKVHKEVDKILNDIIKEHRS GKREGKGIGDQQEAEDLVQVLLDIQDRGDLQFPLTANNIKGVIQDIFVAGGDTSSTTVEWAMSEML RNPITMEKAQAEVRAVFGKKGKVEEARLQELKYMKSVMKETFRIHPPLALLVPRESIDECEVSGFC IPAKTQVILNAWAIGRDPNHWNEPEKFCPERFLETPVDYKGNHFEFIPFGAGRRICPGMPFGIANV ELLLAELLYHFDWKLPNGMRPEDLDMTEMFGIVVRRKKELYLTPISYAN SEQ ID NO: 140 Aquilaria sinensis AsCYP25 (CYP96) MAQDLRLILIIVGAIAIIALLVHGFWILKASRRKSGAEKLSPNLLPGPPKLPIIGNLHQLFGSLPH HVLGEMANKYGPIFHLQLGEASTVVVSTPELAQEVMRTHDVIFANRPSVPSQNVISYNGRDIVSAP YGDHWRQLRKLCTIQLLSHKRIQSYEPIRERVVSDMVQTIASRAGSVVNLSKLIYSAAIQIIMKSA FGEKCQVREDFIQVVHRTTEVTEGMSLSDHFPSKKFLFTLTGMKSQCEKVLNDIDNILNGVIEEHR SRKREGKGSRDEHEAEDLLQILMDIQEKGDPEIPLTMDDIKGVVMDVFVAGAGTSASTVEWTMSEL MRNPRIMEKAQAEVRAVFGKKGKVDEAGLEELTYVKSVIKEDLRVHIPLPLLIPRESTEECELGGF KLPPKTRVIINGWSTGRDPNYWKEPEKFYPERFLGSPVDYKGHHFEFVPFGAGRRICPGVSFGIMN VELLLSNLLYHFDWKLPYGMKPEELDMTEKAGLTVMRKHELFITPTPHLK DB1 / 156198702.2 77 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 141 Aquilaria sinensis AsCYP26 (CYP97) MAQDLRLILIIVGAIAIIALLVHGFWILKASRRKSGAGKLSPKLLPGPPKLPIIGNLHQLSGSLPH HILGDMAKKYGPIFHLQLGEASTVVVSTPELAQEVMKTHDVIFANRPSLPSQYVISYNGQDIVSTP YGDRWRQLRKLCTIQLLSQKRIQSYEPIRERVVSDMVQTIASGAGSVTNLSKFIYSAAIQIIMKSA FGEKCQVRDDFIQVVHRTTEATEGMSLSDHFPSKKFLFMLTGMKPRCEKILNDIDNILNEIIEEHR SRKREGKGSRDEHEAEDLLQILMDIQEKGDPEIPLTMDDIKGVVMDVFVAGAGTSASTVEWTMSEL MRNPRIMEKAQAEVRAVFGKKGKVDEAGLEELTYVKSVIKEDLRVHIPLPLLIPRESTEECELGGF KLPPKTRVIINGWSTGRDPNYWKEPEKFYPERFLGSPVDYKGHHFEFVTFGAGRRICPGVSFGIMN VELLLSNLLYHFDWKLPYGMKPEELDMTEKAGLTVMRKHELFITPTLHLK SEQ ID NO: 142 Aquilaria sinensis AsCYP27 (CYP98) MAQDLRLILIIVGAIAIIALLVHGFWILKASRRKSGAGKLSPKLLPGPPKLPIIGNLHQLSGSLPH HILGDMAKKYGPIFHLQLGEASTVVVSTPELAQEVMKTHDVIFANRPSLPSQYVISYNGQDIVSTP YGDRWRQLRKLCTIQLLSQKRIQSYEPIRERVVSDMVQTIASGAGSVTNLSKFIYSAAIQIIMKSA FGEKCQVRDDFIQVVHRTTEATEGMSLSDHFPSKKFLFMLTGMKPRCEKILNDIDNILNEIIEEHR SRKREGKGSGDEQEAVDLLQILLDVQEKGDPEIALTMGNIKGVVMDVFVAGAGTSASTVEWTMSEL MRNPRIMEKAQAEVRAVFGKKGKVDEAGLEELTYLKALIREDLRVHIPLPIIIPRESTEECELGGF NLPPKTRVIINARAMARDPNYWEEPEKFYPERFLGSPIDYKGHHFEYVPFGAGRRICPGLSFGIMN VEIILSNLLYHFDWKLPNGMKPEELDMTEKAGLTVTRKNELFVTPTLYRE SEQ ID NO: 143 Aquilaria sinensis AsCYP28 (CYP99) MAQDLRLILIIVGAIAIIALLVHGFWRKSEAKKFTKNLPPGPPKLPIIGNVHQLFAPLPHHVLGDM AKKYGPLVHLQLGEASTVLVSSPELAQEVMKTHDLIFANRPYVPSQDVISYHSGDIVTAPYGEFWR LLRKICVVQLLSVKRIQSYEPIRERVVSDMVQTIASGAGSSVNLSKMIYASTIQIIMKSAFGEKCQ VREDFIQVVHKTTEVTEGMALADLFPSRKFLFSLTGLKRRCEKVLKEIDMILDEIIEEHRSRKREG KANGDGQEAEDLVQILLNLQDQGDPEMSLTTDNIKAVIMDVFVAGAGTSASTVEWTMSELLRNPRV MEKAQAEVRAVFGNKGKVDEAGLQELKYLKLVIKENLRTHTPLPLLIPRESTDKCELNGFHIPPKT RVIINAWAMARDPKYWNEPEKFYPERFSDSSRDYKGNHFELIPFGAGRRICPGLSFGIMNVELLLA QLLYHFDWKLPNGMRPEALDMTEKPGLTVMRNSELFVTPIPYLK SEQ ID NO: 144 DB1 / 156198702.2 78 Attorney Docket No.: MAN-042PC / 107590-5041 Aquilaria sinensis AsCYP29 (CYP100) MAQDLRLILIIVGAIAIIALLVHGFWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAP KYGPIMHLRLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNM RKMCTLELLSNLKINSFRRMRKEELNVFIESIKEASQRGGVVNLSEKVTTLIAGMACRMIFGKKYE VNDIDEKGFKDLIQEGMHLFAKPNIGDYIPQISRLDLQGMTKKMKIISEKFDDFLEIIIDEHVEMR RSSIGHMRKTQDFVDVMLEIMGSKEAEYPLERGNVKAIILDMFVAASDTSASIIDWALSELIRHPK VMKKVQKELEDVVGLERMVEESHLEKLNYLEMVVKETLRLHPVGPLLLPHASIEDCTIDGFYIPKK SLLMVNVWAIGRDPTVWLEAEKFWPERFEGCKVDLRGRDFELLPFGSGRRSCPGMQLGLTMVWLVL GQLVHCFDWELPNGILASELDMTKKFGLVTSRAKPLLAMPSYRLNL SEQ ID NO: 145 Aquilaria sinensis AsCYP30 (CYP101) MAQDLRLILIIVGAIAIIALLVHGFWLLKPKASPKKLPPGPRGLPVFGSLHLLGELPHQDLHRLAQ KYGPIMHLRLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNM RKMCTLELLSNLKINSFRRMRKEELNVFIESIKEASQRGGVVNLSEKVTTLIAGMACRMIFGKKYE VNDIDEKGFKDLIQEGMHLFAKPNIGDYIPQIKGFDMQGITKKMKIVAKKFDDFLEMIVDEHVEMR RSSTGNKQNTQDFVDVMLDIMGSREAEYVLERDNVKAIILDMFVAASDTSASIIDWALSELIRHPT VMKKVQKELEDVVGLERMVEESDLEKLNYLEMVVKETFRLHPAGPLLLPHASIEDCTIDGFHIPKK SHLMVNTWAIGRDPMVWPEAEKFWPERFEGSKVDLRGKDFELLPFGYGRRSCPGMQLGLTVVPLVL GQLVHCFDWKLPNGMLVSELDMMEKFGLVTSRAKPLLAMPSYRLNL SEQ ID NO: 146 Aquilaria sinensis AsCYP31 (CYP102) MAQDLRLILIIVGAIAIIALLVHGFWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAQ KYGPIMHLRLGLVHTIVVSSPRAAELFLKAHDLVFASRQPRKAAKHLSYGQKNLTFAPYGSYWRNM CKMCTLELLSNLKINSFRWMRKEELNVFIESVKEASQCGGVVNLSEKVTTLIAGVSCRMIFGNKYE IKGIDEKGFKDLIREGMHLSAKPNTGDYIPQISRLDLQGMTKKMKIISEKFNDLLEMIVDEHVEMK RSSIGRMRKTQDFVDVMLEIMGCKDAEYPLERDNVKAIILDMFVAATDTSASVIDWALSELIRHPR VMKKVQKELEDVVGLERMVEESYLEKLNYLEMVVKETFRLHPVGPLLAPHASIEDCTIDGFYIPKK SLLMVNVWAIGRDPTVWLEAEKFWPERFEGCKVDLRGRDFELLPFGSGRRSCPGMQLGLTMVWLVL GQLVHCFDWELPNGILASELDMTKKFGLVTSRAKDLHAVPSYRLNL SEQ ID NO: 147 Aquilaria sinensis AsCYP32 (CYP103) DB1 / 156198702.2 79 Attorney Docket No.: MAN-042PC / 107590-5041 MAQDLRLILIIVGAIAIIALLVHGFWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAQ KYGPIMHLRLGLVHTIVVSSPRAAKLFLKDHDLVFASRPPREAAKHLSYDQKNLTFAPYGSYWRNM RKMCTLELLSNLKINSFRLMREEELNVFIESIKEASQRGGVVNLSEKVTTLIAGMSCRMIFGKKYK IKEIDDKGFKDLIQEGLHLSAKPNIGDYIPQISRLDLQGMTKKMKIISEKFDDFLEIIIDEHVEMR RSSIGHMRKTQDFVDVMLEIMGSKEAEYPLERGNVKAIILDMFVAATDTSASVIDWALSELIRHPK VMKKVQKELEDVVGLERMVEESHLEKLNYLEMVVKETLRLHPVGPLLLPHASIEDCTIDGFYIPKK SQLMVNVWAIGRDPTVWLEAEKFWPERFEGCKVDLHGRDFELLPFGSGRRSCPGMQLGLTVVRLVL GQLVHCFDWELLNGMLVSELDMTEKFGLVTSRAKDLHAMPSYRLNL SEQ ID NO: 148 Aquilaria sinensis AsCYP33 (CYP104) MAQDLRLILIIVGAIAIIALLVHGFWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAP KYGPIMHLRLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNM RKMCTLELLSNPKINSFRWMRKEELDTLIKSIKKASQCGGMVNLTEKIASLITSMSCRMIFGKKYE DKDIDERGFKDLIQECMHLLAKPSIGNYVPQISRLDIQGMTKKIKIIREKLDVFLEMIVDEHVEMR SSSTGDMSKMQDFVDVMLEIMGSKKAEYPLERDNIKAITLDMFVSALDTSSTTIEWAFSELIRHPM MMEKVKKELEDVVGLERMVEESDLEKLNYLEMVVKETQRLHAVVPLLLPHASMEDCNVDGFNIPKK SRVLVNAWAIGRDPLAWPKAEKFWPERFEGSQVDVHGRYFELLPFGSGRRRCPGMQLGLTVVRLVL AQLVHCFDWELPDGMLPSELDMTEEFGLVISRANHLHAIPSYRLNM SEQ ID NO: 149 Aquilaria malaccensis AmCYP34 (CYP105) MAQDLRLILIIVGAIAIIALLVHGFWLLKPSASTKKLPPGPPGLPIFGSLHLLGELPHRDLHRLAQ KYGPIMHLRLGRVNTIVVSSPRAAELFLKAHDLVFASRPLLEAAKYLSYDQKNLSFAPYGSYWRNV RKMCTLELLSNPKINSFRWMRKEELDTLIKSIKKASQCGGMVNLTEKVASLITSMSCRMIFGKKYE DKDIDERGFKDLIQECMHLLAKPSIGNYVPQISRLDIQGMTKKIKIIREKLDVFLEMIVDEHVEMR SSSTGDMSKMQDFVDVMLEIMGSREAAYLLDRDSVKAIILDMFVAATDTSATVINWALSELIRHPR VMKKVQKELKDVVGLKRMVEESDLEKLNYLEIVVKETLRLHPAGPLLLPHESIEDCTIDGFHIPKK SQLLVNVWAIGRDPTVWLEGEKFWPERFEGCKVDLHGRNFKLLPFGFGRRSCPGMQLGLTMVRLVL GQLVHCFDWELPNGMLVSELDMTEEFRFVTSRAKHLHAMPSYRLNL SEQ ID NO: 150 Aquilaria malaccensis AmCYP35 (CYP106) MAQDLRLILIIVGAIAIIALLVHGFWLLKPKARAKKLPPGPTGLPLIGSLHLLGKHPHRDLHRLAQ KYGPIMHLKLGLVPTIVISSPRAAELFLKDNDLIFADRPPHEAAKHISYGQKNLTFAPYGSYWRDM DB1 / 156198702.2 80 Attorney Docket No.: MAN-042PC / 107590-5041 RKLCTLELLSNLKINSFRWMRKEELDLLIQSIKEASRRQGVVNLSEKVASLSANMSCRMVFGKKYE GKDIDERGFKGLIQEGMHLFATPNIGDYIPHLSRLDLQGLTKKMKIINKKTDDFIEMIIDEHIEIR RSSTGDMGRGQDFVDVMLEIMGSKKAEYPLERDNIKAITLDMFVSALDTSSTTIEWALSELIRHPM MMEKVKKELEDVVGLERMVEESDLEKLNYLEIVVKETLRLHPAGPLLLPHESIEDCTIDGFHIPKK SQLLVDVWAIGRDPTVWLEGEKFWPERFEGCKVDLHGRNFKLPPFGFGRRSCPGMQLGLTMVRLVL GQLVHCFDWELPNGMLVSELDMTEEFRFVTSRAKHLHAMPSYRLNL SEQ ID NO: 151 Aquilaria sinensis AsCYP36 (CYP107) MAQDLRLILIIVGAIAIIALLVHGFWLTRRRNNLPPAPPSLPIIGHLHLLKPPIHRVYHLLSHKYG PIFSLHFGSRHVVVVASSALAEECFTKNDIVLANRPRTIGGKHLNYNHTTMGSSSYGDHWRNLRRI GAVEIFSSARLNAFLTVRTDEIQRLLLRLSRDSRDKFERVELRPLLTDLTFNNIMRMVAGKRYYGN DVPGEEEEARKFRDMITEVFLLGGAVNRGELLPSLNWIGKRRYEKRIKNLAGTFDGLLQGLVDEHR RGQRKNTMIDHLLSLQQSQPDYYTDQIIKGLILVLVLAGTDTSAVTLEWAMSNLLNHPEVLEKVRA ELDAEIGQEKLLEEQDVNKLPDLQNVIWETLRLYPPGPMLLPHVASADCRIGGYDVPRDTMVLVNA WAIHRDPKVWEDAESFKPERFEKEGRQSHKMMPFGLGRRACPGEGLAHRVVALALGSMVQCFDWEK INEDQIEMSEGTGTTMPKAQPLEALCRARPIVHQVFYAAA SEQ ID NO: 152 Aquilaria sinensis AsCYP37 (CYP108) MAQDLRLILIIVGAIAIIALLVHGFWLTRRRNNLPPAPPSLPIIGHLHLLKPPIHRVYHLLSHKYG PIFSLRFGSRHVVVVASSALAEECFTKNDIVLANRPLTIGGKHLSYNHTTIVSSSYGDHWRNLRRI GAVEIFSSARLNTFLTVRTDEIQRLLLRLSRDSKDKFARVELRPLLTDLTFNNIMRMVAGKRYYGN DVPGEEEEARKFRDMITEVFLLGGAVNPGELLPLLNWIGKRRYEKRIKNLAGTFDGLLQGLVDEHR RGERKNTMIDHLLSLQQSQPDYYTDQIIKGLILVLVLAGTDTSAVTLEWAMSNLLNHPQVLEKVRA ELESEIGQEKLLEEQDVNKLPYLQNVIWETLRLYPAAPMLLPHVASADCRIGGYDVPRDTMVLVNA WAIHRDPKVWEDAESFKPERFEKEGRQSHKMMPFGLGRRACPGEGLAHRVVALALGSMVQCFDWEK INEDQIEMSEGTGTTMPKAQQLEALCRARPIVHQVFYAAA SEQ ID NO: 153 Aquilaria malaccensis AmCYP38 (CYP109) MAQDLRLILIIVGAIAIIALLVHGFWLTRRRNNLPPAPPSLPIIGHLHLLKPPIHRVYHLLSHKYG PIFSLRFGSRHVVVVASSALAEECFTKNDIVLANRPLTIGGKHLSYNHTTMASSSYGDHWRNLRRI GAVEIFSSARLNAFLTVRTDEIQRLLLRLSRDSREKFARVELRPLLTDLTFNNIMRMVAGKRYYGN DVPGEEEEARKFRDLITEVFMLGGAVNPGEFLPLLNWIGKLRHEKRIKNLAESFDGLLQGLVDEHR DB1 / 156198702.2 81 Attorney Docket No.: MAN-042PC / 107590-5041 RGERKNTMIDHLLSLQQSQPDYYTDQIIKGLILVLVLAGTDTSAVTLEWAMSNLLNHPQVLKKVRA ELDAEIGQEKLLEEHDVNKLPYLQNVIWETLRLYPPAPMLLPHVASADCKIGGYDVPHDTMVLVNA WAIHRDPKVWEDAESFKPERFEKEGRQSHKMMPFGLGRRACPGEGLAHRVVALALGSMVQCFDWEK INEDQIEMSEGTGTTMPKAQPLEALCRARPIVHQVFYAAA SEQ ID NO: 154 Aquilaria sinensis AsCYP39 (CYP110) MAQDLRLILIIVGAIAIIALLVHGFWLPSKTRRKNLPPGPPSLPFIGHLHLVRPPVHRILLNISQK YGPIISLRFGSRPVVVISSASLAEECFTKHDIALANRPRLLAGKHVGYNYTTMVNSPYGDHWRNLR RIGAIEIFSASRLNAFLEVRKDEIRRLLLRLSTNSRCVFARVELKSMLTDLTFNNIIRMVAGKRYY GHEAHDVKDQAEAEEFKGLIRELLMSGGAANPGDFLPIVKWLGKLEKKLIGLAKRMDRFMQGLIDE QRSKRGANTMIDHLLSLQEQDPEYYSDNIIKGIVMVLVIAGTDTTSVTLEWAMTNLLNHPDVLRKA REEMDAVVGQETLVDEPDVTNLPYLQNIVSETLRLHPAAPLLVPHMPSNDCNIGGYDVPCGTIVLV NAWAIHRDPKLWEDPTSFKPERFEKEEKEGHKMLPFGLGRRACPGAPLAQRLVSLALGSLIQCFEW ERLGEEAIDITEVKVGIAHKAIPLEAMCKARPIVDKLFNAENN SEQ ID NO: 155 Aquilaria sinensis AsCYP40 (CYP111) MAQDLRLILIIVGAIAIIALLVHGFWLLRSKTSRKNLPPGPPSLPFIGHLHLIKPPVHRLFHSLSL KYGPIFSLRFGSRPVVVISSAALAEECFTKHDIVLANRPRLLFGKYIGYDYTTMVNSPYGDHWRNL RRIGAIEIFSASRLNALLGVRKDEIRLLLLRLSTNSRGGFARVELKSMFTDLTFNNIMRMVAGKRY YGEDVKDKAQAEEFKRLVKELVMTGGAGNPSDFLPMVKWFGFEKKLKGLSNRLDRFMQGLIDEQRS NRGANTMIDHLLYLQESDPEYYSDKIIKGIIMVLLLAGTDTTSVTLEWAMSNLLNNPEVLKKAREE MDAIVGQETLIDEPDAANLPHLQNIVTETLRLHPAAPLLVPHTPSSDCTIGGYDVPRDTIVLVNAW GIHRDPNLWEDPTSFKPERFEKEEKEGHKMLPFGLGRRACPGAPLAQRMLGLVLGSLIQCFEWERV SEEAIDMAEARGGIAHKAVPVEAMCRARPIVDKVLHA SEQ ID NO: 156 Aquilaria malaccensis AmCYP41 (CYP112) MAQDLRLILIIVGAIAIIALLVHGFWLRSKIRHKNLPPGPRSLPIIGHLHLIKPPVHGLFHNLSQK YGPILSLRFGSRPVVVISSAALAEECFTKHDIVLANRPRLLFGKYIGYDYTTMVHSPYGDHWRNLR RVGAIEIFSASRLNAFLGVREDEIRRLLLRLSTRARGGLARVELKPMFTDLTFNNIMRMVAGKRYY GDEVKDKAEAEEFKGLIKELVKTGGAGNPADFLPMVKWLGFEKKLKGLSNGLDRFMQRLIDEKRRN RGANTMIDHLLSLQESDPEYYSDKIIKGILMVLLLAGTDTTSVTLEWAMSNLLNNPEILKKAREEM DAIVGHETLINESDVANLPYLQNIVSETLRLHPAAPLLVPHTPSTDCTIGGYDVPRDTIVLVNSWG DB1 / 156198702.2 82 Attorney Docket No.: MAN-042PC / 107590-5041 IHRDPNLWENPTSFKPERFEKEEKEGHKMLPFGLGRRACPGAPLAQRMLGLVLGSLIQCFEWERVS EEAVDLTEARGGVAHKAVPLEAMCRARPVVDRVLYAKK SEQ ID NO: 157 Aquilaria malaccensis AmCYP42 (CYP113) MAQDLRLILIIVGAIAIIALLVHGFLSFKLTRRRYNLPPAPPSLPIIGHLNILKPPIHRLYHRLSH KYGPIFSLRFGSRLVLVVSSSTLAEDCFTTNDIVLANRPRLFASRCLGYNGTVLSTASYGDHWRNL RRIGAVEIFSSVRLNAFLAIRTDEIRRLLLRLSQDSREQFARVQLRHMLTDLTFNNIMRMMAGKRY YGNDVPGEEEEARKFRDLISEAFRAGGVPNPRDYLPILNWFGEGSFQKKIKNLAKSLDGLLQGLLE EHRRGERRNTMIDHLLSLQQSEPDYYTDQIIKGLVLVLVLAGTDTSAVTLEWAMSNLLNYPRVLQK LKVELDEQIGQEKLLEEQDLSKLPYLENVIWETLRLYPPAPLLLPHVASADCRIGGYDVPRDTMVI VNVWAIHRDPDVWEDAESFKPERFETEARESHKLMPFGLGRRACPGAGLAHRVVALALGSMVQCFE WERVGEDPIDMSEGTGSVMPKDQPLEVLCRARPIVHKVFYVL SEQ ID NO: 158 Aquilaria sinensis AsCYP43 (CYP114) MAQDLRLILIIVGAIAIIALLVHGFAIFKLTRRRSNLPPGPPSLPIVGHLHLLKPPIHRFYHRLSH KYGSIFSLRFGSRLVVVLSSSALAEECFTKNDVVLANRPRLIATKYLGYNSTTVSTSSYGDHWRNL RRIGAVEIFSSARLNAFLAVRTDEVRRLLLRLSLDSRDTFARVELKPMLTDLTLNNIVRMVAGRRY YGNDERGDEDEGREFRKLIAGIFRVGGSANPGDYSPVLKWADRGRFEKRIKNLSERLDRVLQGLVD EHRQGETKNTMIDHLLTLQKSQPDYYTDQIIKGLVLVLLLAGTDTSAVTLEWAMANLLNNPRVLQK LKAEIDEQIGHEKLLEEEDAPKLPYLQNVIWETLRLNPALPLLLPHVASDDCSIGGYNVPRDTMVV VNAWAIHRDPQVWEDAESFKPERFEREEIKESRKLMPFGLGRRACPGAGLAHRVVALALGSMIQCF EWRKVGEDPVDMSEGIGSTMPKAQPLEALCRARPVVHRVFYGVSK SEQ ID NO: 159 Hyoscyamus muticus HmCYP71D55 (CYP115) MQFFSLVSIFLFLSFLFLLRKWKNSNSQSKKLPPGPWKLPLLGSMLHMVGGLPHHVLRDLAKKYGP LMHLQLGEVSAVVVTSPDMAKEVLKTHDIAFASRPKLLAPEIVCYNRSDIAFCPYGDYWRQMRKIC VLEVLSAKNVRSFSSIRRDEVLRLVNFVRSSTSEPVNFTERLFLFTSSMTCRSAFGKVFKEQETFI QLIKEVIGLAGGFDVADIFPSLKFLHVLTGMEGKIMKAHHKVDAIVEDVINEHKKNLAMGKTNGAL GGEDLIDVLLRLMNDGGLQFPITNDNIKAIIFDMFAAGTETSSSTLVWAMVQMMRNPTILAKAQAE VREAFKGKETFDENDVEELKYLKLVIKETLRLHPPVPLLVPRECREETEINGYTIPVKTKVMVNVW ALGRDPKYWDDADNFKPERFEQCSVDFIGNNFEYLPFGGGRRICPGISFGLANVYLPLAQLLYHFD WKLPTGMEPKDLDLTELVGVTAARKSDLMLVATPYQPSRE DB1 / 156198702.2 83 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 160 Arabidopsis thaliana AtCYP701A3 (CYP116) MAFFSMISILLGFVISSFIFIFFFKKLLSFSRKNMSEVSTLPSVPVVPGFPVIGNLLQLKEKKPHK TFTRWSEIYGPIYSIKMGSSSLIVLNSTETAKEAMVTRFSSISTRKLSNALTVLTCDKSMVATSDY DDFHKLVKRCLLNGLLGANAQKRKRHYRDALIENVSSKLHAHARDHPQEPVNFRAIFEHELFGVAL KQAFGKDVESIYVKELGVTLSKDEIFKVLVHDMMEGAIDVDWRDFFPYLKWIPNKSFEARIQQKHK RRLAVMNALIQDRLKQNGSESDDDCYLNFLMSEAKTLTKEQIAILVWETIIETADTTLVTTEWAIY ELAKHPSVQDRLCKEIQNVCGGEKFKEEQLSQVPYLNGVFHETLRKYSPAPLVPIRYAHEDTQIGG YHVPAGSEIAINIYGCNMDKKRWERPEDWWPERFLDDGKYETSDLHKTMAFGAGKRVCAGALQASL MAGIAIGRLVQEFEWKLRDGEEENVDTYGLTSQKLYPLMAIINPRRS SEQ ID NO: 161 Gossypium arboreum GaCYP706B1 (CYP117) MLQIAFSSYSWLLTASNQKDGMLFPVALSFLVAILGISLWHVWTIRKPKKDIAPLPPGPRGLPIVG YLPYLGTDNLHLVFTDLAAAYGPIYKLWLGNKLCVVISSAPLAKEVVRDNDITFSERDPPVCAKII TFGLNDIVFDSYSSPDWRMKRKVLVREMLSHSSIKACYGLRREQVLKGVQNVAQSAGKPIDFGETA FLTSINAMMSMLWGGKQGGERKGADVWGQFRDLITELMVILGKPNVSDIFPVLARFDIQGLEKEMT KIVNSFDKLFNSMIEERENFSNKLSKEDGNTETKDFLQLLLDLKQKNDSGISITMNQVKALLMDIV VGGTDTTSTMMEWTMAELIANPEAMKKVKQEIDDVVGSDGAVDETHLPKLRYLDAAVKETFRLHPP MPLLVPRCPGDSSNVGGYSVPKGTRVFLNIWCIQRDPQLWENPLEFKPERFLTDHEKLDYLGNDSR YMPFGSGRRMCAGVSLGEKMLYSSLAAMIHAYDWNLADGEENDLIGLFGIIMKKKKPLILVPTPRP SNLQHYMK SEQ ID NO: 162 Ricinus communis RcCYP726A14 (CYP118) MEQQLLSFPALLSFLLLIFVVLRIWKQYTYKGKSTPPPGPWRLPLLGNFHQLVGALPHHRLTELAK IYGPVMGIQLGQISVVIISSVETAKEVLKTQGEQFADRTLVLAAKMVLYNRNDIVFGLYGDHWRQL RKLCTLELLSAKRVQSFKSVREEELSNFVKFLHSKAGMPVNLTHTLFALTNNIMARTSVGKKCKNQ EALLSIIDGIIDASGGFTIADVFPSVPFLHNISNMKSRLEKLHQQADDILEDIINEHRATRNRDDL EEAENLLDVLLDLQENGNLEVPLTNDSIKGAILDMFGAGSDTSSKTAEWALSELMRHPEEMKKAQE EVRRIFGEDGRIDEARFQELKFLNLVIKETLRLHPPVALIPRECREKTKVNGYDIYPKTRTLINVW SMGRDPSVWTEAEKFYPERFLDGTIDYRGTNFELIPFGAGKRICPGMTLGIVNLELFLAHLLYHFD WKLVDGVAPDTLDMSEGFGGALKRKMDLNLVPIPFTTLP DB1 / 156198702.2 84 Attorney Docket No.: MAN-042PC / 107590-5041 SEQ ID NO: 163 Euphorbia lathyris ElCYP71D445 (CYP119) MELEFRSPSSPSEWAITSTITLLFLILLRKILKPKTPTPNLPPGPKKLPLIGNIHQLIGGIPHQKM RDLSQIHGPIMHLKLGELENVIISSKEAAEKILKTHDVLFAQRPQMIVAKSVTYDFHDITFSPYGD YWRQLRKITMIELLAAKRVLSFRAIREEETTKLVELIRGFQSGESINFTRMIDSTTYGITSRAACG KIWEGENLFISSLEKIMFEVGSGISFADAYPSVKLLKVFSGIRIRVDRLQKNIDKIFESIIEEHRE ERKGRKKGEDDLDLVDVLLNLQESGTLEIPLSDVTIKAVIMDMFVAGVDTSAATTEWLMSELIKNP EVMKKAQAEIREKFKGKASIDEADLQDLHYLKLVIKETFRLHPSVPLLVPRECRESCVIEGYDIPV KTKIMVNAWAMGRDTKYWGEDAEKFKPERFIDSPIDFKGHNFEYLPFGSGRRSCPGMAFGVANVEI AVAKLLYHFDWRLGDGMVPENLDMTEKIGGTTRRLSELYIIPTPYVPQNSA Other Enzymes SEQ ID NO: 164 Cyperus rotundus CroUMO1(FMO1) MAQEKEEVHDIVIVGGGIGGLALSLGLHRKGIKSLVLERSKVLRSEGAAIGVHGNGWYALDQLDVC TDLSNCSIPLTGINYEDDKNVKTYRREPRCLRRKDLIETLARHVPVEQLRFGCQVTSINFDCKENL HVLTTHDGSVVKAKVLIGCDGLNSVVAKSLQLTPPKFFPIWITRGLTTYPEGHPFGNHFLRLVTEK AIFGRLPIDHKCVHFFVTHFDAPADYMRNPEVVKEHILELLKGESNEIMEAVRNCDMNTLNMRQVG YHSPWALYHQKFRRGTMTVAGDAMHVMGPFIGQGGSSAVEDAVVLTRCLSNAMNAVHSGSSDKEWF EKVEEALDMYVTERRPRLMRLAVQSYLIGTLLGTKSWVVKFATNFVLNALFGGNNHKHAVFDCGTI SEQ ID NO: 165 (OGD1) Cyperus rotundus CroOGD1 MASVPRDVSCANKTNYMPPKDFEEFENTKVGVKGLVDSGIDKVPEFFLHNQEVPSETSLALHPGGL QVPLIDLESIDKDEASYSKIIQEIYQASTTWGTFQLVNHGVPKDLLDEVIDKVKEFHEREIEVKKQ LYSRDRHANNVRFFSNLSGLQSGAATWRDTLICVFDGRLNTNKIPSVCREALLKYREKLLEIAERL YGLLSVALGLPSDCIKGTEYGDEQAMLAHYYPACPEPELTMGFRMHTDPTLITVVLQDSLGGLQVL RDGYLVDVTPIPGSLVVNIGDLYKCFTNDKLHSIPHHVLASKRGPRISVSTFIYPAEVSKKVFGPL KEFLSDENPPLYQDFLMADFFDAYFSKGPNSSVLSYFKI SEQ ID NO: 166 (FNR1) Cyperus rotundus CroFNR1 MASSTSIQRLLCPPSKPHRRPTALHAATKTPASTGTEPPAAVDAGRLERRVEKTDNGYWVLKEEHR TSINPQEKVKLEKEPMSLFMEGGIRELAAVPMEEIDKTKLSKDDVDVRLKWLGLFHRRKHQYGRFM DB1 / 156198702.2 85 Attorney Docket No.: MAN-042PC / 107590-5041 MRLKLPNGITTSEQTRYLAGVIDAYGDQGCADITTRQNWQIRGVTLPDVPAIIEGLMAVGLTSLQS GMDNVRNPVGNPLAGIDPHEIVDTRPYTNLLSAYITGNSKGNPEITNLPRKWNVCVIGSHDLYEHP HINDLAYMPAMKNGRFGFNLLVGGFFSPKRCEEAIPLDAWVPGDDIIPVCKAILEAYRDLGNRGNR QKTRMMWLIDELGIEVFRLQVAKRMPGGELERAAEEDLIDKKWERRDYLGVHPQKQPGLSFVGLHV PVGRLQASDMVELARLADQYGSSELRLTVEQNIIIPNVENSKIESLLKEPLLGKFSPEPSLLMKSL VACTGNQFCGQAIIETKARALKVTEEVERLVSVPRTVRMHWTGCPNTCGQVQVADIGFMGCMARDS EGKMCEGADIFLGGKIGSDSHLGEVYKKSVPCKDLVPLVADILVEKFGAVRRDREEDDE DB1 / 156198702.2 86

Claims

Attorney Docket No.: MAN-042PC / 107590-5041 CLAIMS:

1. A method for producing one or more sesquiterpene components of cypriol oil or oud oil, comprising: providing a host cell producing farnesyl diphosphate, and expressing a heterologous cypriol oil or oud oil sesquiterpene biosynthesis pathway, the heterologous biosynthesis pathway comprising one or more terpene synthase (TPS) enzymes, wherein: the one or more TPS enzymes comprise a TPS enzyme comprising an amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-44, 167, 168, and 169; culturing the host cell under conditions to allow for the production of one or more sesquiterpene components of cypriol oil or oud oil; and recovering the one or more sesquiterpene components of cypriol oil or oud oil from the culture.

2. The method of claim 1, wherein the method produces one or more unoxidized sesquiterpene components of cypriol oil.

3. The method of claim 2, wherein the unoxidized sesquiterpene components of cypriol oil are selected from α-copaene, elemene, cyprene, caryophyllene, humulene, and rotundene.

4. The method of claim 2 or 3, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO:

2.

5. The method of claim 4, wherein the TPS enzyme comprises the amino acid sequence of SEQ ID NO: 2, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. DB1 / 156198702.2 87Attorney Docket No.: MAN-042PC / 107590-5041 6. The method of any one of claims 2-5, wherein the unoxidized sesquiterpene components of cypriol oil further comprise β-selinene and / or α-selinene.

7. The method of claim 6, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 36, 41 and 43.

8. The method of claim 7, wherein the TPS enzyme comprises the amino acid sequence selected from SEQ ID NOs: 36, 41 and 43, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

9. The method of any one of claims 2-8, wherein the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes comprising an amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 45-163.

10. The method of claim 9, wherein the method produces one or more oxidized sesquiterpene components of cypriol oil, optionally comprising α-cyperone.

11. The method of claim 10, wherein the one or more CYP enzymes comprises a CYP enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 59, 72, and 93.

12. The method of claim 11, wherein at least one CYP comprises an amino acid sequence selected from SEQ ID NOs: 59, 72, and 93, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. DB1 / 156198702.2 88Attorney Docket No.: MAN-042PC / 107590-5041 13. The method of claim 1, wherein the method produces one or more unoxidized sesquiterpene components of oud oil.

14. The method of claim 13, wherein the unoxidized sesquiterpene components of oud oil are selected from dihydroagarofuran, elemol, γ-eudesmol, and agarospirol.

15. The method of claim 13 or 14, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 21, 35, 36 42, 167, 168, and 169.

16. The method of claim 15, wherein at least one TPS enzyme comprises an amino acid sequence selected from SEQ ID NOs: 21, 35, 36, 42, 167, 168, and 169, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

17. The method of any one of claims 13 to 16, wherein at least one TPS enzyme comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence selected from SEQ ID NO: 21, 167, 168, and 169.

18. The method of claim 17, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions selected from K35E, Y168H, I409M, and T471A with respect to SEQ ID NO:

21.

19. The method of claim 17 or claim 18, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions selected from K35E, S112G, I135S, Y168H, V173A, S180P, V241A, K327E, F385L, R391L, I409M, T471A, and Q492R with respect to SEQ ID NO:

21. DB1 / 156198702.2 89Attorney Docket No.: MAN-042PC / 107590-5041 20. The method of any one of claims 17 to 19, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions selected from N14D, I21V, K35E, S67L, R83G, F100G, S112G, D126E, I135S, Y168H, V173A, S180P, N215T, V241A, G269A, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S with respect to SEQ ID NO:

21.

21. The method of any one of claims 13 to 20, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions with respect to SEQ ID NO: 21 selected from: (i) N79 is substituted with a charged amino acid selected from Glu, Asp, Arg, Lys, and His; (ii) L152 is substituted with an amino acid selected from Val, Ile, Ala and Gly; (iii) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (iv) K204 is substituted with an amino acid selected from Arg and His; (v) L213 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln; (vi) T261 is substituted with an amino acid selected from Val, Ile, Leu, Ala and Gly; (vii) I268 is substituted with an amino acid selected from Leu, Val, Ala and Gly; (viii) C275 is substituted with an amino acid selected from Gln, Asn, Ala, Gly, and Val; (ix) G279 is substituted with an amino acid selected from Ala, Val, Ile, and Leu; (x) F292 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; and / or (xi) I409 is substituted with an amino acid selected from Met, Leu, and Val.

22. The method of claim 21, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions selected from N79E, L152V, Y168H, K204R, L213S, T261V, I268L, C275Q, G279A, F292I, and I409M with respect to SEQ ID NO:

21. DB1 / 156198702.2 90Attorney Docket No.: MAN-042PC / 107590-5041 23. The method of any one of claims 13 to 22, wherein the unoxidized sesquiterpene components of oud oil comprise one or more of elemol, γ-eudesmol, agarospirol, α-guaiene and α-bulnesene.

24. The method of claim 23, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NOs: 5 or SEQ ID NOs:

6.

25. The method of claim 24, wherein the TPS comprises the amino acid sequence of SEQ ID NOs: 5 or 6, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

26. The method of any one of claims 13-26, wherein the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes comprising an amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 45-163.

27. The method of claim 26, wherein the method produces one or more oxidized sesquiterpene components of oud oil, optionally comprising agarofuran.

28. The method of claim 27, wherein the one or more CYP enzymes comprises a CYP enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence of SEQ ID NO: 133 or SEQ ID NO:

135.

29. The method of claim 18, wherein the CYP enzyme comprises the amino acid sequence of SEQ ID NO: 133 or SEQ ID NO: 135, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. DB1 / 156198702.2 91Attorney Docket No.: MAN-042PC / 107590-5041 30. The method of any one of claims 13 to 29, wherein the method further comprises extracting a sesquiterpene compound from the culture and subjecting the sesquiterpene compound to a chemical reaction.

31. The method of claim 30, wherein the chemical reaction converts the sesquiterpene compound to an oxidized sesquiterpene components of oud oil.

32. The method of claim 31, wherein the chemical reaction converts the oxidized sesquiterpene components of oud oil is agarofuran.

33. The method of claim 32, wherein the chemical reaction comprises reaction with a strong acid optionally a strong organic acid.

34. The method of claim 33, wherein the strong acid an aryl sulfonic acid.

35. The method of claim 34, wherein the aryl sulfonic acid is p-toluene sulfonic acid.

36. The method of any one of claims 1 to 35, wherein the host cell further expresses a heterologous farnesyl diphosphate synthase (FPPS).

37. The method of any one of claims 1 to 36, wherein one or more enzymes of the heterologous pathway are expressed from extrachromosomal elements.

38. The method of any one of claims 1 to 37, wherein one or more enzymes of the heterologous pathway are expressed from genes that are chromosomally integrated.

39. The method of any one of claims 1 to 38, wherein the host cell is a microbial host cell overexpressing one or more enzymes in the methylerythritol phosphate (MEP) or the mevalonic acid (MVA) pathway. DB1 / 156198702.2 92Attorney Docket No.: MAN-042PC / 107590-5041 40. The method of any one of claims 1 to 39, wherein the host cell is a bacterium, optionally selected from Escherichia spp., Bacillus spp., Corynebacterium spp., Rhodobacter spp., Zymomonas spp., Vibrio spp., and Pseudomonas spp.

41. The method of claim 40, wherein the bacterial host cell is selected from Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis, Vibrio natriegens, and Pseudomonas putida.

42. The method of any one of claims 1 to 39, wherein the host cell is a yeast, optionally selected from Saccharomyces, Pichia, and Yarrowia.

43. The method of claim 42, wherein the host cell is Saccharomyces cerevisiae, Pichia pastoris, or Yarrowia lipolytica.

44. The method of any one of claims 39 to 45, wherein the host cell is cultured in a carbon source comprising glucose, sucrose, fructose, xylose, and / or glycerol.

45. The method of any one of claims 39 to 44, wherein culture conditions are selected from aerobic, microaerobic, and anaerobic.

46. The method of claim 45, wherein the host cell is cultured at a temperature in the range of about 22° C to about 37° C, or about 27° C to about 37° C, or about 30° C to about 37 ° C.

47. A host cell producing one or more sesquiterpene components of cypriol oil or oud oil, comprising an upstream biosynthesis pathway producing farnesyl diphosphate (FPP) and a heterologous cypriol oil or oud oil sesquiterpene biosynthesis pathway, the heterologous biosynthesis pathway comprising one or more terpene synthase (TPS) enzymes, wherein: the one or more TPS enzymes comprise a TPS enzyme comprising an amino acid sequence comprising at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 1-44, 167, 168, and 169. DB1 / 156198702.2 93Attorney Docket No.: MAN-042PC / 107590-5041 48. The host cell of claim 47, wherein the host cell produces one or more unoxidized sesquiterpene components of cypriol oil, optionally selected from α-copaene, elemene, cyprene, caryophyllene, humulene, and rotundene.

49. The host cell of claim 48, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO:

2.

50. The host cell of claim 49, wherein the TPS enzyme comprises the amino acid sequence of SEQ ID NO: 2, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

51. The host cell of any one of claims 54-56, wherein the host cell produces β-selinene and / or α-selinene.

52. The host cell of claim 51, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to an amino acid sequence selected from SEQ ID NOs: 36, 41 and 43.

53. The host cell of claim 52, wherein the TPS enzyme comprises an amino acid sequence selected from SEQ ID NOs: 36, 41 and 43, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

54. The host cell of any one of claims 48-53, wherein the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes comprising an DB1 / 156198702.2 94Attorney Docket No.: MAN-042PC / 107590-5041 amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 45-163.

55. The host cell of claim 54, wherein the host cell produces one or more oxidized sesquiterpene components of cypriol oil, optionally comprising α-cyperone.

56. The host cell of claim 55, wherein the one or more CYP enzymes comprises a CYP comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NOs: 59, 72, and 93.

57. The host cell of claim 56, wherein the CYP comprises an amino acid sequence selected from SEQ ID NOs: 59, 72, and 93, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

58. The host cell of claim 57, wherein the host cell produces one or more unoxidized sesquiterpene components of oud oil, optionally selected from dihydroagarofuran, elemol, γ-eudesmol, and agarospirol.

59. The host cell of claim 58, wherein the one or more TPS enzymes comprises a TPS enzyme having an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NOs: 21, 35, 36, 42, 167, 168, and 169.

60. The host cell of claim 59, wherein the TPS comprises an amino acid sequence selected from SEQ ID NOs: 21, 35, 36, 42, 167, 168, and 169, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions. DB1 / 156198702.2 95Attorney Docket No.: MAN-042PC / 107590-5041 61. The host cell of claim 59 or 60, wherein the one or more TPS enzymes comprises a TPS enzyme having an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

21.

62. The host cell of claim 61, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions selected from K35E, Y168H, I409M, and T471A with respect to SEQ ID NO:

21.

63. The host cell of claim 62, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

167.

64. The host cell of claim 61 or claim 62, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions selected from K35E, S112G, I135S, Y168H, V173A, S180P, V241A, K327E, F385L, R391L, I409M, T471A, and Q492R with respect to SEQ ID NO:

21.

65. The host cell of claim 64, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

168.

66. The host cell of any one of claims 61 to 65, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions with respect to SEQ ID NO: 21 selected from N14D, I21V, K35E, S67L, R83G, F100G, S112G, D126E, I135S, Y168H, V173A, S180P, N215T, V241A, G269A, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S. DB1 / 156198702.2 96Attorney Docket No.: MAN-042PC / 107590-5041 67. The host cell of claim 66, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

169.

68. The host cell of any one of claims 59 to 67, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions at positions with respect to SEQ ID NO: 21 selected from: (i) N79 is substituted with a charged amino acid selected from Glu, Asp, Arg, Lys, and His; (ii) L152 is substituted with an amino acid selected from Val, Ile, Ala and Gly; (iii) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (iv) K204 is substituted with an amino acid selected from Arg and His; (v) L213 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln; (vi) T261 is substituted with an amino acid selected from Val, Ile, Leu, Ala and Gly; (vii) I268 is substituted with an amino acid selected from Leu, Val, Ala and Gly; (viii) C275 is substituted with an amino acid selected from Gln, Asn, Ala, Gly, and Val; (ix) G279 is substituted with an amino acid selected from Ala, Val, Ile, and Leu; (x) F292 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; and / or (xi) I409 is substituted with an amino acid selected from Met, Leu, and Val.

69. The host cell of claim 68, wherein the one or more TPS enzymes comprises a TPS enzyme that comprises one or more substitutions selected from N79E, L152V, Y168H, K204R, L213S, T261V, I268L, C275Q, G279A, F292I, and I409M with respect to SEQ ID NO:

21.

70. The host cell of any one of claims 47 to 69, wherein the host cell produces elemol, γ-eudesmol, agarospirol, α-guaiene and / or α-bulnesene. DB1 / 156198702.2 97Attorney Docket No.: MAN-042PC / 107590-5041 71. The host cell of claim 70, wherein the one or more TPS enzymes comprises a TPS enzyme comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NOs: 5 or SEQ ID NOs:

6.

72. The host cell of claim 71, wherein the TPS comprises the amino acid sequence of SEQ ID NOs: 5 or 6, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

73. The host cell of any one of claims 47-72, wherein the heterologous biosynthesis pathway further comprises one or more cytochrome P450 (CYP) enzymes comprising an amino acid sequence having at least 70% sequence identity to an amino acid sequence selected from SEQ ID NOs: 45-163.

74. The host cell of claim 73, wherein the host cell produces one or more oxidized sesquiterpene components of oud oil, optionally comprising agarofuran.

75. The host cell of claim 74, wherein the one or more CYP enzymes comprises a CYP comprising an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence of SEQ ID NO: 133 or SEQ ID NO:

135.

76. The host cell of claim 75, wherein the CYP comprises the amino acid sequence of SEQ ID NO: 133 or SEQ ID NO: 135, optionally with from 1 to 20 or from 1 to 10 or from 1 to 5, or from 1 to 3 amino acid modifications independently selected from substitutions, deletions, and insertions.

77. The host cell of any one of claims 47 to 76, wherein the host cell further expresses a heterologous farnesyl diphosphate synthase (FPPS). DB1 / 156198702.2 98Attorney Docket No.: MAN-042PC / 107590-5041 78. The host cell of any one of claims 47 to 77, wherein one or more enzymes of the heterologous pathway are expressed from extrachromosomal elements.

79. The host cell of any one of claims 53 to 78, wherein one or more enzymes of the heterologous pathway are expressed from genes that are chromosomally integrated.

80. The host cell of any one of claims 53 to 79, wherein the host cell is a microbial host cell overexpressing one or more enzymes in the methylerythritol phosphate (MEP) or the mevalonic acid (MVA) pathway.

81. The host cell of any one of claims 53 to 80, wherein the host cell is a bacterium, optionally selected from Escherichia spp., Bacillus spp., Corynebacterium spp., Rhodobacter spp., Zymomonas spp., Vibrio spp., and Pseudomonas spp.

82. The host cell of claim 81, wherein the bacterial host cell is selected from Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis, Vibrio natriegens, and Pseudomonas putida.

83. The host cell of any one of claims 53 to 82, wherein the host cell is a yeast, optionally selected from Saccharomyces, Pichia, and Yarrowia.

84. The host cell of claim 83, wherein the host cell is Saccharomyces cerevisiae, Pichia pastoris, or Yarrowia lipolytica.

85. The host cell of any one of claims 80 to 84, wherein the host cell uses a carbon source comprising glucose, sucrose, fructose, xylose, and / or glycerol.

86. The host cell of any one of claims 80 to 85, wherein host cell is culturable under conditions selected from aerobic, microaerobic, and anaerobic. DB1 / 156198702.2 99Attorney Docket No.: MAN-042PC / 107590-5041 87. The host cell of claim 86, wherein the host cell is culturable at a temperature in the range of about 22° C to about 37° C, or about 27° C to about 37° C, or about 30° C to about 37 ° C.

88. A terpene synthase (TPS) enzyme comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 21 and comprising one or more substitutions with respect to SEQ ID NO: 21 selected from: (i) K35 is substituted with a negatively charged amino acid selected from Glu and Asp; (ii) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (iii) I409 is substituted with an amino acid selected from Met, Leu, and Val; and / or (iv) T471 is substituted with Ala, Gly, and Val.

89. The TPS enzyme of claim 88, wherein the TPS enzyme comprises one or more substitutions with respect to SEQ ID NO: 21 selected from K35E, Y168H, I409M, and T471A.

90. The TPS enzyme of claim 87 or 88, wherein the TPS enzyme comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

167.

91. A terpene synthase (TPS) enzyme comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 21, and that comprises one or more substitutions at positions with respect to SEQ ID NO: 21 selected from: (i) K35 is substituted with a negatively charged amino acid selected from Glu and Asp; (ii) S112 is substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val; (iii) I135 is substituted with an amino acid selected from Ser, Thr, Tyr, and Cys, DB1 / 156198702.2 100Attorney Docket No.: MAN-042PC / 107590-5041 (iv) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (v) V173 is substituted with an amino acid selected from with Ala and Gly; (vi) S180 is substituted with a non-polar amino acid selected from Pro, Ala, Gly and Val; (vii) V241 is substituted an amino acid selected from with Ala and Gly; (viii) K327 is substituted with a negatively charged amino acid selected from Glu and Asp; (ix) F385 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (x) R391 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (xi) I409 is substituted with an amino acid selected from Met, Leu, and Val; (xii) T471 is substituted with Ala, Gly, and Val; and / or (xiii) Q492 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His.

92. The TPS enzyme of claim 91, wherein the TPS enzyme comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

168.

93. The TPS enzyme of claim 91 or 92, wherein the TPS enzyme comprises one or more substitutions with respect to SEQ ID NO: 21 selected from K35E, S112G, I135S, Y168H, V173A, S180P, V241A, K327E, F385L, R391L, I409M, T471A, and Q492R.

94. A terpene synthase (TPS) enzyme comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 21, and that comprises one or more substitutions at positions with respect to SEQ ID NO: 21 selected from: (i) N14 is substituted with a charged amino acid selected from Asp, Glu, Arg, Lys, and His; (ii) I21 is substituted with an amino acid selected from Val, Leu, Ala, and Gly; DB1 / 156198702.2 101Attorney Docket No.: MAN-042PC / 107590-5041 (iii) K35 is substituted with a negatively charged amino acid selected from Glu and Asp; (iv) S67 is substituted with a non-polar amino acid selected from Leu, Ile, and Val; (v) R83 is substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val; (vi) F100 is substituted with an amino acid selected from Gly, Ala, Ile, Leu, and Val; (vii) S112 is substituted with a non-polar amino acid selected from Gly, Ala, Ile, Leu, and Val; (viii) D126 is substituted with Glu; (ix) I135 is substituted with an amino acid selected from Ser, Thr, Tyr, and Cys, (v) (x) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (xi) V173 is substituted with an amino acid selected from with Ala and Gly; (xii) S180 is substituted with a non-polar amino acid selected from Pro, Ala, Gly and Val; (xiii) N215 is substituted with an amino acid selected from Thr, Ser, and Gln; (xiv) V241 is substituted an amino acid selected from with Ala and Gly; (xv) G269 is substituted with an amino acid selected from Ala, Val, Ile, and Leu; (xvi) K327 is substituted with a negatively charged amino acid selected from Glu and Asp; (xvii) G365 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His; (xviii) T369 is substituted with an amino acid selected from Ile, Leu, Val, Ala, and Gly; (xix) F385 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (xx) R391 is substituted with an amino acid selected from Leu, Ile, Val, and Ala; (xxi) N394 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (xxii) I409 is substituted with an amino acid selected from Met, Leu, and Val; (xxiii) D412 is substituted with a polar amino acid selected from Asn, Gln, Ser, and Thr; DB1 / 156198702.2 102Attorney Docket No.: MAN-042PC / 107590-5041 (xxiv) S427 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; (xxv) L428 is substituted with an amino acid selected from Val, Ile, Ala and Gly; (xxvi) T434 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; (xxvii) A438 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; (xxviii) T471 is substituted with Ala, Gly, and Val; (xxvxi) E489 is substituted with an amino acid selected from Gly, Ala, Ile, Leu, and Val; (xxx) Q492 is substituted with a charged amino acid selected from Arg, Lys, Glu, Asp, and His; and / or (xxxi) C510 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln.

95. The TPS enzyme of claim 94, wherein the TPS enzyme comprises an amino acid sequence that is at least 80% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

169.

96. The TPS enzyme of claim 94 or 95, wherein the TPS enzyme comprises one or more substitutions with respect to SEQ ID NO: 21 selected from N14D, I21V, K35E, S67L, R83G, F100G, S112G, D126E, I135S, Y168H, V173A, S180P, N215T, V241A, G269A, K327E, G365R, T369I, F385L, R391L, N394H, I409M, D412N, S427I, L428V, T434I, A438I, T471A, E489G, Q492R and C510S.

97. A terpene synthase (TPS) enzyme comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 21 and that comprises one or more substitutions with respect to SEQ ID NO: 21 selected from: (i) N79 is substituted with a charged amino acid selected from Glu, Asp, Arg, Lys, and His; (ii) L152 is substituted with an amino acid selected from Val, Ile, Ala and Gly; (iii) Y168 is substituted with a charged amino acid selected from His, Arg, Lys, Glu and Asp; (iv) K204 is substituted with an amino acid selected from Arg and His; DB1 / 156198702.2 103Attorney Docket No.: MAN-042PC / 107590-5041 (v) L213 is substituted with an amino acid selected from Ser, Thr, Asn, and Gln; (vi) T261 is substituted with an amino acid selected from Val, Ile, Leu, Ala and Gly; (vii) I268 is substituted with an amino acid selected from Leu, Val, Ala and Gly; (viii) C275 is substituted with an amino acid selected from Gln, Asn, Ala, Gly, and Val; (ix) G279 is substituted with an amino acid selected from Ala, Val, Ile, and Leu; (x) F292 is substituted with an amino acid selected from Ile, Leu, Val, and Ala; and / or (xi) I409 is substituted with an amino acid selected from Met, Leu, and Val.

98. The TPS enzyme of claim 97, wherein the TPS enzyme comprises one or more substitutions with respect to SEQ ID NO: 21 selected from N79E, L152V, Y168H, K204R, L213S, T261V, I268L, C275Q, G279A, F292I, and I409M.

99. The TPS enzyme of claim 97 or claim 98, wherein the TPS enzyme comprises an amino acid sequence that is at least 85% identical, or at least 90% identical, or at least 95% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical to the amino acid sequence selected from SEQ ID NO:

21. DB1 / 156198702.2 104

Images